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ISummary in English
Hypertension afflicts 21% of the Canadian population and is a leading cause of death as it is
associated with an increased risk of cardiovascular diseases. Blood pressure (BP) regulation is a
complex trait controlled by multiple genes and influenced by environment. Little is known about
the genes responsible for BP regulation. Inbred rats genetically predisposed to hypertension
have been developed to facilitate the study of the genetic basis to this disease. Preliminary
linkage and congenic experiments have shown the presence of at least one BP quantitative trait
loci (QTL) in a 80cM region of rat chromosome (chr) 2. The objective of the present thesis was
to identify and characterize the rat chr 2 regions involved in the genetic control of hypertension.
We are using congenic strains in which various segments from the Dahl sait-sensitive (DSS) rat
chr 2 are replaced by the homologous segments coming from the Milan normotensive rat
(MNS). This model has allowed to narrow down the rat chr 2 BP QTL to three non-overlapping
regions each containing at least one distinct BP QTL: C2QTL1 (5.7cM), C2QTL2 (3.5cM) and
C2QTL3 (1.5cM). These closely linked BP QTL showed epsitatic and additive interactions. We
also identified a QTL for vascular smooth muscle celi (VSMC) number acting independently of
BP. The gene coding for the angiotensin receptor lb Agtr1b) is located in the region containing
the QTL for $MCN. Agtr]b is a candidate for the SMCN QTL because 1) two non-synonymous
mutations were found in the coding region between DSS and MNS rats, and 2) contractile
responses to Ang II are reduced in rats harbouring the MNS allele of the gene compared with
DS$ rats. The cunent work provide new insights about the genetic determination of
hypertension and of vascular remodelling disorders. In the future, these knowledge may be
useful in the development of new therapeutic targets, genetic diagnostic tools and
pharmacogenomics.
Keywords: genetics of hypertension, Dahi salt-sensitive rat, quantitative trait loci,
aortic hyperpiasia, vasoreactivity.
II
Résumé en français
L’hypertension affecte 21% de la population canadienne et est un facteur de mortalité important
car elle est associée à un risque accru de maladies cardiovasculaire. La régulation de la pression
artérielle (PA) est un trait complexe impliquant plusieurs gènes et une composante
environnementale. Les gènes responsables de la régulation de la PA sont peu connus. Les
modèles de rats consanguins ont été développé pour faciliter l’étude des bases génétiques de
l’hypertension. Des études préliminaires de liaison génétique et de lignées congéniques ont
démontré la présence d’au moins un iocus pour trait quantitatif (QTL) pour la PA dans une
région de 80 cM sur le chromosome (chr) 2 du rat. L’objectif de cette thèse était d’identifier, de
définir et de caractériser les régions du chr 2 du rat impliquées dans la détermination génétique
de l’hypertension. Pour atteindre cet objectif, nous utilisons des lignées congéniques dans
lesquelles divers segments du chr 2 du rat Dahl sait-sensitive (DSS) ont été remplacé par la
région homologue provenant du rat Milan normotendu (MNS). Ce modèle a permis de réduire la
région d’intérêt du QTL du chr 2 du rat à 3 régions non-chevauchantes contenant chacune un
QTL pour la PA distinct: C2QTL1 (5.7 cM), C2QTL2 (3.5 cM) and C2QTL3 (1.5 cM). Ces loci
ont démontré des interactions additives et épistatiques. Nous avons aussi identifié un QTL pour
le nombre de cellules musculaire lisses (SMCN) vasculaires agissant indépendamment de la PA.
Le gène codant pour le récepteur lb de l’angiotensine (Agtrl b) est situé dans la région contenant
le SMCN QTL. Agtrlb est un gène candidat pour le SMCN QTL puisque 2 mutations non-
synonymes ont été identifiées dans la région codante entre les séquences du rat DSS et du MNS,
et 2) la réponse contractile à l’angiotensine II est diminuée dans les rats portant les allèles MNS
du gène comparativement aux rats DSS. Ce travail apporte de nouvelles précisions sur les
déterminants génétiques de l’hypertension et des maladies de remodelage vasculaire. Ces
connaissances pourraient être utiles au développement de nouvelles cibles thérapeutiques,
d’outils de diagnostique génétique et à l’avancement de la pharmacogénomique.
Mots clé: génétique de l’hypertension, rat Dahl sait-sensitive, ioci pour trait quantitatif,
hyperplasie aortique, vasoréactivité.
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CHAPTER f
INTRODUCTION
1.1 PHYSIOLOGY 0F BLOOD PRESSURE
The cardiovascular system is responsible for the distribution of blood to ail parts of the
organism. It is composed of a pump, the heart and of a network of conduits, the blood
vessels. The heart provides the force necessary for the blood to circulate through the
arteries and veins. The blood is the vehicle ensuring the transport of several substances.
A proper blood flow allows the distribution of heat, ensures that the nutriments and
oxygen (02) reach the tissues and that carbon dioxide (C02) and waste are removed
from the tissues. Blood also ensures the maintenance of a stable pH in the organism
with the buffer substances it contains.
1.1.1 Definition
Blood pressure (BP) is defined as the force exerted by the blood per unit of vessel wall
area. Circulation of the blood in the body follows a pulsatile pattem reaching its highest
peak during ventncular contractions of the heart and its lowest level between cardiac
contractions. The foi-ce necessary for the propulsion of the blood in the entire organism
relies on the strength of heart beats and on the pressure gradient present in the
cardiovascular system. In effect, there is a progressive lowering of the blood pressure as
it travels from large arteries such as aorta to arterioles until it reaches heart atria through
vena cava. Systolic blood pressure (SBP) corresponds to the blood pressure during
ventricular contraction whereas diastolic blood pressure (DBP) is defined as the blood
pressure between each ventricular contraction. Mean arterial pressure (MAP) is the
average between diastolic and systolic blood pressures and reflects the pressure to which
small vessels are continuously submitted. Pulse pressure (PP) is calculated by
subtracting DAP to SAP and is an indication of the compliance of large arteries. BP is
measured in millimetres of mercury (mmHg). 1
21.1.2 Hemodynamics
From a hemodynamic point cf view, MAP is function cf two major variables: j) cardiac
output (CO), which is the quantity of blood ejected by the left ventricle during systole;
and ii) total penpheral resistance (TPR) exerted by small arteries and arterioles.
Thereby:
MAP=CO X TVR
Where CO is influenced by systolic precharge and heart rate, and total vascular
resistance is determined by the rayon of small arteries and the physical properties of the
blood which include viscosity and concentration of fibrinogen. 1
1.1.3 Regulation
A complex system of regulation is responsible blood pressure control te ensure constant
blood flow to tissues and adjustment to meet specific demands cf the organism.
Regulation is achieved thrcugh the conttcl of blood volume and cf resistance vessels. It
involves the participation cf the endocrine system, of the central and peripheral nervous
systems and cf vasoactive substances acting lccally.
1.1.3.1 Nervous system
The nervous system is a major player in the BP homeostasis as it is involved in short
term and long-term regulation. The effects cf the nervous system on the cardiovascular
system require the integration of afferent input from visceral organs and varicus brain
regions by the central nervous system (CNS) and the transduction of the input in the
appropriate cardiovascular adaptation via the parasympathetic and sympathetic divisions
of the autonomic peripheral nervous system (PNS). The autonomïc nervous system is
responsible for controlling vital functions including heart rate and BP. Its actions are
mostly involuntary. The autonomic nervous system is dïvided into the parasympathetic
nervous system (PSNS) and the sympathetic nervous system (SNS) on the basis cf
structural and functional differences. Peripheral nervous system projects to target
organs where it regulates cardiovascular function. The influence cf the two divisions is
opposed. 2
31.1.3.1.1 Afferents inputs
The hypothalamus, the baroreceptors and the chemoreceptors ensure a constant
monitoring of the cardiovascular system. The hypothalamus is the brain region
responsible for the integration of environmental and behavioural input. It is the link
between the endocrine and the neural systems to maintain homeostasis. Arterial
baroreceptors are located mainly in the carotid sinus and in the wall of the aortic arch.
They are ïnvolved in adaptation to rapid and important changes in blood pressure, like it
is the case during postural changes. Cardiac baroreceptors are positioned in the walls of
atria and ventricles. Baroreceptors respond to an increase in pressure or stretching.
Chemoreceptor are found proximity to baroreceptors in carotid sinus and aortic arch.
They are specialized in detecting changes in 02, C02 and H levels. 2,3
1.1.3.1.2 Integration of afferent inputs
The nucleus tractus solitarius (NTS) of the medulla oblongata is the principal site of
termination of afferent fibres arising from cardiovascular receptors, hypothalamus and
cerebral cortex. Signal from different types of cardiovascular afferent fibres have
different sites of termination in the NTS. The NTS integrates information from afferent
fibres and adjust the cardiovascular system accordingly. 2,3 The NT$ controls the
parasympathetic nerves of the penpheral nervous system directly and projects to the
rostral ventrolateral nucleus (RVLN) in the medulla. The RVLN is responsible for
controlling the output of the sympathetic preganglionic neurons. The signalling of the
NTS to RVLN is inhibitory, which means that excitatory signalling to NTS are
translated by an increase in inhibition of RVLN and sympathetic output.
1.1.3.1.3 Efferent outputs
Both division of the penpheral nervous system require two neurons to reach the target
organs: a preganglionic neuron to conduct influx from the central nervous system to the
ganglion and a postganglionic neuron which transmit the signal form the ganglion to the
target organ. Preganglionic neurons of the PSNS and SNS signal by releasing the
neurotransmitter acetylcholine (Ach) which binds to nicotinic receptors on
postganglionic cells. Ail major organs are innervated by both, the P$NS and the SNS,
4with the exception of the adrenal medulïa which is under the control of the SNS
exc!usively. 2 The PSNS inhibitory tone predominates at rest whereas SNS stimulation
is triggered in a stress or exercise situation.
1.1.3.1.3.1 PSNS
The parasympathetic system exerts its effect via the vagal postgang!ionic nerves using
acetylcholine as the main neurotransmitter. Parasympathetic postganglionic neurons are
very short since the ganglion is located at organ. These neurons are cholinergic as they
release Ach which binds muscarinic receptors at target organs. Effects of PSNS
signalling include a decreased rate and force of contraction of the heart and vesse!
dilation.
1.1.3.1.3.2 SNS
The sympathetic neurons are !onger since they run from the gang!ion in the spinal cord
to the target organ. They are adrenergic as they release the neurotransmitter
norepinephrine which can bind to several subtypes of the adrenergic receptors.
Sympathetic stimulation increases heart rate and cardiac output through f31 adrenergic
receptors, provokes constriction of arteries and veins through OEl adrenergic receptors,
and lead to dilation of vessels and renin secretion through f32 adrenergic receptors. AI!
the effects of sympathetic activation contribute to the ‘fight or flight response aiming at
preparing the body to respond to danger. More specifical!y, SNS actions allow to
redistribute the blood away from skin and viscera to concentrate it to skeletal musc!es,
brain and heart, it stimulates heart beat, raises BP and promotes the release of adrenaline
in the bloodstream by the adrena! medu!Ia. This latter action of the SNS is necessary for
ensuring that ail the body is reached by SNS effects. 5,6
1.1.3.2 Endocrine system
1.1.3.2.1 Renin angiotensin system (RAS)
The circulating RAS is a major system responsible for maintenance of body fluid
vo!ume homeostasis and regulation of BP. It consists of a proteolytic cascade that
5resuits in the production of a biologically active peptide, angiotensin II (Ang II), which
exerts its effects via a signal transduction system.
1.1.3.2.1.1 Angiotensin II proteolytic cascade
Generation of Ang II begins with the molecule angiotensinogen (AGT), expressed
constitutively from the liver and secreted in the circulation. Under normal conditions,
AGT levels remain constant at a concentration near its Km for cleavage by renin .
AGT is cleaved by the aspartic protease renin to yield angiotensin I (Ang I). In the
lddney, pre-prorenin (406aa) is first synthesized and is converted to prorenin by the
removal of 23 amino acids as it enters the rough ER. Through a secretory pathway,
prorenin is processed to renin by the cleavage of 43 amino acids. In response to low
perfusion pressures, low sodium delivery to the distal tubules or 13 adrenergic
stimulation, renin is secreted in the circulation. The opposite situation inhibits renin
secretion from the kidneys. Inhibition of renin secretion by the product of the cascade
itself, Ang II allows negative feedback regulation. 2 As the biologically inactive peptide
Ang I reaches pulmonary circulation, it is converted to active Ang II by the Angiotensin
converting enzyme (ACE). ACE is a zinc metallopeptidase that exists in 3 isoforms:
somatic ACE, soluble ACE and testicular ACE. Somatic ACE is mainly responsible for
the conversion of Ang I to Ang II by cleavage of a dipeptide from its C-terminal end.
ACE lias a broad substrate specificity. In addition to cleaving Ang I, it can also
inactivate bradykinin by removal of a C-terminal dipeptide.
1.1.3.2.1.2 Angiotensin receptors and signalling
Ang II exerts its effect by binding to two receptors, the Ang II receptor 1 (AT1) and the
Ang II receptor 2 (AT2).
1.1.3.2.1.2.1 AT1
Most known effect of Ang II are mediated through coupling with the AT1 receptor. The
AT1 receptor is a member of the G-protein-coupled 7-transmembrane receptor family.
The tertiary structure of the 4 extracellular loops is stabilized by disulfide bonds and
contains 3 glycosylation sites. The cytoplasmic tau is rich in serine and threonine
6residues, which are potential phosphorylation sites. Ail receptors exhibit a wide tissue
distribution in aduit including spleen, liver, lddney, heart, vascular smooth muscle celis
(SMC), blood vessels, adrenal gland, liver and brain. Molecular cloning studies have
distinguished 2 receptor subtypes, AT1a and AT1b differing in their distribution and
regulation. At the molecular level, AT1a and AT1b show differences in the carboxy
domain of the protein and in the 3’ and 5’ untranslated region (UTR). The 2 receptor
subtypes are present in the mouse and in the rat. In human, only one AT1 subtype is
found. 8,9
Upon activation by Ang II, the AT1 receptor couples to G proteins of the Gi/Gq family
which in mm activate a wide range of signalling cascades including the phospholipase C
(PLC), phospholipase D (PLD), and phospholipase A2 (PLA2) pathways. In addition,
Ang II stimulation of the Ail receptor has an inhibitory effect on adenylate cyclase. 10
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Activation of PLC leads to the production of inositol triphosphate (1P3) and
diacylglycerol (DG) from the hydrolysis phosphatidylinositol 4,5 biphosphate (PP2).
In parallel, PLD generates choline and phosphatidic acid (PA) from phosphatidylcholine
(PC). PA is subsequently converted to DG. W3 production is involved in the
mobilization of intracellular calcium (Ca2) resulting in contraction of smooth muscle
celis (SMC) and vasoconstriction. DG and intracellular Ca2 mobilization both
contribute to the activation of protein kinase C (PKC) which mediates the proliferative
effects of Ang II via the phosphorylation and activation of the mitogen-activated protein
kinases (MAPK). PC is also hydroÏyzed by phospholipase A2 upon Ang II binding to
AT1R. This cascade generates arachidonic acid (AA), a precursor for the production of
eicosanoid vasoactive substances. 8,9,11
The consequence of the inhibition of adenylate cyclase is a decrease in cyclic AIVW
(cAMP) levels and as a resuit a reduction in protein kinase A (PKA) activity. In renal
proximal tubules, the net effect is a reduction in Na’H exchange inhibition leading to
an augmented sodium reabsorption. In the adrenal cortex, a decrease in adenylate
7cyclase activity resuits in a reduction in inhibition of adrenocorticotropic-hormone
(ACTH)-stimulated aldosterone secretion. ‘“
Effects of AT1R on stimulation of growth and proliferation involves additional
signalling mechanisms including the Janus kinase signal transducers and activators
transcription (JAKISTAT) system and ras/raf activation of MAPK. 12
1.1.3.2.1.2.2 AT2
The structure of the AT2 receptor resembles that of the G-protein-coupled 7-
transmembrane receptor famiiy. Despite the similarities to the family, a G protein
coupling AT2 to its signaliing pathways has yet to be identified. The AT2 receptor
shares 34% sequence homology with the AT1 receptor. ° Contrarily to AT1 which is
expressed mainly in aduit tissue, AT2 expression is stronger in foetuses and declines
after birth. Weak AT2 expression remains in aduit endothelium, myocardium, brain,
adrenal gland, ovaries and uterus
Description of signalling from AT2 receptor remains incomplete. Its effects are thought
to balance the effects of ATY on cellular proliferation. In effect, AT2 is believed to have
effects in cell differentiation and anti-proliferation. These effects are thought to be
mediated by the activation of phosphotyrosine phosphatase which in tum inactivates
mitogen-activated protein (MAP) kinase. 10 AT2 is also involved in vasodilatation and
natriuresis via a local increase in nitric oxide and bradyldnin. 10
1.1.3.2.1.3 Local RAS
In addition to the well described endocrine RAS, evidence for the local generation of
Ang II within tissues accumulates. In addition to their presence in the circulation, the
components of the RAS are also found in several tissues including brain, kidney,
adrenals, testis and arterial wall. 14 It is believed that the circulating RAS mediates the
acute effects of Ang II on vasoconstriction, sait and water homeostasis and cardiac
rhythm. In contrast, tissue RAS seems to be involved in the establishment of the long
term effect on Ang II including celluiar proliferation and differentiation. 13
$1.1.3.2.1.4 Biological actions of Ang II
In the vasculature, Ang II increases total peiipheral resistance by directly causing
vasoconstriction and indirectly by facilitating SNS transmission. Ang II is a mitogenic
factor for vascular SMCs and myocardium. In addition, Ang II interacts with other
endocrine factors as it is one of the main stimulus for the synthesis of aldosterone by the
adrenal cortex and the release ACTH and vasopressin by the pituitary. ACTH
stimulates the adrenals to release aldosterone. Aldosterone acts on distal tubules where
it stimulates sodiumlpotassium exchange leading to increased sodium reabsorption.
Vasopressin triggers the insertion of water pores in the distal tubules and the collecting
duct of the kidney, thereby promoting water reabsorption. Ang II also regulates sodium
and fluid reabsorption from proximal tubules of the kidney by affecting localiy the
constriction state of the renal vasculature. From its action on the CNS, Ang II induces
thirst and sait appetite. Inhibition of renin secretion in the lddney provides a negative
feedback loop mechanism for the effects of Ang
1.1.3.2.2 Natriuretic peptïdes
The natriuretic peptide famiiy inciudes the atriai natriuretic peptide (ANP), the brain
natriuretic peptide (BNP) and the C-type natriuretic peptide (CNP). ANP is synthesized
and released mainly by the atria and BNP is synthesized and reieased predominantiy by
the ventricuiar myocytes. 16 These peptides exert their function as circulating hormones.
17 Even though ANP and BNP are constitutively released from the heart, mechanical
stimuli such as atrial stretch or endocrine stimuli may affect their rate of synthesis and
secretion 16 CNP is a paracrine factor produced by the cerebrai cortex and endotheiial
ceils of the vesseis. 18
1.1.3.2.2.1 Receptors and signalling
Natriuretic peptides exert their function by binding to the natriuretic peptide receptors
(NPR) A and B. NPR-A and NPR-B have a guanyiyl cyclase intracellular domain that
catalyses the formation of cyciic guanosine monophosphate (cGMP) second messenger
from guanosine triphosphate (GTP). Targets of cGMP include cGMP-dependent protein
9kinases and cGMP-gated ion channels. 16 ANP and BNP have higher affinity for NPR
A whereas CNP associates preferentially with NPR-B “r.
1.1.3.2.2.2 Biological actions
Natriuretic peptides have an important influence on the cardiovascular homeostasis.
More specifically, ANP and BNP antagonize the RAS by inhibiting the synthesis and
release of renin and aldosterone. They also increase natriuresis by constriction of
efferent arterioles and dilation of afferent arterioles in the glomeruli which results in an
increased glomerular filtration rate (GFR), they inhibit the effects of endothelin,
vascular SMC proliferation, and SNS. In a general way, the effects of ANP and BNP
oppose those of the RAS. ‘ In contrast to ANP and BNP, CNP lias only minimal
natriuretic effects and doesn’t inhibit the RAS. It is an venous and arterial vasodilator
which can inhibit endothelin and SMC proliferation. 17,18
1.1.3.2.2.2 Metabolism
Metabolism of natnuretic peptides include enzymatic degradation by neutral
metalloendopeptidase (MME) and receptor-mediated clearance via NPR-C. In effect,
NPR-C is similar to NPR-A and NPR-B, but lacks the guanylate cyclase activity due to
a truncated intracellular domain. 16
1.1.3.3 Vasoactive substances
Regulation of blood flow is also achieved by locally acting vasoactive compounds that
control the contractile state in a paracrine or autocrine fashion. Some of the vasoactïve
substances have a constrictor action (endothelins, Ang II, eicosanoids) and some of them
exert a dilator effect (nitric oxide, ldnins, eicosanoids). The balance of vasoconstrictors
and vasodilators will determine the contraction state of the vessel. A detafled
description of the effects of Ang II on the vasculature can be found in section 1.1.3.2.1.
1.1.3.3.1 Endothelin
The endothelium responds to mechanical stress and to humoral stimulation by producing
endothelin 1 (ET-1). Humoral factors such as Ang II, vasopressin and catecholamines
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can also trigger the release of ET-1 by endothelial ceils. The endothelial ceils first
produce a precursor, preproendothelin, which is processed to a 21 amino acid
bioiogically active peptide by a series of cleavage reactions occurring inside or outside
the endothelial ceils. Upon release by endothelial ceils, ET-1 binds to ET1A and ET1B
receptors at the surface of underlying SMC. Endothelin receptors are members of the 7
transmembrane domain family of receptors coupled to G proteins and signal through
PLC, PLD, PLA2, and intracellular calcium modulation. Activation of the MAPK is
involved in mediating the effect of ET-1 on cellular growth. 19
ET-1 induces vasoconstriction and stimulates SMC proliferation in the vasculature. The
vasculature of lddneys is especially sensitive to the vasoconstrictor effects of ET-1,
which resuits is a decrease in sodium excretion and water retention. ET1 can also
indirectly induce vasodilatation through ET1B receptor via the release of NO. In the
heart, ETY increases contractility and stimulates ANP production and release. It has
growth promoting effect on myocytes and cardiac fibroblasts, mediates collagen
production leading to fibrosis and impaired myocardial relaxation. 20
1.1.3.3.2 Nitric oxïde
Nitric oxide is a small lipophilic molecule that exerts its function by diffusing to nearby
cells. 21 is produced from the precursor L-arginine in a reaction catalyzed by nitnc
oxide synthase (NOS). 22 NOS exists in 3 different isoforms that are differentially
expressed throughout the cardiovascular system and the kidney. 22 The constitutive
forms of NOS (eNOS and nNOS) are aiways expressed and activated upon binding of
calcium and calmodulin. In contrast, iNOS is expressed upon stimulation by
proinflammatory signais and act in a calcium-independent fashion. 23 In the cell, iNOS
and nNOS isoforms are soluble whereas eNOS is membrane bound. 23 Table I
summarizes the sites of expression, the regulation of expression, the subcellular
localization and the requirements for the activation of the different isoforms of NOS.
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Table I Properties of the different isoforms of NOS
Isoform Sites of expression Regulation of Subcellular Activation
expression localization
eNOS Vascular endothelium, cardiomyocytes 22 Constitutive Membrane Ca2+
bound dependent
iNOS Endothelium, hepatocytes, monocytes, Induced by Soluble Ca2+
mast ceils, macrophages and smooth proinflammatory independent
muscle cells 23 signals
nNOS Nerve terminals, vascular smooth muscle Constitutive Soluble Ca2+
celis, cardiomyocytes, macula densa celis dependent
and collecting duct. 22
NO has a wide spectrum of biological actions throughout the body. In the
cardiovascular system, NO is involved in the maintenance of vascular tone, in cardiac
contractility, and in vascular remodeling. 22 By diffusing to nearby platelets in the
lumen of the blood vessels, NO inhibits platelet aggregation and adhesion 21 In the
lddney, NO contributes to water and sodium homeostasis, hemodynamics and renin
secretion. 24 NO also acts as a neurotransmitter in the central and peripheral nervous
systems, and participates in immune responses. 25
NO exerts its functions via cGMP-dependent and cGMP-independent pathways. 25 It
acts as a paracrine signal and an intracellular messenger. 26 The short half life of NO
limits its capacity to spread and restricts its actions to cells in close proximity. 21
Activation of eNOS and nNOS by transient intracellular calcium increases promotes the
formation of NO at relatively low concentrations. 25 Most of the effects of eNOS and
nNOS derived NO are mediated through binding to the soluble guanylyl cyclase (S
GC).27 Binding of NO to S-CG leads to an increase in cyclic guanosine monophosphate
(cGMP) levels. 27 Subsequently, cGMP activates downstream effectors including the
activation of cGMP-gated ion channels, cGMP-dependent protein kinases (PKG), and
cGMP- regulated phosphodïesterase (PDE). 27 In contrast, induction of iNOS in the
context of a immune response leads to the production of high levels of NO over a long
period of time 25 In this situation, NO exerts pro-apoptotic effects by releasing the
cytochrome c from the mitochondria, by increasing p53 expression, and by regulating
the expression of apoptosis associated proteins. 25
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It is interesting to note that nNOS and eNOS are both involved in the regulation of the
vascular tone. In knock out mice for the gene encoding nNOS, no changes in vascular
tone was observed. 22 In contrast, in the knock out mice lacking the eNOS gene, the BP
increase was accompanied by an increase in peripheral resistance. 22 From these data, it
was proposed that eNOS might play a role in the regulation of vascular tone under basal
conditions, whereas nNOS would be involved in adjusting the vessel contractility in
response to specific modifications of its environment. 22 It was shown that nNOS
activity is regulated at the transiational level in response to hypoxia leading to changes
in vesse! contractility. 26
1.1.3.3.1 Kinins
Kinin peptides are formed from the precursor ldnininogen. The glycoprotein enzyme
kallikrein is responsible for the formation of bradyldnin and kallidin in plasma and
tissue, respectively. Kinins exert their effects through the kinin receptors Bi and B2.
The B2 receptor, a G-protein coupled receptor mediates most of the known biological
actions of ldnins. Kinins are converted to metabolically inactive peptides by the action
of kininases. 28
Kinins are known to produce vasodilatation in vessels of the heart, lddney, intestines,
skeletal muscles and liver. 2$ Effect of ldnins on the renal vasculature is believed to
promote natriuresis and diuresis. 29 Other functions of ldnins include inflammatory
process and stimulation of pain receptors. 2$
1.1.3.3.2 Eicosanoids
Eicosanoids are 20-carbon unsaturated fatty acids synthesized in response to a
mechanical trauma, cytokines, growth factors or bradykinin. 30 Because eicosanoids are
rapidly metabolized, they act locally on neighbouring cells. Biosynthesis of eicosanoids
is initiated with the release of arachidonic acid (AA) from membrane phospholipids by
PLA2 or from DG by PLC pathway. AA is further oxidized by 1) the cyclooxygenase
(COX) pathway to produce prostaglandins (PGs) and thromboxanes (TX5), 2) the
lipoxygenase pathway producing leukotnenes (LT) and 3) the P-450 epoxygenase
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pathway resulting in the formation of epoxyeicosatrienoic acids (EETs). Eicosanoids
exert their effects by binding G-protein linked receptors in an autocrine or paracrine
fashion. 31
Eicosanoids are involved in a large array of biological functions including immunity,
vascular and renal functions. Products of the COX pathway can lead either to
vasodilatation of resistance vessels and diminution of SNS activity by a decrease in
release of norepinephrine from sympathetic nerves (PGI2, PGE2) or to stimulation of
VSM cells contraction and facilitation of sympathetic activity (TXA2, PGF2). 32
Through their effects on renai vasculature, proastaglandin and thromboxanes also affect
salt and water excretion. 32 PGI2, PGE2 also increase renin release in the kidney and
inhibit platelet aggregation. In contrast TXA2 is a potent platelet aggregator. 31
Leukotrienes are synthesized mostly by mast celis, eosinophils, neutrophils and
macrophages. The effects of LTC4, LTD4, LTE4 leukotrienes include vasoconstriction
and increased vascular permeability and LTB4 act as a chemo attractant Major
cytochrome P450-derived eicosanoids include the vasodilator 5,6-epoxyeicosatrienoic
acid (5,6-EET) and the vasoconstrictor 20-hydroxyeicosatetraenoic acid (20-HETE). In
the preglomerular microvasculature, vasoconstriction by 20-HETE decreases GFR and
consequently promotes sait and water reabsorption. 32
1.2 HYPERTENSION
1.2.1 Definition and classifications
A disruption in the homeostasis of the systems regulating blood pressure resuits in a
condition known as hypertension. According to the recommendations established by the
World Health Organization, blood pressure (SBP/DBP in mmHg) can be classified in
the following categories: optimal (<120/80 mmHg), normal (<130/85 mmHg), normal
high (130- 139185-89mmHg), hypertension grade 1 (140-159/90/99 mmHg),
hypertension grade 2 (160-179/100-109 mmHg) and hypertension grade 3 ( 180/1 10
mmHg)
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For 5% of the hypertensive patients, high blood pressure is explained by an underlying
renal or endocrine abnormality. This type of hypertension for which the physiological
cause is known is called secondary hypertension. The remaining 95% of hypertensive
patients suffer from primary or essential hypertension. The pathological process leading
to the development of this type of hypertension remains unknown.
1.2.2 Sequelae
Hypertension is often referred to as the ‘suent killer’ because it is asymptomatic and
painless until complications develop. However, with time, hypertension is associated
with an increased risk of cardiovascular or renal complication (Table II). Oxidative
stress and endothelial dysfunction, atherosclerosis and remodeling of the heart and
vessels are at the basis of a sequelae to hypertension including coronary artery diseases,
renal damage, angina pectoris, myocardial infarction, stroke and congestive heart failure
(Figure 1).
Table II Risk of cardiovascular or renal event in hypertensive subjects
Cardiovascular or renal disease Relative risk
Men Women
2.0 2.2
3.8 2.6
4.0 3.0
3.1 -
Coronary artery disease*
Stroke*
Cardiac failure*
End stage renal disease**
The relative risk refers to the ratio of incidence rate of cardiovascular events/renal disease among
hypertensive subjects to the incidence rate cardiovascular events/renal disease among normotensives
subjects. Adjusted for age. * Adapted from Kannel, W.B. ; ** Adapted from Klag, M.J.
(hypertension stage 1 patients only).
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Figure 1- The sequelae of hypertenion. See text for detailed explanation.
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1.2.2.1 Oxidative stress and endothelial dysfunction
Reactive oxygen species (ROS) are a family of molecules including free radicals
(molecules that possess unpaired electrons) and other molecules that have an oxidizing
effect. 38 They are part of normal cellular processes such as metabolic events, or growth
factors and cytokines signaling. Under normal physiological conditions, scavenging
mechanisms protect against the toxic effects of excess ROS. The rate of oxidant
formation is balanced by the rate of their elimination. 40 Oxidative stress refers to the
situation where there is an overproduction of ROS that cannot be buffered by
scavenging mechanisms.
Several evidences are in favor of a role of oxidative stress in the development of
hypertension. Correction of oxidative stress lowers BP whereas creation of oxidative
stress raises BP in most animal models of hypertension. 41 Xanthine oxidase,
NADHINADPH oxidase and uncoupled eNOS lias been extensively studied as sources
of ROS in pathological situations. It is noteworthy that Ang II induced hypertension
in rats is accompanied by an increase in expression and activity of NADHINADPH
oxidase. 41 Mechanical stress on the vascular waII can also trigger increases in
NADHINADPH oxidase. 38 As a resuit of increased oxidative stress, the endothelium
dependent vascular relaxation is impaired, a condition known as endothelial
dysfunction. 40 the consequence, at least in part, of a diminished bioavailability of
NO. 42 The reduction in NO-mediated relaxation could be explained by a decreased
synthesis, increased breakdown or interaction and inactivation of NO by other
endothelium derived substances. u For example, ROS react with NO which resuits in
the production of peroxinitrite, a cytotoxic oxidant that has poor relaxing properties on
the vessels. 42
1.2.2.2 Atherosclerosis
Atherosclerosis is a chronic immune-inflammatory disease leading to the progressive
accumulation of plaques wïthin the arterial wall. Several epidemiological studies
have revealed that hypertension is associated with an increased frequency of
complications due to atherosclerosis.
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According to the response-to-injury hypothesis, elevated blood pressure would result in
sustained endothelial damage which would be responsiNe for initiating the formation of
a plaque. Regions of curvature and in close proximity to brandi sites in the large
arteries are especially susceptible to plaque formation. 46 early stages of
atherosclerosis, several elements are required for the plaque to form: 1) increased
permeability of the endothelium facilitates the migration of oxidized low density
lipoproteins (LDL) through the endothelium into the underlying extracellular matrix, 2)
oxidized LDL stimulate blood monocytes to migrate towards the endothelium, 3)
following their adhesion to the activated endothelium, the monocytes migrate across the
endothelium to reach the intima. In the intima, the majority of the monocytes
differentiates in macrophages, and starts intemalizing lipids to become foam cells. As
the plaque progresses, the foam celis aggregate and a core of lipids and necrotic debris is
formed. ‘ A fibrous cap composed of extracellular matrix components and recruited
SMC cover the necrotic core. 46
Atherosclerotic plaques built up over the years and as they grow in size, they can
interfere with blood flow partially or completely. In this advanced state of the disease,
calcification and increased degradation of the extracellular matrix by matrix
metalloproteinases predispose to plaque rupture. Once the plaque is released from the
arterial wall, k produces a thrombus that can travel in the circulation and eventually
block blood flow in an organ different from the site of plaque formation.
1.2.2.3 Vascular remodeling
Essential hypertension has been associated with an increase in peripheral resistance in
animal models and human. 40 The resistance vessels responsible for this increased
peripheral resistance are the small arteries and arterioles. ‘ The vascular resistance cf a
blood vessel is function of its structural properties (media: lumen ratio and media
thickness) and its active properties (force per cross sectional area). 48 The increased
peripheral resistance observed in hypertension is explained by: 1) vascular remodeling
18
of the vessels, which affects their structural properties, and 2) modifications of the
active properties of the vessel and hence, of the vascular tone. 40
During the development of hypertension, inward hypertrophic remodeling and inward
eutrophic remodeling have been observed in small arteries. Inward hypertrophy is
characterized by a decrease in the lumen diameter accompanied by an increase in the
cross sectional area of the vessel.48 In eutrophic remodeling the lumen diameter also
decreases but there is no change in the cross sectional area. 48 Therefore, eutrophic and
hypertrophic remodeling lead to a reduced lumen diameter. However, the increase in
wall thickness is only present in hypertrophic remodeling. In contrast, eutrophic
remodeling is a rearrangement of the same material around a smaller lumen. In
hypertension, a process called rarefaction also contributes to the increase in vascular
resistance. Rarefaction refers to a decrease in the number of parallel-connected vessels
and is observed in arterioles. 50
Vascular remodeling of resistance vessels is the consequence of humoral factors,
oxidative stress and mechanical factors. 40 It involves cell growth, cell death by
apoptosis, celi migration and modifications of the extracellular matrix. 51 Vasoactive
agents (Ang II, ET-1, catecholamine, vasopressin), growth factors and cytokines
mediate vascular remodeling via activation of the MAP kinases. 40 The increase in wall
stress, that results from high BP indLtces the stimulation of integrins, recruitment of the
focal adhesion kinase (FAK), and remodeling processes in the vasculature through MAP
kinase signaling. 48 Reactive oxygen species also contribute to vascular remodeling by
stimulating growth of the vascular smooth muscle cells and accumulation of ECM. 40
1.2.2.4 Cardiac remodeling
In situations where the work load is increased, the heart responds by a compensatory
increase in mass, or hypertrophy. Dunng exercise, a repeated but episodic mechanical
stress is imposed to the heart. In this case, the increase in cardiac mass is explained by
the homogenous remodeling of cardiomyocytes and non-cardiomycocytes. In contrast
to exercise, hypertension exerts a constant mechanical and non-mechanical stress on the
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heart. An increase in left ventricular hypertrophy (LVH) is accompanïed by
proliferation of fibroblasts, accumulation of extracellular matrix (ECM) components and
loss of cardiomyocytes by apoptosis or necrosis. Pathologie remodeling of the heart
may also lead to dilated cardiomyopathy, a condition characterized by a decrease in wall
thickness, increase in volume of the heart chambers and !oss of contractility. It is a
consequence of increased blood volume in the heart and cardiomyocyte death. In
hypertrophie cardiomyopathy, sarcomeres are added in parallel, leading to a thickening
of the cardiomyocytes. In contrast, dilated cardiomyopathy presents a lengthening of
the cardiomyocytes due to addition of new sarcomeres in series. 52
Mechanical and non-hemodynamic factors are the initiators of molecular events leading
to a complex reorganization of the cardiac tissue. At the surface of the ce!! membranes,
integrins act as mechanoreceptors that can detect changes in the work load of the heart.
When submitted to mechanica! force, the interaction between ECM components and
integrins triggers intracel!ular signalling via the activation of the focal adhesion kinase
(FAK). Among the mechanisms leading to the build-up of fibrosis in the
myocardium, a disregulation of the MMP-1 was shown to be involved. MMP1 is the
metalloproteinase responsible for degrading co!lagen type I, one of the predominant
ECM component observed in fibrosis. Activation of G-protein coupled receptors by
Ang II, ET-1, and activators of the adrenergic receptors, is also known to mediate the
different manifestations of pathologica! hypertrophy. 52
1.2.2.5 Coronary artery disease
The coronary arteries are the vessels that distribute oxygenated b!ood to the heart.
Myocardial ischemia refers to the !ack of oxygenation of the myocardium tissue
resulting from a partial or complete obstruction of the coronary arteries. Hypertension
can facilitate partial obstruction by an atherosclerotic plaque growing in the coronary
arteries combined to an increased metabo!ic demand from thickening of the ventricular
wall in LVH. The combination of plaque formation in the coronary arteries and
increased metabo!ic demand due to LVH results in a b!ood flow to the heart that is flot
sufficient to meet the organ requirements, a condition called coronary heart disease
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(CHD). Chest pain resulting from partial blockage of the arteries in CI-ID is known as
angina pectoris and is usually triggered by physical exertion or emotional stress.
Altematively, the blood supply to heart can be interrupted completely by a thrombus
originating from a plaque rupture. Complete privation of oxygen to heart tissue is
known as myocardial infarction or heart attack. In this case, part of heart muscle will
die from ischemia. The extend of the damage will depend on the proportion of
myocardium that suffers from the lack of oxygen.
1.2.2.6 Congestive heart failure
Congestive heart failure (CHF) refers to a condition in which the heart cannot supply
enough blood to meet the metabolic requirements of the body, due to a progressive
weakening of the pump function of the organ. LVH or loss of myocytes due to past
events CHD or MI are important risk factors for the development of CHF. 56 In addition
to an increase in LVH, remodeling of the heart is accompanied fibrosis. One of the
consequence of the accumulation of ECM is a decreased compliance of the left ventricle
resulting in diastolic dysfunction. To maintain the cardiac output and fuI the left
ventricle to normal levels, the heart compensates the diastolic dysfunction by increasing
the left atrial pressure. Pulmonary oedema can occur if the elevated atrial pressure is
transmitted to the pulmonary circulation. In advanced states of CHF, the condition
progresses to a state of uncompensated CHF resulting in a lowenng of the CO that will
eventually lead to pump failure. 58
1.2.2.7 Stroke and cerebral aneurysms
Stroke is the term used to define the vascular events leading to cerebral ischemia.
Several studïes came to the conclusion that hypertension is the most important
modifiable risk factor for stroke. In addition, active treatment of hypertension can
reduce the occurrence of stroke by 25 to 45 %. Damage to the brain linked to
hypertension can occur via several mechanisms. In large vessels, cerebral ischemia can
resuit from partial or total blockage of a cerebral artery by an atherosclerotic plaque or
from the interruption of the blood flow by a thrombus. Another type of stroke occurs
from cerebral hemorrhage. The latter can be the result of an aneurysm, which us a blood
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filled sac forming in the wal! of an artery due to increased pressure on a thrombus or
from bursting of an artery. Because the sma!! diameter penetrating end arteries that
supp!y cerebrai tissue arise directly from main arterial trunk, these are especia!ly
vuinerable to the effect of high blood pressure.
1.2.2.7 Renal damage
As a resuit of hypertension, glycoproteins and collagen matrix form a homogeneous
deposit on the wall of the renal vessels accompanied by atrophy of smooth muscle ceils
and irregular thickening of the basement membrane. Preglomerular arterioles also
undergo hypertrophic and hyperpiasic remodelling of the smooth muscle cells. At the
molecular level, these modifications of the renal microvasculature are known to involve
changes in cell cycle and activation of genes encoding proteins relating to growth and
secretion of matrix. Deposition of fibrin and fibrinogen is also observed. A graduai
obstruction of the biood flow to the giomeruli is associated with a decrease in function
and subsequent atrophy due to the resulting ischemia. Altematively, the kidney can
suffer direct damage from an increase in blood pressure entering the glomeruli due to
the incapacity of preglomerular vesse! to adjust diameter in responses to changes in
blood pressure. These mechanisms lead to glomeruiosclerosis and eventually renal
failure.
In larger arteries, lesions attributable to atheromatous plaque obstruction and smooth
muscle hyperplasia and fibrosis can lead to renai artery stenosis, which is a complete or
partial narrowing of the artery. If occurring unilaterally, renal arterial stenosis will lead
to secondary hypertension.
1.2.3 Epidemiology and burden
Statistics indicate that hypertension, obesity, physical inactivity, and tobacco smoking
are among the modifiable risk factors of developing a cardiovascular disease. 80.2% of
Canadian adults aged between 20 and 59 years have at least one of these risk factors. 60
High blood pressure alone affects 21.1% of the Canadian population according to the
198$-1994 evaluation of the Canadian Heart Health $urvey (CifiIS). 61
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The biennial publication of the Heart and Stroke Foundation of Canada ranks
cardiovascular diseases as the leading cause of death in Canada, responsible for 74 626
deaths in 2002 only. 62 In addition to the high mortality associated with cardiovascular
diseases, Health Canada classifies cardiovascular diseases as the most costly contributor
to both direct and indirect health costs, accounting for 11.6 % of total illness costs in
Canada. In 1998, the cost rising from cardiovascular disease was evaluated at 18.5
billion dollars, 6.8 billion in direct cost related to hospitalisation, prescription drug
consumption and physician care expenditure and 11.7 billion dollars in indirect cost
explained by disability and mortality. 6
1.2.4 Ireatment
When it cornes to treating hypertension, modification to the lifestyle and
pharmacological treatments are often needed to reach therapeutic BP levels. Lifestyle
modifications can reduce SBP by 4.6- 11.4 mmHg and the diastolic pressure by 2.5 - 7.5
mrnHg. 63 Changes recommended include weight loss, diminution of alcohol and salt
consumption and regular exercise. 64 In cases where BP is higher than stage I
hypertension, various classes of drugs can be used alone or in combination to reach
target values of BP. The major classes of agents available to fight hypertension are the
diuretics that act by depleting body sodium, the sympathoplegic agents that act on the
SNS, the direct vasodilators that relax smooth muscle celis and the molecules that
prevent the actions of the RAS such as the ACE inhibitors and the angiotensin receptor
blockers. 65 Reduction of the blood pressure below 140/90 mmHg is achieved in only
13% of the patients suffering from hypertension 61 leaving room for improvement in
awareness and efficiency of treatment.
1.3 GENETICS 0F HYPERTENSION
Primary hypertension can be sub-divided into monogenic and essential hypertension.
Monogenic hypertension represents 5% of alI cases of primary hypertension. It is
explained by a single gene defect inherited following a Mendelian transmission. The
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remaining 95% of hypertension cases are classified as essential hypertension and are
under a polygenic influence with an environmental component. The search for genes
responsible for Mendelian forms of hypertension has been a successfui one, but the
genes invoived in essentiai hypertension remain unknown.
1.3.1 Monogenic hypertension
Mendelian forms of hypertension include Liddie’s syndrome, glucocorticoid remediable
aidosteronism (GRA), apparent mineraiocorticoid excess (AME), and
pseudohypoaldosteronism type II (PHAII). Ail these forms of hypertension affect
homeostasis of sait and water reabsorption. Even though Mendelian forms of
hypertension are more rare and severe than essential hypertension, there was a
tremendous effort to better understand their etiology in the hope that it wouid lead to
dues about the pathophysiology of essential hypertension.
1.3.1.1 Glucocorticoid Remediable Aldosteronism
Normaily, cortisol is synthesized in the zona fasciculata of adrenai cortex whereas
aldosterone is synthesized in the zona giomerulosa. Ïïf3hydroxylase encoded by the
gene CYP11B1 is invoived in the synthesis of cortisoi and the aldosterone synthase
encoded by the gene CYP]]B2 is part of the biosynthetic pathway leading to aldosterone
production. CYPJJBJ and CYP]]B2 are both located on human chromosome (chr) 8.
Both genes have 9 exons sharing 95% DNA simiiarity and $ introns simiiar to 90%. 66
The major difference between CYPJJBJ and CYPJ]B2 resides in the 5’flanking region.
CYPJJBJ expression is regulated by adrenocorticotropic hormone (ACTH) and
CYP]1B2 is reguiated by angiotensin II.
In GRA, an autosomai dominant form of hypertension, there is an increased and ectopic
synthesis of aldosterone. 67 was shown that in families suffering from GRA, there is a
chromosomai rearrangement resulting from unequal meiotic cross over between
CYFJ1B1 and CYP]]B2 leading to an additional copy of a chimeric gene made of the
S’flanking sequence and first few exons of CYPJJBJ and of the 3’exons of CYP]]B2.
68,69 The resuk is that the gene aidosterone synthase is placed under the regulatory
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control of ACTH. The rate of cortisol to aldosterone secretion is normally 1000:1. 70
Under the control of ACTH aldosterone is produced in excessive quantities therefore
leading to sait retention, volume expansion and hypertension.
1.3.1.2 Apparent Mineralocorticoid Excess
Mineralocorticoid receptors have similar affinity for mineralocorticoid aldosterone and
glucocorticoid cortisol. It was proposed that specificity of aldosterone its receptor in
target tissues is achieved by tissue specific expression of 11 f3-hydroxysteroid
dehydrogenase (11f3HSD) which converts cortisol to cortisone, an anaiog that has no
affinity for the mineralocorticoid receptor. 71 Therefore, in the distal tubule, 1 1I3HSD
acts as a protector of the mineralocortïcoid receptor by preventing high leveis of cortisoi
to occupy the aidosterone receptor. 72
AME is an autosomal recessive form of hypertension. It is caused by stimulation of the
mineralocorticoid receptor despite low levels of aldosterone. Mutations in the lddney
isoform of 11f3HSD that affect enzyme activity or pre m-RNA spiicing have been
identified in AME patients. A deficiency of 113HSD in the lddney impairs the
conversion of cortisol to cortisone, thereby leaving the mineralocorticoid receptor
unprotected from high levels of cortisol. 72 The activation of the aldosterone receptor
by cortisol leads to hypertension through sodium and water retention.
1.3.1.3 Liddle’s syndrome
The amiloride-sensitive epithelial sodium channel (ENaC) is expressed in the distal
portion of kidney tubules and is regulated by aldosterone. This channel is made up of
three subunits: Œ, E3, and ‘y. Reabsorption of sodium through ENaC is an important
determinant of BP homeostasis. 67
Liddle is characterized by early onset severe hypertension. Early linkage studies have
shown association between f3ENaC locus on human chr. 16 and Liddle’s Syndrome.
Further analysis of ENaC gene have revealed mutations in the f3 subunit gene 75,76 and in
the ‘y subunit gene “. Ail mutations identified consist in a premature stop codon or
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frameshift mutation in the carboxy terminal domain of the protein resulting in the
removal of the normal carboxy terminal. Subsequently, it was shown that
truncation or frameshift of the carboxy terminal domain does flot affect the biophysical
properties of the channel but causes an increase in the number of receptors present in the
plasma membrane. 78 Nedd4 (neuronal precursor celi expressed developmentally
downregulated) is a ubiquitin-protein ligase that binds to afryENaC PY (xPPxY) motif
located in the COOH terminus of the channel. Upon ENaC/Nedd4 interaction, the
channel is ubiquitinated and targeted for degradation by lysosomes. ‘ The loss of
Nedd4 binding sites in Lidddle’s syndrome may resuit in impaired degradation of the
channel and hence, increased channel activity would result in abnormal renal
reabsorption of sodium and water, and explains hypertension.
1.3.1.4 Pseudohypoaldosteronïsm type II
Pseudohypoaldosteronism type II (PHAII), or Gordon’s syndrome, is an autosomal
dominant form of hypertension. ° In PHAII, hypertension is accompanied by
hyperkalemia, hyperchioremic metabolic acidosis, and normal to high levels of
aldosterone. 72 Genomic wide linkage search of families affected with PHAII have
revealed strong linkage on regions of chr. 1, 12 and 17. 72 Subsequently, identification
of two of the genes responsible for PHA11 lead to the discovery of a novel family of
serine/threonine kinases, the WNK.
The WNK (with no lysine kinases) are recognized by the lack of a key lysine residue in
the catalytic domain. 82 In the epithelium of the distal nephron, WNK4 is necessary for
the coordination of the transcellular and paracellular flux to achieve NaC1 and K+
homeostasis. This function is accomplished by: 1) inhibition of the NCCT (NaCÏ co
transporter) by preventing its insertion into the membrane, 2) induction of clathrin
dependent reduction of renal outer medullary potassium channel (ROMK) expression at
celi surface, and 3) regulation of paracellular permeability to Cl- by phosphorylation of
claudin proteins in the tightjuctions. 80 In the kidney, WNK1 expression is restricted to
the cytoplasm of distal epithelial cells.83 Its function is to prevent WNK4-induced
inhibition of NCCT. 80 The mechanism behind the inhibitory effect of WNK1 on
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WNK4 is flot fully understood, but it may involve a direct interaction between the two
kinases.80
Mutation in genes encoding WNK1 (on human chr.12) and WNK4 (on human chr.17)
are responsible for PHAII. In the gene coding for WNK4, missense mutations
clustered to a highly conserved sequence 20-25 amino acids downstream of the coiled
cou domains of the enzyme have been identified. The mutated WNK4 protein looses
the ability to retain NCCT in the cytoplasm leading to increased expression of NCCT on
the celi surface and excessive Na+ reabsorption. In a gain of function fashion, the
mutations in WNK4 gene increase intemalization of the ROMK channel and the
permeability of tight junctions to Ci- leakage across the epithelium thereby explaining
hyperkalemia associated with PHAII. ° The mutation in the WNKJ gene are large
deletions in the first intron resulting in increased WNK1 expression without altering the
protein structure. 83 The presence of higher leveis of WNK1 in the kidney increases the
inhibitory effect of WKN1 on WNK4, which results in increased amount of NCCT at
the celi surface and increased sodium reabsorption. 80
1.3.2 Essential Hypertension
1.3.2.1 Evidence for a genetic contribution
As described in the previous section, the search for a genetic basis to several forms of
monogenic hypertension has been a successful one. However, Mendelian forms of
hypertension represent merely 5% of ail cases, the remaining being polygenic with an
environmental component. The challenge now resides in identifying genes involved in
essential hypertension.
It has been known for a long time that hypertension aggregates in certain families.
Familial clustering of high BP could be the consequence of genetic inheritance of blood
pressure gene or genes, household environment or a combination of both. Familial
aggregation studies have shown that clustering occurs early in life since siblings living
apart do flot become dissimilar and spouses do flot become more similar as they share
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the same environment. Despite these observations, studies of familial aggregation were
flot sufficient to estimate the relative contribution of genetic and household environment
to hypertension.
In an effort to define more precisely the genetic contribution to BP determination,
adoption and twin studies have been carried out. Adoption studies have demonstrated
that the correlation between parents and their natural children is two times greater than
the correlation between parents and their adoptive chiidren. In addition, natural siblings
have correlation coefficients twice those of adopted chiidren. Together, these
observations are in favour of a genetic contribution to blood pressure. On the other
hand, the conelation coefficient of BP of chuidren within the same household is greater
than that of parents and their chiidren, indicating that the household environment, which
is more closely shared within than between generations, also plays a part in the blood
pressure regulation. Overall, adoption studies have estimated the genetic contribution to
be 30-50%. The household environment would be responsible of 11% of the population
BP variability. Remaining variability would be explained by environmental non-
familial components. 84
In twin studies, the phenotypic resemblance of monozygotic twins, who share 100% of
their genes, is compared to that of dizygotic twins, who share only 50% of their genes.
Twin studies assume that the environment is constant. Results of several twin studies
have shown that BP correlation is very high in monozygotic twins and much lower in
dizygotic twins. However, the heritability was estimated to be higher than with
adoption studies. This may be explained by the fact that monozygotic twins share more
closely their environment than dizygotic twins. 84
It is cunently accepted that hypertension shows familial aggregation, which is explained
by both genetic factors and the household environment. Continuous distribution of
blood pressure results from a genetic component involving several genes, each of which
interacts with the environment and with other genes. Therefore, essential hypertension
is now recognized as a polygenic complex trait. 84
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1.3.2.2 Rat models
1.3.2.2.1 General characteristics
Identification of the genetic bases of essential hypertension is limited by the genetic
heterogeneity of populations and environmental factors. To overcome these probiems,
animal models of hypertension have been deveioped. Working with animal models
allows one to conduct the experiment in a controlled environment following strict
protocols. Such rigor would flot be possible in a clinical setting. Even though the
mouse, the rabbit and the dog have been used as tools to study hypertension, the rat
remains the most widely used model for hypertension studies. Compared to the mouse,
its size is more suitable for physiologicai measurements and it retains the advantages of
the mouse. The rat bas a short life span ailowing studies of the progression of the
disease on a relatively short period of time, it reaches maturity for breeding at early
ages, the gestation period is short and it yields reasonabie litter size.
To ensure the use of homogeneous populations of hypertensive rats, several inbred
strains of rats have been developed. An inbreeding program consists of two steps: 1)
from an outbred stock, animais are selected for the phenotype of interest over several
generation to fix the trait, 2) animaIs are then brother-sister mated for at least 20
generations in order to achieve genetic homogeneity. In the case of several inbred
models of hypertension, a normotensive control was developed simultaneously using
similar inbreeding techniques.
Most of the genetically inbred modeis of hypertension have been developed from
original stocks of Wistar, Sprague-Dawley and Otago rats. Genetïcally hypertensive
rats can be classified in two categories. In some rat models, hypertension appears
spontaneously or without stimulation from the environment. Examples include the
Spontaneously Hypertensive Rat (SHR) and the SHR stroke prone (SHR-SP) 86, the
New Zealand (GH) Rat the Milan Hypertensive Strain (MIlS) and the Lyon
Hypertensive (LH) rat The second type of genetically hypertensive rat was selected
for the development of high blood pressure after an environmental stimulus. The DahI
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Sait-Sensitive (DSS) is an exampie of such a strain 90,91 Normotensive control strains
commonly used are Milan Normotensive (MNS), Wistar Kyoto (WKY), Lewis (Lew),
and Dahi Sait-Resistant (DSR).
It is interesting to note that ail the rat strains iisted above represent polygenic modeis of
hypertension. In effect, the distribution of the blood pressure in a F2 population
originating from a cross between any of these strains and a normotensive control follows
a normal distribution rather than a bimodal distribution. Rat models of hypertension are
therefore likeiy to be realistic modeis of the human disease, since human hypertension is
also a polygenic trait. u
1.3.2.2.2 The Dahi Sait-Sensitive rat
1.3.2.2.2.1 Development of the strain
The Dahl Salt-Sensitive (DSS) model of hypertension was developed after the
observation that consumption of sait resulted in hypertension in some individuals
whereas others remained normotensive despite a high sait diet. The objective was to
separate, by selective inbreeding, strains that would differ in their sensibiiity to sait
consumption. A population of 55 Sprague-Dawley rats constituted the original breeding
stock. Each animai was subjected to a diet containing 7.3% Sodium chloride (NaCi) and
L-triiodothyronine, an agent that accelerates the appearance of salt-induced
hypertension. The rats with the lowest blood pressure values were selected for the
creation of a normotensive strain. In parallel, the rats with the highest blood pressure
values were used to generate the hypertensive strain. Selected rats were brother sister
mated for 3 generations leading to the DSS and the Dahl Salt Resistant (DSR) strain.
The initial characterisation of these strains showed that after 3 weeks of the combined
NaCÏ-triiodothyronine diet, the DSS rat deveiops hypertension whereas DSR strain was
resistant to sait. 91
However, in his original work, Dahl had inbred the rats for the first few generations
only. The strain was then maintained by introducing foreign stocks whule keeping
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selecting for high biood pressure at very generation. In 1985, John Rapp described the
production of inbred rats from the Dahi coiony. He randomiy seÏected 5 breeder pairs
from Dahi DSR colony and 7 breeder pairs from DSS stock. Each pair were brother
sister mated for 20 generations several sub-iines for each strain. Only one inbred strain
of DSR and of DSS rat were retained. 90
1.3.2.2.2.2 Blood pressure
In the DSS, a high sait diet starting from weaning at 3 weeks of age will provoke
fulminant hypertension reaching 200 mmHg and the death of the animai within 16
weeks. By contrast, the DSR rat submitted to the same conditions will remain
normotensive and show a 80% survival rate at the 48 week. If sait feeding is delayed
to 3 months of age, hypertension wiii develop less rapidiy and reach 185 mmHg by 16-
20 weeks of age. It should be noted that even on regular diet containing 1% NaCI, the
DSS rat wiii eventuaiiy deveiop hypertension. On the Iow sait diet (0.4% NaCi), DSS
BP is 15-20 mmHg higher than that of DSR rat. 92
1.3.2.2.2.3 Hemodynamics
Hemodynamic modifications generated by an increase in sait consumption in the DahI
rats are dependent on the sait load and on the amount of time sait was consumed. The
first 4 weeks on a 8% sodium chloride diet resuit in an increase in biood volume and
cardiac output. After 8 weeks on the same diet, blood volume and cardiac output
return to normai values and an increase in peripheral resistance is responsible for
sustaining hypertension. The hemodynamic pattem is different with proionged
consumption of 1% NaCl diet for 46 weeks as it is characterised by an increase in totai
peripherai resistance without the preceding increase in blood voiume and cardiac output
observed on a 8% saIt diet. Studies of the regional blood flow distribution determined
that the increase in total peripherai resistance in the DSS under high sait diet was
uniformly distributed among most vascular beds except for the kidney where it was
more important in comparison to other organs.
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1.3.2.2.2.4 Kidney
Initiai evidences for a role of the lddney in BP response to sait in DSS and DSR rats
were first obtained from iddney transplant experiment. Transpianting a kidney from the
DSS rat to the DSR rat is sufficient for the DSR to develop hypertension. In addition,
the BP increase in the transplanted rat is more important when 2 iddneys are
transplanted than when oniy one iddney is transplanted. Converseiy, the transfer of a
kidney from a DSR to a DSS rat reduces biood pressure significantiy. The mechanism
explaining the different response to sait in DSS iddneys compared to DSR is flot known
to date. But it is thought to invoive a shift in pressure-natriuresis curve since at any
renai perfusion pressure, DSR kidney excrete more urine and sodium than DSS. 92
Renai interstitiai hydrostatic pressure is a major player in adjusting sodium excretion in
responses to changes in sodium load. Despite equivaient BP and GFR, pre-hypertensive
DSS rats show significant decreases in proximai tubuie and whoie iddney natriuretic
response to increases in renai interstitial hydrostatic pressure (RIITP) compared with
DSR rats . These resuits suggest that a reduced sensibiiity of the kidney to changes in
RIIIP couid be one of the defects contributing to sait-sensitivity of DSS rats.
1.3.2.2.2.5 Vasculature: endothelial dysfunction
Measures of contractile responses to acetyichoiine in aortas of Dahi rats revealed a
depressed endotheiium-dependent relaxation of aortas in DSS on a 8%NaC1 diet when
compared to DSS on low sait diet or DSR. 96 Since endothelin causes vasodilatation
through the release of NO, it was hypothesized that a decrease in NO couid be
responsibie for increased peripheral resistance in DSS rats consuming a high sait diet.
96,97 Subsequent studies using a competitive inhibitor of NO synthesis L-MVIIvIA,
provided evidence for the roie of NO in maintaining a constant BP despite an increase in
sait consumption in DSR rats. One of the defects ieading to hypertension in DSS
would invoived reduced NO production, since BP is normaiized by an infusion of L
arginine, a precursor of NO synthesis. ‘ Measures of the ratio of reduced-to-oxidized
giutathione in the whoie blood of DSS and DSR rats on high sait diet showed that an
increase in the ievei of oxidative stress may induce endotheiiai dysfunction in this
modei.
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1.3.2.2.2.6 Vasculature: Na+ICa2+ exchanger
Vascular contractility is determined mostly by intracellular calcium concentration. The
mechanisms regulating intracellular calcium concentration include influx and efflux
from the plasma membrane as well as calcium mobilisation from intracellular storage
sites. The Na/Ca2 exchanger (NCX) is an ATP-dependent pump located at plasma
membrane transporting 3 Na ions in exchange for 1 Ca2 ion. Studies of isolated
afferent renal artenoles and cultured mesangial celis have shown that the baseline the
activity of NCX is upregulated upon PKC activation in DSR but flot in DSS rat. 99-101 It
was proposed that a failure of the DSS to upregulate the pump could lead to excess
accumulation of Ca2 in the cells and contribute to increased vascular resistance,
decreased GFR and high blood pressure in DSS rat
Comparison of the kidney cDNA sequence of the gene coding for Na/Ca2 in DSS and
DSR showed a substitution of an isoleucine for a phenylalanine at position 21$ in the
carboxy terminal membrane spanning domain. 101 In addition, the region coding for the
cytoplasmic domain varies at an alternative splice sites leading to the production of
different isoforms in DSS and DSR. 100 Activation of the pump by PKC results in an
increase in the protein levels at plasma membrane, and the time frame of the increase
was not suggestive of de novo protein synthesis. 100 Since the DSS rat model is know to
be associated with increased oxidative stress, a link between oxidative stress and the
differential regulation in the DSS and DSR was investigated and showed that in the
presence of oxidative stress, celis expressing DSS NCX show significant increase in
intracellular calcium levels when compared to cells expressing DSR NCX. 102 A link
between sequence differences, protein levels and sensibility to oxidative stress remains
to be demonstrated.
1.3.2.2.2.7 Renin angiotensin system
The pathology of DSS implicates the local lddney and cardiac RAS rather than the
circulating RAS. The plasma renin activity and the circulating levels of Ang II are low
in this animal model. 103 In the lddney, renin mRNA is not suppressed in presence of
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dietary sodium 104 and blockade of the AT1R with candesartan has no beneficial effect
on the BP but ameliorates glomerular injury. 105,106 The renoprotective effect of
candesartan is explained by a decrease in Ang II ievels and MAP kinase activities. 106 In
the heart, a combination of ACE inhibitor and ATÏR blocker improves cardiac
remodeling and function without affecting BP. 107 From these evidences, it seems that a
derangement of RAS in DSS affects renal injury and cardiac remodeling independentiy
ofBP.
1.3.2.3 Genetic tools
1.3.2.3.1 Genetic markers
Before undertaking genetic analyses, it is fundamental to develop tools for genotyping
individuals or animais. A genetic marker is defined as a segment of DNA whose
physicai location on a chromosome is known and whose inheritance can be followed.
Eukaryotic DNA contains very short simple sequence repeats spread throughout the
genome. 108 Known as microsatellites, these markers are inherited following a
codominant pattem and variations in the number of repeats between individuals is
frequent, making them extremely useful for genotyping. 109 Microsateilites can be
amplified by polymerase chain reaction using primers specific to their unique flanking
DNA and typed on poiyacrylamide sequencing gels or agarose gel electrophoresis. 109
The informativeness of the microsateliites was shown to be dependent of the length of
the repeats for perfect repeats. 110 An interrupted repeat shows lower informativeness
than expected on the basis of his length.
Early studies evaluated that in the human genome, there are approximately
100 000 CA blocks whose length averages 25 repeats. 108 Subsequently, hybridization
experiments and searches in the Genbank and EMBL sequences revealed that other
microsatellites ranging from mononucleotides to tetranucleotides also exist and exhibit
iength polymorphisms. 111,112 Even though AC is the most frequent repeat with a
frequency of one every 30 kb in human, and one every 21 kb in the rat 113 AG, AAAN,
and A are example of other repeats that were abundantly represented in the human and
34
rat genomes When ail types of microsatellites repeats are combined, one is expected
to encounter on average one microsatellite every 6 kb in the human genome.
1.3.2.3.2 Mapping of genetic markers
To align the genetic makers along the chromosomes and to determine the distance
between them, different mapping techniques are available. These include linkage,
radiation hybnd (RH), and physical mapping.
1.3.2.3.2.1 Linkage mapping
Genetic linkage maps are based on the principle that the frequency of recombination
between two given ioci is dependent on the physical distance that separates them. In a
linkage map, the distances are measured in centiMorgan (cM). Hence, 1 cM is equal to
a 1% chance that a marker at one genetic locus will be separated from a marker at
another locus due to crossing over in a single generation. Although crossovers are
random events, they are flot uniformly distributed along the mammalian genome. 114 In
human, mouse, and rat, the local recombination rate is inftuenced by the OC content of
the sequence, the CpG density, the presence of repetitive elements, and the neutral
mutation rate. 114 As a result of the variable recombination rates along the
chromosomes, the distances obtained from linkage does flot always correlate with the
physical distance. In addition, lïnkage mapping is limited to polymorphic genetic
markers, since the detection of recombination events necessitates informative markers.
1.3.2.3.2.2 Radiation hybrid mapping
Genetic distances in cM are influenced by the recombination rate and restricted to
polymorphic markers. RH mapping techniques were developed to fulfill the emerging
need to map of non-polymorphic markers as well.
The principle behind RH mapping is that the further apart two markers are on a
chromosome (chr.), the less chances they have to be separated by a given dose of X-ray
irradiation. In the construction of a RH map 115 donor cells (human, rat or mouse) are
submitted to x-rays irradiation before being fused to hamster celis by somatic cell
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fusion. The generation of somatic celi hybrids resuits in the recovery of broken
chromosomal fragments by insertion or translocation in the hamster chromosomes.
Every hybrid ceil contains the complete hamster genome, but only a limited number of
chr. segments from the donor celis. A panel of several different clones is then screened
for the presence or absence of the marker one wishes to test. Finally, linkage determines
if the marker of interest is linked to markers of known position on a framework map.
On a RH map, the distances between markers are expressed in centiRays (cR). For
example, a value of 1 cR3000 corresponds to a 1% frequency of breakage between two
loci after exposure to 3000 rads of x-rays. A panels of 106 ratlhamster hybrids is
available commercially. 116
The scientific community has greatly beneficed of this methods of mapping since it
allows the mapping of non-polymorphic markers. Examples of such markers include
expressed sequence tags (ESTs) and sequence tag sites (STS) markers. However, it also
presents some limitations. The resolution of a RH map depends the size of the
fragments after irradiation. It is determined by 1) the radiation dose used, and 2) the
retention frequency of the fragments in the generation of the hybrid celI. It was
observed that there is a wide variation in the retention frequency between and across
chr. 117 Some of the variation is attributable to an effect of the centromere and the
influence of the chr. size. 117 Consequently, the cR distances may flot correlate with the
actual physical distances.
1.3.2.3.2.3 Physical mapping
The publication of the draft sequences for human , mouse 119 and rat 120 genomes has
greatly facilitated the mapping of markers. It is now possible to locate the genetic
markers simply by blasting their sequence on the human, rat or mouse genomic
sequence. The maps obtained provide the physical position of a marker and the
distances are measured in base pairs.
Physical maps are flot based on pattem of inheritance like the linkage maps. Therefore,
they include polymorphic and non-polymorphic markers. Since the distances are given
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in base pairs, the physical map provide the most accurate estimate of the relative
position of the makers and of the distance separating them.
1.3.2.3.3 Quantitative trait locus definition
The following section details a genetic strategy that allows one to identify the genetic
bases to hypertension. It involves the localization of quantitative trait loci (QTLs) on
chr. regions. A QTL is defined as a chr. region that genetically determines a blood
pressure difference between two contrasting strains of rats or between individuals.
1.3.2.3.4 Co-segregation analyses
Co-segregation analysis are tools frequently used to identify loci related to BP
regulation. It is based on the principle that the frequency of recombination between two
given loci is dependent on the physical distance that separates them. As illustrated in
Figure 2a, since the M marker is very close to the blood pressure gene, the A allele will
aiways be inherited with the high blood pressure allele and the B allele will co-segregate
with the low pressure phenotype, since no recombination occurs. On the contrary,
Figure 2b shows that if more physical distance separate the M marker from the blood
pressure gene, recombination will occur at a higher frequency. In this case, some
individuals will inherit the A allele of M marker with the low blood pressure phenotype,
and the B allele of M with the high blood pressure genotype. Co-segregation analyses
provide a statistical assessment of the probability that a marker is inherited in
conjunction with the blood pressure phenotype because the two loci are physically close
or by chance only. 121
Co-segregation analysis can be performed using different samples. In linkage studies,
co-inheritance is evaluated in families. For example, a certain allele for a marker
associated with a blood pressure gene would be shared between siblings of similar
phenotype more frequently than expected by chance. An alternative to linkage is the
association study, known in some cases as a case-control study. In this approach, the
frequency of alleles at a marker loci is compared between a group of hypertensive
individuals (cases) and a group of normotensive individuals (controls). If a marker is
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close to a blood pressure gene, the frequency of alleles at this loci should be
significantly different between cases and controls. This approach generally uses the
general population rather than families or sibpairs.’22
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Duplicated meiotic Meiotic products
parental chromosomes (gametes)
a
MA HBP Gene MA HBP Gene
o o
MA HBP Gene MA HBP Gene
MB LBP Gene MB LBP Gene
MB LBP Gene MB LBP Gene
b
MA HBP Gene MA HBP Gene
o________ o
MA HBP Gene MA LBP Gene
MB LBP Gene MB HBP GeneO;;;;:
MB LBP Gene MB LBP Gene
Figure 2 The prïnciple of linkage Adapted from Rapp, J.P. 121 M refers to genetic marker,
allele A and B, BP gene refers to the gene involved in blood pressure regulation, L for the
BP lowering allele and H for the BP increasing allele. a represents meiotic products of
two loci closely linked where no recombination events occur and b illustrates
the meiotic products after recombination between distant loci. See text for detailed explanation.
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1.3.2.3.4.1 Candidate gene approach
In identifying the genetic basis of essential hypertension, the candidate gene approach is
based on the knowledge conceming biochemical and physiological basis of blood
pressure regulation. In theory, genetic vanants in the sequence of genes coding for
proteins involved in the cardiovascular system could explain some of the variation in the
blood pressure levels between individuals.
In the candidate gene approach, the gene of ïnterest is positioned on the genome and its
DNA sequence identified. Subsequently, the sequence of the gene is searched for the
presence of variations between different individuals or between contrasting strains of
rats. Variants are tested for co-segregation with the biood pressure phenotype using
linkage or association.
Despite the tremendous number of candidate genes involved in the regulation of the
cardiovascular, renai and nervous systems, the candidate approach is limited to
molecules that are already known to be involved in the regulation of blood pressure
(either in normal or pathologicai conditions).
1.3.2.3.4.2 Total genome scan approach
An alternative to the candidate gene approach is the total genome scan. This strategy
presents the advantage of studying a genomic locus for its involvement in blood
pressure regulation, without maidng any assumption on its function. Therefore, it
expands the search for genes beyond the known proteins towards new possibilities.
The genome scan allows one to identify quantitative trait loci, or QTL, which can be
defined as chromosomal locations that genetically determine blood pressure differences
between normotensive and hypertensive individuals or animais. Using polymorphic
anonymous genetic markers, such as microsateilites, equally spread in the genome, the
genome scan assesses which locations co-segregate with the blood pressure phenotype.
Therefore, rather than associating a gene or a variant to the BP phenotype, a genome
scan allows one to identify a region of interest.
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1.3.2.3.5 Congenic strains
Linkage and association studies provide a statistical evaluation of the probability of a
QTL being in a given region of the genome. A more definitive evidence for the
presence of a QTL is obtained by the construction of congenic strains. A congenic
strain can be made by replacing a region from a hypertensive strain (recipient) by the
homologous region coming from a normotensive strain (donor). The blood pressure of
the resulting congenic strain is measured and compared to that of the hypertensive
parent. If the region replaced contains a blood pressure QTL, a significant lowering of
the BP of the congenic strain is expected when compared to the hypertensive parent. In
parallel, the inverse strain can be built. This strain consists in a hypertensive region on a
normotensive background. In the inverse congenic strain, a significant increase in the
BP is expected when compared to that of the normotensive parental strain. 123
Figure 3 illustrates the breeding steps needed for the construction of a congenic strain, a
process requiring 3 to 4 years on average. The construction starts with two parental
strain, a hypertensive strain and a normotensive strain. The parental strains are bred to
yield the first filial generation (Fi). The Fi generation is then backcrossed to the
recipient parent, leading the first backcross generation (Bd). Rats that retained an
allele from the donor parent in the region of interest are identified by PCR amplification
of anonymous genetic markers located in the region of interest. Rats selected are
backcrossed again to the recipient parent. The backcross/selection cycle is repeated
until the BC8 are obtained. At BC8, more than 99% of the donor genome have been
replaced by that of the recipient except for the selected region of study. Finally, brother
sister mating makes the region of interest homozygous for the donor alleles. 123,124
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figure 3 — Construction of a congenic strain. Adapted from Rapp, W et tJ 123
Construction of a congenic strain. The white square represents the selection of the
donor genotype at the genetic marker targeted. See text for detailed explanation.
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What is the mechanism responsible for the replacement of the background genome by
the recipient genome? Fi rats have received one ailele from each parental strain, these
rats are heterozygous at ail loci. According to Mendel’s laws, the loci other than the
region selected have 50% chances of retaining the recipient allele at each backcross.
Therefore, the percentage of the genetic background coming from the recipient strain
increases following each back-cross: 75% at Bd, 87.5% at Bd, 93.8% at BC3 and 50
on until it reaches 99% at BC8. 123,124
In recent years with the constant progress made in the development of new polymorphic
microsatellite markers spread ail over the genome, the traditional protocol for building
congenic strains has evolved towards a more efficient and less time consuming method.
In speed congenics, the most suitable breeders are chosen based on the genotyping of
polymorphic markers spread throughout the genome. The rats that have maintained
recipient alleles at the highest number of loci and that have acquired the donor allele in
the region targeted are selected as the best breeders for generating the next BC
generation. An initial study in the mouse showed that the use of markers distributed
every 25 centiMorgans (cM) combined with the selection of at least 16 best breeders at
every generation aiiows to achieve more than 99% homozygocity in 3 to 4 backcross
generations. 125 Using the speed congenic approach, one can establish a congenic strain
in 15-18 months. Subsequentiy, the same strategy has successfully been applied to the
rat. 125
1.3.2.3.6 Congenic substrains
The original congenic strain allows one to confirm the presence of a QTL in a given
region of interest. However, the size of the region replaced (usually around 20cM) does
flot allow the moiecular analysis of which gene within the intervai may be responsible
for the blood pressure effect. Construction of congenic substrains will allow one to
narrow down the QTL region until it reaches 1-2cM.
In generating congenic substrains, the original congenic strain is bred with the recipient
parental strain. Therefore, the background remains homozygous for alleles coming from
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the recipient parents. In the QTL region, there is the possibility for meiotic
recombination between the congenic and the recipient parental strain. The rats obtained
from this cross are screened at markers flanking the QTL for the presence of a cross
over in the QTL region. Progeny showing recombination are bred to the recipient
parents and in the subsequent generation, rats that have retained the QTL region are
brother-sister mated to achieve homozygocity. Such recombination events allow to
reduce the region of the QTL to gradually smaller regions.
Congenic strains BP
effect
J—I
I—.-..———.—-—
+
+
QTL region
Fïgure 4- Substitution mapping using congenic strains. Adapted ftom
Rapp et. al 123 Black bars represent the regions coming from the donor strain
on a recipient background. + sign designates the strains for which a blood
pressure effect was observed and — sign designate the strains showing no blood
pressure effect. QTL region is designated by a striped line. See text for detailed
explanation.
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Several substrains can be obtained with this method in relatively few generations. The
blood pressure of these strains is measured and substitution mapping (Figure 4) allows
to locate the QTL to a nanow chromosomal region. Some of the strains obtained will
retain the blood pressure effect observed in the original congenic strain whereas others
will show no blood pressure difference with the hypertensive parental strain. The QTL is
located in the region retained by the substrains showing a blood BP but not conserved in
the substrains that lost the BP effect. Detection of crossovers in regions becoming
progressively smaller requires the development of a dense genetic map with
polymorphie markers distributed every 1-2 cM. 123
1.3.2.4 Candidate genes for essential hypertension
In the past, several studies evaluated candidate genes for hypertension using a
combination of several approaches in animal models as well as in various human
populations. Examples of candidates studied include genes coding for proteins involved
in the renin angiotensin system and other molecules whose function might be relevant to
the cardiovascular homeostasis.
1.3.2.4.1 Renin angiotensin system
It has been known for a long time that variations in the level of several components of
the renin-angiotensin system including renin, angiotensinogen, and angiotensin II
correlate with inter-individual variance in blood pressure. 126 Given the well established
role of the RAS in blood pressure regulation and sodium handling, the question arise
whether some variants in one or more components of the RAS could be responsible for
the genetic susceptibility to hypertension in animal models or human.
1.3.2.4.1.1 Angiotensinogen gene
The observation that hypertensive subjects and offspring of hypertensive parents have
higher concentration of plasma AGT compared with normotensive controls 127 was the
rationale that lead to a tremendous amount of studies assessing the role of AGT gene
polymorphisms in genetic predisposition to hypertension. Following the original
publication of a linkage between AGT gene locus and hypertension in hypertensive
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sibships from france and United States, and the identification of two variants M235T
and T174M that were more prevalent in hypertensive subjects 128 studies yielded
conflicting resuits. Linkage detection was reproduced in African Caribbeans 129 but not
in Europeans 130,131 or Australian Anglo-Caucasians 132 families. Furthermore, allelic
ftequency of M235T polymorphism was associated with high blood pressure in some
studies 133-138 but not in others 129,131,132,139-142 Association of T174M variant with
hypertension was not confirmed 131,140 Association studies cannot rule out the
possibility that a locus in close proximity with the disease locus could be responsible for
the blood pressure variations observed. A G to A substitution located 6 residues
upstream of initiation site for transcription and in linkage disequilibrium with M235T
143,144 This variation was shown to affect the promoter basal rate of transcription of the
gene 144 thereby suggesting that the -6A polymorphism could be the causative mutation
explaining the association between M235T and hypertension.
When it cornes to polymorphisms of the AGT gene, hundreds of studies have published
variable results. The different studies have looked for associations in various ethnic
groups using a wide range of experimental designs, which makes it difficuit to draw
general conclusions. A meta-analysis was designed to investigate the association of the
M235T polymorphism of the AGT gene with angiotensinogen levels, systolic and
diastolic BP, hypertension and risk of ischemic heart disease. This meta-analysis
reviewed and averaged the data published in 63 studies with a total of 45 267
participants from 3 different ethnic groups (Asian, black and white). 145 The major
findings of this study confirm that the M235T polymorphism of AGT is associated with
increased levels of plasma angiotensinogen in white, accornpanied by a higher risk of
developing hypertension in white and Asian subjects. The plasma angiotensinogen
levels and the risk of hypertension are lower in homozygotes MM and follow a stepwise
increase in heterozygotes MT and in homozygotes TT. In black subjects, no association
was detected between M235T polymorphisrn and hypertension. Despite the
clarifications brought by this study, one should note that the rneta-analysis rnethodology
presents sorne limitations. These include unmatched cases and controls, lack of
adjustment for confounding factors, and heterogeneity of the selection criteria for cases
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and controls. 145 Ultimately, the quality of the meta-analysis is dependent on the quality
of the studies it combines. 146
The AGT gene has also been studied in animal models. In the rat, there was
cosegregation of the AGT locus on rat chr 19 with pulse pressure in a F2 (SNRXWKY)
population. 147 Aorta of SHR and WKY showed tissue- and age-specific differences in
AGI mRNA. 147 In contrast, in a cross F2 (SHR-SP X WKY), no significant linkage of
the AGT locus to systolic or diastolic pressure were found. 148
1.3.2.4.1.2 Renin gene
Conversion of angiotensinogen to Ang I by renin is the rate limiting step for generation
of the biologically active peptide of the RAS, Angli. Furthermore, transgenic rats
expressing high amount of the mouse renin gene develop fulminant hypertension from 4
weeks of age. 149 For these reasons, the renin gene was a logical candidate for the
genetic basis of hypertension.
In the DSS rat, a 1 .2Kb deletion in intron 1 of the renin gene was shown to be associated
with blood pressure. 150 Various crosses involving the Dahi rat and several contrasting
strains (Lew, IVINS, WKY, DSR, SHR) revealed the existence of 7 alleles for the renin
intron 1 polymorphism. 151 In ah populations, the DSS allele had a blood pressure
raising effect, though the magnitude of the effect varied, indicating an effect of the
genetic background. A restriction fragment length polymorphism (RFLP) in intron 1 of
the renin gene also cosegregated with the blood pressure phenotype in the SHR. 152
Since no differences were observed in the coding, 5’ regulatory sequence or sphice
pattem between DSS and DSR rats, it was suggested that the BP effect observed is
either explained by a locus linked to the renin gene or to regulatory sequences situated
farther from the renin gene. 153
Human association of renin RFLP polymorphisms 154 and hinkage studies of renin
haplotypes on affected sib pairs 155 both failed to implicate the renin gene as a genetic
determinant of human essential hypertension.
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1.3.2.4.1.3 Angiotensïn I converting enzyme gene
The angiotensin I converting enzyme is involved in the conversion of Ang I to the active
peptide Ang II and in the degradation of bradykinin to inactive fragments. 8 Interest in
ACE as a candidate for genetic determination of blood pressure comes from the fact that
despite large inter-individual difference in ACE level, healthy families show significant
intra-familial resemblances in plasma ACE level. 156
Interest in ACE as a candidate gene has allowed the identification of an
insertion/deietion polymorphism of 250 bp in intron 16 of human ACE gene. 157
Association of the IJD polymorphism with plasma ACE levels has been demonstrated.
157 However, studies investigating the implication of the polymorphim in genetic
determination of blood pressure yielded conflicting resuits. In effect, no association was
detected between blood pressure and the IJD genotype in normal subjects 158 or in Dutch
hypertensive subjects 159 In contrast, the TID genotype was associated with sait
sensÏtivity in hypertensive patients 160 and wïth hypertension in men in the Framingham
Heart Study 161 in the Suita study in a Japanese popuiation 162 and in old hypertensive
subjects with severe early onset familial hypertension 163 IID poiymorphism was not
associated with blood pressure in healthy young Caucasian aduits with genetic
predisposition to high or low blood pressure. 159,164 Positive 165 and negative 165 linkage
of genetic markers in linkage disequilibrium with the ACE locus have been reported.
In the rat, a highiy significant iinkage between a bd cioseiy iinked to ACE on
chromosome 10 was reported in a F2 (WKY X SHRSP) population. 166 Fine
substitution mapping using congenic strains excluded the ACE iocus from the QTL. 167
1.3.2.4.1.4 Angiotensin II receptor gene
The angiotensin type 1 receptor mediates most of the known biologicai actions of Ang
II. The receptor is encoded by a 55kb gene consisting of 5 exons and 4 introns 168 which
maps to human chr. 169 In the rat, the 2 sub-types of AT1R, a and b have been
mapped to chr. 17 and 2, respectively 169 Anaiysis of the sequence variations in human
ATJR have revealed that an A to C transversion at position 1166 in 3’ untransiated
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region was more frequent in a hypertensive than in a normotensive group. 170
Association of the Al 166C polymorphism with hypertension was confirmed in other
populations. 171,172 Linkage of the ATJR locus to blood pressure failed to reach
statistical significance in some studies 170 but showed evidence of a suggestive peak in
others. 171 In rat models of hypertension, weak linkage was detected near the locus of
the b subtype of AT1R. 173
1.3.2.4.2 Others
1.3.2.4.2.1 SA gene
Based on the information that blood pressure regulation and renal function are linked,
the SA gene was originally identified from a pool of complementary DNA differentially
expressed between SUR and WKY rats lddneys. 174 In effect, it was observed that the
mRNA for this novel gene was 10 times more abundant in SHR kidneys than in those of
WKY, an increase observed at 28 days of age, preceding blood pressure increase. 174
Subsequently, the site of increased expression SA mRNA in SHR was naffowed to the
lddney proximal tubules, a region well known for its involvement in sodium handling.
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SA gene showed no significant homology to any lmown gene 174 and was mapped to
rat chr. 1 169,176
Following its discovery, the SA gene has motivated a number of studies assessing its
probable role in BP control and in the genetic basis of hypertension. In the rat, a
cosegregation study in an F2 (SUR X WKY) population showed a significant effect of
the genotype at the SA locus on blood pressure. 177 These resuits were reproduced in a
F2 (DSS X Lew) population 178 and in a F2 (SHRSP X WKY) population 176 but not in
a F2 (DSS X WKY) population 178 indicating that the expression of the SA phenotype is
influenced by the genetic background. Initial congenic strains harbouring a segment of
WKY in a SUR background and its reciprocal strain brought further evidence in favour
of a role of the SA gene in the genetic basis of hypertension in the genetically
hypertensive rats. 179 Subsequently, refining of the regions introgressed in chr. 1
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congenics issued from WKY X SHRSP 180 and from Dahi X Lew crosses 181 ruled out
the SA iocus for these specific strains.
Mice and human experiments have yielded conflicting resuits. A SA nuli mice showed
no blood pressure reduction under basal conditions, or under sait loading when
compared to the wild type counterpart. 182 The human homologue of rat SA was cloned
and mapped to human chromosome 16. 183,184 An association study in a Japanese
population was able to associate the rare allele of a Pst I RFLP of the SA gene with a
significant increase in BP. 183 These resuits could flot be confirmed by linkage in
affected sib-pairs 184 or by association 184,185 in French Caucasians. In young aduits
predisposed to hypertension (Caucasian from Scotiand), the SA Pst I RFLP
polymorphism was also excluded as a genetic determinant of blood pressure and
physiological renal parameters using the four corner approach. 186 These discrepancies
suggest that either SA is flot involved in the genetic determination of BP in the White
populations studied, or alternatively, the polymorphism tested is flot in complete linkage
disequilibrium with the causative variants of hypertension. 185
1.3.2.4.2.2 Nitric oxide synthase gene
In human and animal models of hypertension, high blood pressure is associated with a
decrease in NO levels. 187 Linkage studies looldng for association of the endothelial
NOS (NOS3) with hypertension were not positive. 188,189 In the rat, the blood pressure
phenotype did not cosegregate with the NOS] locus in the cross tested but cosegregated
with the NOS2 locus in F2 (SXMNS) and F2 (SXWKY) populations. 190 Markers in
close proximity to NOS3 were not linked to BP phenotype in various F2 populations
involving the DSS rat. 191 Fine mapping of the region surrounding NOS2 locus by the
use of congenic substrains has ruled out NOS2 as a gene involved in the genetic
predisposition of the DSS rat. 167
1.3.2.4.2.3 Epithelial Na channel gene
Mutations in the sodium epithelial channel are responsible for the autosomal dominant
form of hypertension in Liddle syndrome. It was hypothesized that more subtie
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changes in ENaC coding genes that would affect the enzyme activity without causing a
phenotype as severe as the Liddle syndrome might also be involved in polygenic
essential hypertension. In human, coding variants have been identified in the gene
coding for the beta subunit of ENaC. 192 Even if some of the variants could slightly alter
the activity of the corresponding channel, they did not cosegregate with the blood
pressure phenotype. 192 The rat homolog to the human epithelial Na channels was
mapped to rat chr. 1 ([3 and y subunits) and to rat chr. 4 (c subunit). 193 However,
despite linkage of the loci of the [3 and y subunits to the blood pressure phenotype in a
SHR-SP X WKY cross, no biologically meaningful mutations were identified in the
coding sequence comparing the two strains and no difference in expression levels was
noted in kidneys. 194 These data fail to implicate ENaC gene in the genetic
determination of essential hypertension.
1.3.2.4.2.4 WNK kinases genes
Most of the Mendelian forms of hypertension occur rarely and are characterized by early
onset moderate to severe hypertension. In contrast, the graduai increase in BP described
in forms of PHA11 involving WNKJ mutations might be more representative of the slow
and progressive development of essential hypertension with aging. 83 For this reason,
the WNK kinases are especially appealing as candidates for the genetic control of
essential hypertension.
Initially, SNP in intron 10 of WNK4 was showed to be associated with hypertension in a
white American population, but not in an African American population. 195 These
resuits were flot reproduced in an Anglo-Australian 196 or in a white European
population . In the Japanese population, the WNK] SNPs studied did flot show
significant association with hypertension, whereas the genotype at a SNP in intron 14 of
WNK4 did.’98 A family-based association study of extremely hypertensive white
Europeans have showed positive association of a SNP located in close proximity of the
promoter region with hypertension. 199 Finally, a population-based have revealed that
several common variant of WNKJ were associated with mean 24-hour SBP and DBP. 197
This study provided extremely convincing data implicating WNK] locus in essential
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hypertension in the general population. Its impact resides in 1) the use of 24hr
ambulatory BP rather than punctual measures, 2) the association of the genetic
polymorphisms in samples that have flot been selected for the presence or absence of
hypertension. In the study of continuous traits such as blood pressure, such an approach
should be privileged.
1.3.2.4.3 Limitations of linkage and association studies
In general, the numerous studies looking at association between polymorphisms in
candidate genes and hypertension have yielded conflicting results. Some general
conclusions about this approach can be drawn. First, one can expect variable resuits
across different population or strains of rats. Second, a particular attention should be
paid to analyse intermediate phenotypes rather than BP alone. Third, one should
recognize that since BP is flot a dichotomous phenotype, studying association across the
BP range in population-based association studies rather than in case versus controls
might be more appropriate to the continuous distribution of BP in the population.
Furthermore, the variations associated with hypertension in severe cases might not be
relevant to the majority of the hypertensive population which presents a milder
phenotype. Fourth, a given polymorphism can be statistically associated with
hypertension for two reasons: it is possible that the variation studied itself contributes to
the physiological changes resulting in high BP; altematively, it may be a marker for
another variation in close proximity. Molecular studies investigating the effect of
individual variations on the biological function of proteins and on the regulation of
protein levels are necessary to discriminate between these possibilities.
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1.4 RATIONALE AND GENERAL OBJECTIVE
Attention to a possible role of rat chr. 2 in the genetic determination of hypertension
cornes from the observation that the Iocus of the gene coding for the atrial natriuretic
peptide receptor A (Gca) cosegregates with the blood pressure phenotype in F2(DSS X
MNS) and F2(DSS X WKY) population. 200 A second study the region sunounding Gca
gene confirmed the linkage in a region containing several candidate genes including the
gene coding for the Na+,K+-ATPase al isoform and calmodulin-dependent protein
kinase II-delta. In addition, a suggestive peak unique to the F2(DSS X MNS) cross was
detected around the gene coding for the angiotensin receptor 1 b (AT1b). 201 Since
statistical evidence is flot definitive, congenic strains were built in which a segment of
WKY or MNS rat chr. 2 was introgressed within the background of DSS rats. The two
congenic strains showed significant lowering of blood pressure when compared to the
DSS rat. These data established without a doubt the presence of a BP QTL on rat chr 2.
202 However, the length of the region involved in maldng the congenic strain was about
$0 cM and contained several candidate genes.
The aim of the present work was to study the rat chr. 2 region involved in the genetic
control of hypertension. Specific objectives included 1) to determine the number of
QTL in the original $0 cM region, 2) to develop a detailed genetic map of the chr 2
region of interest, 3) to reduce the region of interest for the chr 2 BP QTL and 4) to
assess the possible implication of candidate genes present on chr 2 in genetic
determination of hypertension in the DSS rat model.
CHAPTER 2
METHODS
2.1 GENETIC MAPS
Genetic maps for the chr 2 regions of interest were built by integrating different sources
of information: Ï) a previously published linkage genetic map of rat chr. 2 203, 2) data
obtained by the use of a radiation hybrid panel 3) data available in rat database websites
and genotyping data for existing strains.
Most of the genetic markers used are microsatellites of di-, tri- or tretra-nucleotide
repeats. For regions where the density of markers from existing rat databases was
insufficient, screening of the rat genome and design of new markers was undertaken as
described below. The regions of interest were first identified by blasting informative
markers at the website, http://www.ncbi .nlm.nih .gov/genome/seglRnBlast.html. The
sequence obtained was searched for regions containing microsatellites. From these
regions, new markers were designed for genotyping of rats based on PCR. These new
markers were designated with D2Chm prefixes, where Chm stands for Centre
Hospitalier de l’Université de Montreal (CHIJIVI).
2.2 CONGENIC SUBSTRAINS
Congenic substrains are obtained from meiotic recombination events between an
existing congenic strain or substrain and the hypertensive parental une, DSS. The
strategy for obtaining of congenic substrains is described in section 1.3.2.3.6 (page 42).
Genotyping of the of the genetic makers is verified by amplification by polymerase
chain reaction (PCR) amplification of rat tau DNA followed by electrophoretic
migration on a 4% agarose gel or on a polyacrylamide gel when agarose resolution is
not sufficient. The specific breeding scheme for each of the congenic substrain
presented in this work is available in sections in sections 3.3.2 (page 62), 4.3.2 (page
76), and 5.3.2 (page 94).
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2.2.1 Nomenclature and genetic boundaries of congenic strains
The designation of a congenic strain includes the following information: the recipient
strain (MNS) goes first, followed by a period and the donor strain (S/DSS). After the
dash, the two genetic markers represent the region from the recipient strain that was
replaced by the homologous region coming from the normotensive strain. 204 The
genetic maps used to define the strains the boundaries of the strains are constantly
evolving as new genetic markers are developed. As a resuit, the number of
microsatellite markers available for mapping, and the resolution of mapping of the
congenic strains are aiways improving. For these reasons, nomenclature of the congenic
strains evolves as well. In chapter 3 to 6, more than one designation/abbreviation may
be used for a given congenic strain. In certain cases, different markers are used to
describe the same boundary for a given congenic strain. Table III is a guide to the
nomenclature of the different congenic strains presented in chapters 3 to 6 and to the
genetic markers mentioned to define them.
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Table III Nomenclature and genetic markers defïning the congenic strains
presented in chapters 3-6.
Nomenclature of the congenic strains Genetic markers
full designation Abbreviation SS (1) MM (1) MM (2) SS (2)
S.MNS-Adh/D2Mit6 S.M Prlr D2Mit6 Adh -
S.MNS-D2Mit6/D2Ratl66, S.M1, Prir D2Mit6 D2Ratl66 Nep,
S.MNS-D2Mit6/Nep C2S.M1 D2Mit9
S.MNS-D2Mit6/D2Rat3O3, S.M2, Prir D2Mit6 D2Rat3O3, D2Ratl66
S.MNS-D2Mit6/D2Rat3O2 C2S .M2 D2Mco9,
D2Rat3O2
S.MNS-Nep/D2Mitl4 S.M5 D2Ratl66 Nep D2Mitl4 D2Wox37
S.MNS-Nep/Gca, S.M6, D2Ratl66 Nep Gca, D2MghlO
S.MNS- Mme/D2Ratl3l C2S.M6 D2Ratl3l
DSS.MNS-D2Ratl83/D2Chml 13 C2S.M7 D2Chm33 D2Ratl83 D2Chmll3 D2Chm9O
DSS.MNS-D2Chm25/D2Mitl4 C2S.M8 D2Mco8 D2Chm25 D2Mitl4 D2Wox27
DSS.MNS-D2Chm25/D2Ratl3l C2S.M9 D2Mco8 D2Chm25 D2Ratl3l D2Chm57
DSS.MNS-D2Wox27/Adh C2S.M1O D2Mitl4 D2Wox27 Adh -
DSS.MNS-D2Chm5l/D2Rat34l, C2$.M1 1 D2Chm9O D2Chm5l D2Rat38, D2Chm225
DSS.MNS-D2Chm5 1/D2Rat3$ D2Rat34l
DSS.MNS-D2Chm25/Fgg C2$.M12 D2Mco8 D2Chm25 Fgg Gca
Table III Genetic markers are the markers at the extremity of the MNS region for each congenic strain.
Each strain is defined by two markers homozygous MM (1 and 2) and two markers homozygous SS (1
and 2). Detailed genetic maps for each strain are presented in figure 1 of chapter 3, figure 1 of chapter 4,
figure 1 and 2 of chapter 5 and figure I of chapter 6. Adh Alcohol dehydrogenase, Prtr prolactine
receptor, Nepiliine neutral endopeptidase, Fgg fibrinogen gamma.
2.3 PREPARATION 0F ANIMALS
Male rats were weaned at 21 days of age, maintained on a low sait diet (0.2% NaCÏ,
Harlan Teklad 7034) and then fed a high sait diet (2% NaCI, Harlan Teidad 94217)
starting from 35 days of age until the end of the experiment. Teiemetry probes are
implanted after 3 weeks of the high sait diet with their body weights between 250-320
grams. After the surgery, the rats are allowed at least 10 days for the postoperative
recuperation. The BP measurements lasts until the time of sacrifice. Rats are sacrificed
by decapitation 30 days after the commencement of their BP measurements, i.e. at 14
weeks of age. The organs of interest are removed, cleaned carefully from surrounding
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adventitial connective tissues and fat, blotted to remove excess blood, and prepared for
subsequent experiments.
2.3.1 Radiotelemetry
The radiotelemetry system from Data Science Inc (St. Paul, MN) was used to measure
BP. The telemetry system consist in a probe (surgically implanted in the rat) that sends
data to a receiver through radiotransmission. The data are then processed and forwarded
to a computer by an exchange matrix. The dataquest software stores, processes and
displays the physiological data detected.
The telemetry probe consists in a fluid-filled catheter attached to a body containing the
sensor, the battery and the electronic section for radiotransmission. The catheter of a
telemetry probe is inserted to the descending aorta via the renal artery and secured by a
suture to the blood vessel. The telemetry probe is then fixed to the muscle wall in the
abdominal cavity. (Figure 5a). 205
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2.4 STATISTICAL ANALYSIS
Congenic strains are compared to the DSS rat for each phenotype studied. The ANOVA
is the first step to detect a difference between any of the groups compared. For BP
measures, a variation of the traditional ANOVA, the repeated measures ANOVA, allows
to take into account that for any given animal, BP is measured at several points in time.
In cases where the ANOVA detects no significant difference, it indicates that there is no
significant difference between any of the groups tested and no further analysis is
required. If the ANOVA detects a significant difference it indicates a significant
difference between some of the groups compared. To distinguish which pairs of groups
are different, a Dunnett post hoc companson is perfonned. The Dunnett test allows one
to perform multiple pairwise comparisons to determine which congenic strains are
different from a reference control, the DSS rat. It adjusts thep values for differences in
sample size and multiple comparisons. SYSTAT 9.0 program (SPSS Sci. Chicago, IL) is
used for statistical analysis.
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3.1 ABSTRACT
A region on rat Chromosome (Chr.) 2 of the Dahi sait-sensitive rat (S) was shown
previously to contain a quantitative trait locus (QTL) for biood pressure (BP). This was
achieved first by linkage, followed by the use of congenic strains. A congenic strain,
designated S.MNS-D2Mit6/AdJz, contained a segment of Chr. 2 from the Milan
Normotensive (MNS) rat in the S genetic background. Since the region containing the
QTL was roughly 80 cMs in size, a further reduction is needed towards the positionai or
candidate gene cloning. Cunently, two congenic substrains were made from the original
strain S.IVINS-D2Mit6IAdh. One of these two substrains showed a BP-lowenng effect,
whereas the other substrain did not. Deducing the segment flot shared in the two
substrains, the BP QTL bas to be present in a chromosome region of roughly 5.7 cMs
between the marker D2Rat3O3 and the iocus for the neutroendopeptidase gene (Nep).
Nep is flot inciuded in within the segment. This region does flot seem to contain any
candidate genes well-known for the BP control. Thus the final identification of the QTL
wiii most likely iead to the discovery of a brand new gene for the BP reguiation.
3.2 INTRODUCTION
The mapping of quantitative trait loci (QTL) for biood pressure (BP) using animai
models bas been greatly facilitated by the genetic approach, such as linkage analysis and
the use of congenic strains (Rapp and Deng 1995, Deng 199$, Dominiczak et ai. 2000).
In our previous work, regions on rat Chr.2 were shown to contain QTL, first by iinkage
analysis (Deng and Rapp 1992, Deng et ai. 1994) followed by the use of two congenic
strains (Deng et al. 1997a). In one congenic strain, the chromosome region of interest
from the Dahi sait-sensitive strain (S) was replaced by that of the Milan normotensive
(MNS) rat (Deng et al. 1997a). The length of the region involved in making the
congenic strain was about $0 cMs, because the iinkage evidence suggested (Deng et al.
1994) that one QTL was near the iocus for the Na/KATPas subunit a gene (Atp]a])
and another near the locus for the angiotensin receptor AT1B gene (Agtr] b) in an F2(S x
MNS) popuiation. These two QTL could be separated by more than 40 cMs.
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To further naiow down the region containing the QTL, we made congenic substrains
from the original strain, S.MNS-D2Mit6/ alcohol dehydrogenase (Adh) (Deng et al.
1997a), and studied blood pressure of these substrains.
3.3 METHODS
3.3.1 Animais
The SS/Jr rat used for making congenic substrains was provided by Dr. J. Rapp and will
be designated as S in the present report. The genomic DNA for every S rat used for
maintaining the strain and BP studies at each generation has been extracted and verified
by genotyping. In order to insure that the S strain remains as genuine as the SS/Jr rat
directly obtained from Dr. J. Rapp in our facility, a rigorous and strict quality control
procedure has been instituted. li consists of two parts, (a) genetic testing; (b) physical
distinction. In an approximate genomic scan, 88 markers roughly evenly spaced (on
average 10-15 cM) throughout the rat genome were tested. Each DNA sample for every
S rat tested was compared with the true S DNA standard that we used in our original
work (Deng et al. 1997a). So far, no marker differences have been detected (data flot
shown). Moreover, ail our S rats have, in addition to a skin tag, an ear mark punch hole
designed to facilitate their identification and to reduce potential handling errors.
The original congenic strain used to initiate the study is designated as S.MNS
D2Mit6/Adh, and is the same as published previously (Deng et al. 1997a). In brief, it
was made by 8 consecutive backcrosses, and consequently putting the MNS
chromosome region between D2Mit6 and Adh markers on the S genetic background.
This strain, therefore, is homozygous MNS (i.e. MM) for the region in question and
homozygous SS for the rest of the genome. This conclusion lias been supported by the
genotyping of 57 markers scattered throughout the rat genome other than on Chr.2 (data
not shown). Figure 1 contains the Chr. 2 map, additional markers tested for the Chr.2
regions, and the chromosome fragment in question in the congenic strain. This original
congenic strain is abbreviated as S.M. The authenticity of the strain has been
established by genotyping the markers betwcen D2Mit6 and AcÏh on Chr.2 (Figure 1).
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Protocols for handiing as well as maintaining animais were approved by our institutionai
animal committee. Ail the procedure for the experiment was in accordance with the
guidelines of local, provincial and federal regulations.
3.3.2 Breeding scherne for generating substrains
Rats of the original congenic strain, S.M (Figure 1) were first bred with S to produce F1
rats, which in tum were intercrossed to produce F2. An F2 rat with crossovers in the
region between D2Mit6 and Adh markers was retained, and then backcrossed (BC) to a
S rat to duplicate the region of interest. A female and a male BC rats were crossed to
finally generate rats homozygous MM for the region of interest, but homozygous 55 for
the rest of Chr. 2 and rest of the genome. The progeny of each of these crosses constitute
a congenic substrain dividing the initiai segment involved in S.MNS-D2Mit6/Adh.
Substrains, S.MNS-D2Mit6/D2Ratl66 and S.MNS-D2Mit6/D2Rat3O3 are abbreviated
as, S.Ml and S.M2 respectively (Figure 1). The chromosome region homozygous Mlvi
in the substrain and the original S.M strain are shown as solid bars in Figure 1. Ail the
markers in the region were genotyped for each congenic strain in question.
3.3.3 Preparation of rats for BP measurements
The mating pairs for the S strain and congenic strains to be studied were bred
simultaneously and in the same facility. Male rats were chosen from two separate litters
of the same strain when possible, in order to minimize potential litter effects. The
chosen rats were weaned at 21 days of age, maintained on a low sait diet (0.2% NaCi,
Harian Teklad 7034) and then fed a high sait diet (2% NaC1, Harlan Teklad 94217)
starting from 35 days of age until the end of the experiment.
Telemetry probes were implanted when rats were 56 days oid with their body weights
between 250-320 grams. Before the surgery, the rats were anesthetized by the
inhalation of isoflurane at a dose of 4% for 3 min. During surgery, the state of
anesthesia was maintained by isoflurane at a dose of 1.5-2%. The catheter of a
telemetry probe was implanted through the femoral artery until it reached ail the way up
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to the abdominal aorta, and secured by a suture to the blood vessel. Some investigators
place the catheter in the abdominal aorta directly. In our experience and as advised by
Data Sciences Inc., the placement in the abdominal aorta could cause more paralysis in
the rats than it was through the femoral artery. Both methods are reliable for BP
measurements. The telemetry probe was fixed to the muscle wall, and the transmitter
was left in the abdominal cavity. After the surgery, the rats were allowed to recuperate
for 10-17 days. In the first three days of recuperation, the rats were fed Jello-O
containing the analgesic buprenorphine at 0.5% mglkg. Afterwards, they were given a
diet of Ensure milkshake with chocolate in addition to the 2% NaCI regular food. This
supplement usually lasted up to 5 days to facilitate their appetite and thus weight gain.
In total, the rats are allowed at least 10 days for the postoperative recuperation.
3.3.4 BP measurement
The telemetry system from the Data Sciences Inc. (St. Paul, MN) was used. Each
telemetry probe was calibrated before and cleaned after each usage according to
manufacturer’s instructions. A dedicated technician was thoroughly trained by the Data
Sciences Inc. for the procedure of telemetry.
3.3.5 Statistical analysis
Repeated measures’ Analysis of variance (ANOVA) followed by Tukey in the SYSTAT
9 program (SPSS Sci. Chicago, IL) was used to compare the significance level for a
difference or a lack of it in a BP component between a congenic strain (or substrain) and
the S strain. In the analysis, a BP component was compared at each day for the period
of measurement among the strains.
3.3.6 DNA extraction and Genotyping
DNA for each rat was extracted by tail biopsy using a Qiagen Genome kit and the
genotype of each rat was determined by PCR based on the methods previously
published (Deng et al. 1994, 1997a, b).
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3.3.7 Radiation Hybrid mapping
A ratlhamster (RH) panel of 96 radiation hybrids was purchased from Research Genetics
(Huntville, AL, http://www.resgen.com/). For chromosome mapping, each marker was
genotyped using RH by PCR according to a previously published protocol (5-7). To
locate a marker of interest onto an existing RH framework map, the results of
genotyping were entered into a web site, http://rgd.mcw.edu/RHMAPSERVER.
3.4 RESULTS
3.4.1 Congenic strain monitoring
Ail the congenic strains in Figure 1 have been tested for 57 markers scattered throughout
the chromosomes and turned out to be SS homozygous (data not shown). Ail the
markers for the region of interest on Chr. 2 in each congenic strain are IVIM
homozygous. An effort was made to produce a congenic strain, which is homozygous
MM for a Chr.2 region, but does flot show a BP-lowering effect. This strain is
designated as a negative control (e.g. S.M2 in Figures 1 and 2).
3.4.2 BP Study designs
The basic design of raising animais is similar to our previous congenic work regarding
the age and sex, andin terms of the timetable of dietary treatments (Deng et al.1997a).
The most apparent difference is that BP measurements in the current study were direct
and continuous for a period of 10-20 days. Ail the BP components were measured
including systolic, diastolic and mean arterial pressures.
3.4.3 BP measurements
Readings for each BP parameter were recorded every 10 seconds for each rat.
Theoretically, one could obtain 10 x 6 x 60 x 24 = 8640 readings for a rat daily.
However, to cover ail the rats in one experimental setting, a ten-second reading was
done for each rat at a 2- minute interval during a 24-hour period for the duration of the
experiments. As a resuit, 60/2 x 24 = 720 measurements were collected daily for each
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rat. For the simpÏicity of presentation, each point in the graphs in Figure 2 represents
averaged 24-hour readings taken from every four hours.
3.4.4 Mapping of a BP QTL by analyzing BP effects associated with
chromosome segments
Figure 2 shows the comparison of MAP, DAP and SAP of S rats with those of two
congenic rats. The chromosome regions containing MNS substitutions in the congenic
rats are shown in Figure 1. A total of 9 S rats were pooled from separate and
independent cohorts of measurement for different periods of times, because the
differences in S rats among the separate cohorts tumed out not to be statistically
significant (P>0.39). Two independent cohorts for each of S.M1 and S.M2 substrains
were pooled also for the same reason (p>0.86).
The Mapping of a QTL of interest can be done as follows. Congenic strains were
compared w each other in the Iength of the chromosome replacements and for their
effects on BP. The region containing the QTL can be localized to the segment either in
common between two strains both having a BP effect; or in the fragment flot shared in
two strains, one having and the other tacking a BP effect.
3.5 DISCUSSION
Mean arterial (MAP), diastolic (DAP) and systolic (SAP) pressures of the original
congenic strain S.M was significantly (p<O.0001) lower than that of the S strain (lowest
une tracing in each graph in Figure 2), thus confirming the presence of BP QTL in the
chromosome segment involved. S.M. differs from the S strain essentialÏy in the Chr.2
regions in question, i.e. homozygoLis MM (Figure 1), and homozygous SS for the rest
of the genome as shown by genotyping 57 markers across the rat genome (data flot
shown). More importantly, no matter what effects the remaining MNS genome had in
the S background in the congenic S.M strain, it definitely did not influence BP because
S.M2, which was entireïy derived from S.M, showed the same BP as that of S. This fact
indicates, without doubt, that the BP-lowering effect shown in S.M is entirely due to the
66
Chr.2 segment flot shared between S.M and S.M2. Therefore, at least one BP QTL has
to exist in the Chr.2 segment between D2Mco9 and Aclh markers.
A region containing a BP QTL can be narrowed further by comparing S.M1 and S.M2.
S.M1 has a BP significantly (p<O.O3) iower than that of S, whereas S.M2 is practically
the sarne (p>O.$7, Figure 2). Thus, one can conclude that a BP QTL should exist in the
non-overlapping region. That is between D2Rat3O2 and Nep markers, which effectively
places the QTL in question within a segment of 5.7 cM. The current work provides the
first une of evidence for locating a BP QTL to such a srnail region on Chr 2. A
definitive proof will corne from making a congenic substrain just for this 5.7 cM section,
which would show a comparable BP-lowering effect.
It is noteworthy that BP of the S.M1 congenic strain is significantly (p<O.03) lower than
that of the S strain, but significantly (p<O.O2) higher than that of the S.M congenic strain
(Figure 2). This observation indicates that the entire BP effect contained in S.M can flot
be fuliy accounted for by S.M1. Therefore, there seems to be another QTL located in
the region between Nep and Adh markers.
The work of investigators using other hypertensive models lias also shown that there is a
QTL in the same, but broad chromosome region (Pravenec et al. 1995, Schork et al.
1995, Samani et al. 1996, Vincent et al. 1997, Jeffs et al. 2000). The QTL of interest
appears to be common to most of the hypertensive rat strains. By extrapolation, the
QTL rnight be conserved in other mammals potentially including humans. Although,
our experiments put rats on 2% NaCI, this setup was largely designed to hasten the
expression of hypertension without killing the animais in a shorter period of time than
otherwise would have been without it. The salt sensitive nature of the S rats may restrict
the general applicability of other BP QTL discovered from the S strain to different
hypertensive strains.
Because the S.M2 substrain does flot show a BP effect, the Agtr]b gene can flot be
supported as a candidate for a BP QTL. Combining our previous sequencing analysis
67
(Deng and Rapp 1994), the Agtrlb gene does flot appear to be a candidate. The various
linkage analyses conducted in different crosses (Deng et al. 1994, Deng and Rapp 1994,
Dubay et aI. 1993) most likely resulted from statistical artifacts. Once again, our cuiTent
work illustrates the importance of the congenic approach to either support or refute the
resuits of linkage analyses.
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3.8 FIGURE LEGENDS ANI) FIGURES
Figure 1. Chr. 2 regions replaced in the original congenic strain and two
substrains. The linkage map is essentially the same as published previously (Deng et
al. 1997b), which is based on an F2(S x MNS) population. Numbers to the left of the
linkage map are units in cM. The order of most of the loci on the map has been initially
determined by iinkage using the MAPMAKER program, and then verified by scoring
crossovers during the construction of congenic substrains. RH map refers to the map
based on ratlhamster radiation hybrids, in which units are in centiRays (cR). S.M
represent the original congenic strains S.MNS-AdÏz/D2Mit6 (Deng et al.1997a). S.M1
and S.M2 are substrains that have been derived from S.M and studied. Solid bars under
congenic strain and the substrains symbolize the S chromosome fragments that have
been replaced by that of the MNS rat. The entire region indicated by solid bars and
junctions between the solid and open bars are homozygous MM on the map for ail the
markers listed in the corresponding positions. Open bars on ends of solid bars indicate
the ambiguities of crossover breakpoints between markers. Junctions between solid and
open bars as weli as ends of chromosome regions of interest in each strain are connected
by dotted unes to the marker positions on the map. AcÏh, alcohol dehydrogenase;
Agtr]b, angiotensin receptor type lB; Atpla] , NaK-ATPase ai; Camk2d, calmodulin
dependent protein kinase II-delta; Cpb, carboxypeptidase B; Fgg, fibrinogen gamma;
Gcct, guanylyl cyclase A/atrial natriuretic peptide receptor; Hsd3b, 3-hydroxysteroid
dehydrogenase/delta 5 isomerase; Nep, neutral endopeptidase; Prir, prolactin receptor.
The rest of the markers are anonymous (Deng et al. 1997b,
http://waldo.wi.mit.edu/ratlpublic/). S.Mi and S.M2 represent substrains S.MNS-D2Mit6/166
and S.MNS-D2Mit6/D2Rat3O3 respectiveiy. S, the Dahl sait-sensitive strain.
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Figure 2. Comparison in BP components between the S.M, S.M1 and S.M2
congenic strains, and the S strain. Mean arterial (MAP, a), diastolic (DAP, b) and
systolic (SAP, c) pressures were significantly different (p<O.0001) betwccn the S.M
(n=5) congenic and the S (n=9), different (p<O.O3) between the S.M1 (n=$) congenic
strain and the S (n=9) strains, and different (p<O.O2) between S.M1 and S.M. In
contrast, the difference in MAP, DAP and SAP between the S.M2 (n=8) and S (n=9)
strains is flot significant (p>O.87). Each time point on the graph represents an average of
24-hour readings. (d) represents a sampling of the diumal variations in two strains. Ail
the numbers on the vertical axes (or Y) are in mmHg. S.M, S.Ml and S.M2 represent
S .MNS -D2Mit6/Adh, S .MNS -D2Mit6/Nep and S .MNS -D2Mit6/D2Rat3O2 strains
respectively. S, the Dahi sait-sensitive strain.
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4.1 ABSTRACT
Both linkage and use of congenic strains have shown that a region on rat Chromosome
(Chr.) 2 of Dahi sait-sensitive rats (S) contained a quantitative trait locus (QTL) for
blood pressure (BP). A congenic strain was made by replacing a segment of the S rat
by the homologous region of the Milan normotensive rat (MNS). Since the region was
roughly $0 centiMorgans (cMs) in size, a further reduction is required towards the final
identification of the QTL. Currently, three congenic substrains were made by replacing
smaller sections within the 80 cM. Each strain contains a specific region of MNS in the
S genetic background. Two of the three congenic strains shared a segment in common
and both showed a BP-lowering effect. One of the three congenic strains carried a
unique segment and had the same BP as S. Deducing the fragment shared in the two
substrains having an effect, the BP QTL has to be present in a region of roughly 15 cMs.
In contrast to BP, heart rates of ail the congenic rats were the same as that of the S rat.
Thus, BP and the heart rate are under the control of independent genetic determinants.
Key words: genetic hypertension, rat Chromosome 2, Milan normotensive rat
4.2 INTRODUCTION
The mapping of quantitative trait loci (QTL) for biood pressure (BP) using animal
models has been greatly facilitated by the genetic approach, such as linkage analysis and
the use of congenic strains (1, 7, 13). In our previous work, regions on rat Chr.2 were
shown to contain a QTL first by linkage analysis (2, 3, 5). The evidence suggested (2)
that there might be two QTL separated by more than 40 cM, one near the locus for the
Na/KATPase subunit ct gene (Atp]a]) and another near the locus for the angiotensin
receptor ATÏB gene (Agtrlb) in an F2(S x MNS) population. The presence of a QTL
vas proved by the use of two congenic strains (3). In one congenic strain, the
chromosome region of interest from the Dahi salt-sensitive strain (S) was replaced by
that of the Milan normotensive (MNS) rat (3). The length of the region invoived in
maldng the congenic strain vas about 80 cMs.
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To further narrow down the region containing the QTL, we made congenic substrains
from the original strain, S.MNS-D2Mit6/ alcohol dehydrogenase AcÏh) (3), and studied
blood pressures of these straïns using telemetry.
4.3 METHODS
4.3.1 AnimaIs
The S rat used for making congenic strains was provided by Dr. John Rapp. The
original litter of 5 male and 5 female S rats was obtained directly from Dr. John Rapp
(January 14, 1998). From these rats, the first independent breeding of them by Alan
Deng was donc on February 6, 1998, followed by three more generations at the Medical
Collcgc of Ohio, Toledo, USA. On December 7, 1998, two littcrs of S rats were shippcd
to the authors’ cun-cnt location at Montreal, Canada. After a period of quarantine and at
the third generation thom on December 10, 1999) bred from thc shipped S rats, the
current tclemctry studies began. Therefore, a total of 6 generations had clapscd from the
time the rats originatcd from Dr. John Rapp to our first tclemetry study. The genomic
DNA for every S rat uscd for maintaining the strain and BP studies at each gencration
has been extractcd and verified by genotyping.
In order to insurc that thc S strain rcmains as genuine as the SS/Jr rat directly obtained
from Dr. J. Rapp in our facility, a rigorous and strict quality control procedure has becn
institutcd. li consists of two parts, (a) genetic testing; (b) physical distinction. In an
approximate genomic scan, 88 markcrs roughly evcnly spaced (on avcragc 10-15 cM)
throughout thc rat genome were tcsted at cvery third gcncration of breeding starting
from gcncration 5. At cvery generation at least one marker randomly chosen for each
chromosome was genotyped, and at evcry othcr generation, at lcast 2-3 markers for each
chromosome were genotyped. Each DNA sample for every S rat tested was compared
with the truc S DNA standard that we used in our original work (3). At the time the
current work was donc, there were only S, S.M and S.M strain derivatives present in our
animal facilities (sec below). If any potential gcnctic contamination of the S strain
would happcn, it could only come from an accidcntal breeding between the S and S.M
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strains. This possibility was categorically eliminated by genotyping markers (shown in
Figure 1) on the rats of the S strain in each generation. Moreover, ail our S rats have, in
addition to a skin tag, an ear mark punch hole designed to facilitate their identification
and to reduce potential handiing elTors.
The original congenic strain used to initiate the study is designated as S.MNS
D2Mit6/Adh, and is the same as published previously (3). This original congenic strain
is abbreviated as S.M. In brief, it was made by 8 consecutive backcrosses, and
consequently putting the MNS chromosome region between D2Mit6 and Adh markers
on the S genetic background. This strain, therefore, is homozygous MNS (i.e. MM) for
the region in question and homozygous SS for the rest of the genome. This conclusion
has been supported by the genotyping of 57 markers scattered throughout the rat
genome other than on Chr.2 (data not shown). Figure 1 contains the Chr. 2 map, and the
chromosome fragment in question in the congenic strain.
The S.M strain was transfelTed to Alan Deng from Dr. John Rapp (January 14, 1998)
and has been maintained for approximately the same generations as S. Two S.M litters
were then shipped along with the S rats to Montreal at the same time as S. The
authenticity of the strain has been established by genotyping the markers between
D2Mit6 and Aclh on Chr.2 (Figure 1).
Protocols for handiing as well as maintaining animais were approved by our institutional
animal committee. Ail the procedure for the experiment was in accordance with the
guidelines of local, provincial and federal regulations.
4.3.2 Breeding scherne for generating substrains
Rats of the original congenic strain, S.M (Figure 1) were first bred with S to produce F1
rats, which in tum were intercrossed to produce F2. An F2 rat with crossovers in the
region between D2Mit6 and Adh markers was retained, and then backcrossed (BC) to an
S rat to duplicate the region of interest. A female and a male BC rats were crossed to
finally generate rats homozygous MM for the region of interest, but homozygous SS for
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the rest of Chr. 2 and rest of the genome. The progeny of each of these crosses constitute
a congenic substrain dividing the initial segment invoÏved in S.MNS-D2Mit6/Adh.
S.MNS-D2Mit6ID2Rat3O3 is simplified as S.M2; S.MNS-NeutraÏ endopeptidase
(Nep)/D2Mitl4 as S.M5; and S.MNS-Nep/atrial natriuretic peptide receptor/guanylyl
cyclase A (Gca) as S.M6. The chromosome region homozygous MM in each substrain
is shown as solid bars in Figure 1.
The first backcross between the S and S.M rats occurred on February 6, 1998, and ail
the substrains were finally fixed to the MNS homozygosity for each region in question
by January 9, 2000. The chromosome region homozygous MM in the substrain and the
original S.M strain are shown as solid bars in Figure 1. Ah the markers in the region
were genotyped for each congenic strain in question.
4.3.3 Preparation of rats for BP measurernents
The mating pairs of the S and congenic strains to be studied were bred simultaneously
and in the same facility. Male rats were chosen from two separate litters of the same
strain when possible, in order to minimize potential litter effects. The chosen rats were
weaned at 21 days of age, maintained on a iow sait diet (0.2% NaC1, Harlan Teklad
7034) and then fed a high salt diet (2% NaC1, Harian Teklad 94217) starting from 35
days of age until the end of the experiment.
Telemetry probes of PA-D70 implantable device were implanted when rats were 56
days old with their body weights between 250-320 grams. The procedure follows that
of Data Sciences Inc (St. Paul, MN, USA). Before the surgery, the rats were
anesthetized by the inhalation of isofturane at a dose of 4% for 3 min. During surgery,
the state of anesthesia was maintained by isoflurane at a dose of 1.5-2%. The pressure
catheter, which contains the Biocompatible gel at the tip and the noncompressable fluid
connecting the tip to the pressure sensor, was implanted through the femoral artery until
it reached ail the way up to the abdominal aorta. It is secured by sutures to the biood
vessel. The telemetry devise body, which includes the pressure sensor, the reusable
electronics module and a battery, was fixed to the muscle wall, and was Ïeft in the
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abdominal cavity. After the surgery, the rats were allowed to recuperate for 10-17 days.
In the first three days of recuperation, the rats were fed Jello-O containing the analgesic
buprenorphine at 0.5% mglkg. Afterwards, they were given a diet of Ensure milkshake
with chocolate in addition to the 2% NaCI regular food. This supplement usually lasted
up to 5 days to facilitate their appetite and thus weight gain. In total, the rats are
allowed at least 10 days for the postoperative recovery.
4.3.4 BP measurernent
The telemetry system from the Data Sciences Inc. was used. Each telemetry probe was
calibrated before and cleaned after each usage according to manufacturer’s instructions.
A dedicated technician was thoroughly trained by the Data Sciences Inc. for the
procedure of telemetry.
4.3.5 Statistical analysis
Repeated measures’ Analysis of variance (ANOVA) followed by Tukey in the SYSTAT
9 program (SPSS Sci. Chicago, IL) was used to compare the significance level for a
difference or a lack of it in BP between a congenic strain (or substrain) and the S strain.
In the analysis, BP was compared at each day for the penod of measurement among the
strains.
4.3.6 DNA extraction and Genotyping
DNA for each rat was extracted by tail biopsy using a Qiagen Genome kit and the
genotype of each rat was determined by PCR based on the methods previously
published (2-4).
4.3.7 Radiation Hybrid mapping
A ratlhamster (RH) panel of 96 radiation hybrids was purchased from Research Genetics
(HuntvilÏe, AL, http://www.resgen.com/). For chromosome mapping, each marker was
genotyped using RH by PCR according to a previously published protocol (2-4). To
locate a marker of interest onto an existing RH framework map, the resuits of
genotyping were entered into a web site, http://rgd.rncw.edu/RHMAPSERVER (9).
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4.4 RESULTS
4.4.1 BP Study designs
The basic design of raising animais is similar to our previous congenic work in terms of
age and sex, and for the timetable of dietary treatments (3). The most apparent
difference is that BP measurements in the cunent study were direct and continuous for a
period of 10-20 days. Ail the BP components were measured including mean arteriai
(MAP), systolic (SAP), and diastolic (DAP) pressures.
4.4.2 BP measurements
Readings for each BP parameter were recorded every two minutes during a 24-hour
period for the duration of the experiments. As a resuit, 60/2 x 24 = 720 measurements
were coiiected daiiy. For the simpllcity of presentation, each point in the graphs in
Figure 2 represents averaged 24-hour readings taken from every four hours. Each error
bar represents SEM for ail the individuai data points coiiected from every four hours for
ail the rats of that strain. MAPs, SAPs and DAPs for ail the strains are given to show
their magnitudes and ranges.
4.4.3 Mapping of BP QTL by analyzing BP effects associated with
chromosome segments
Figure 2 shows the comparison of MAPs, SAPs and DAPs of S rats with those of
congenic rats. The chromosome regions containing MNS substitutions in each congenic
strain are shown in Figure 1. A total of 9 S rats were pooled from separate and
independent cohorts of BP measurement during different periods of times, because the
differences in S rats among the separate cohorts tumed out flot to be statistically
significant (P>0.39). The BP data from two independent cohorts for the S.M2 substrain
were pools aiso for the same reason (p>0.87).
As shown in Figure 2, MAPs, DAPs and SAPs werc significantiy lowered (p<O.001) in
the S.M (n=5), S.M5 (n=4) and S.M6 (n=7) congenic strains in comparison with that of
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the S (n=9) strain. But the difference in MAP, DAP and SAP between the S.M2 (n=8)
and S (n=9) strains is flot significant (p>O.86).
Heart rates of the rat strains were measured and are shown in Figure 3. Each graph
represents the rat strains compared simultaneously during the same period of time. The
heart rates of S rats were significantly different from one cohort to another, and thus
could flot be pooled. This fluctuation probably reflects mostly the effects of the
environment.
4.5 DISCUSSION
BP of the original congenic strain S.M was shown to be significantly lower than that of
the S strain (Figure 2), thus confinning the presence of BP QTL in the chromosome
segment involved. To narrow down the location of the QTL, the original segment was
spiit into subsections (shown as solid bars for S.M2, S.M5 and S.M6 in Figure 1).
Our congenic strains differ from the S strain essentially in the Chr.2 regions in question,
i.e. homozygous MM (Figure Ï), and homozygous SS for the rest of the genome as
shown by genotyping a number of markers across the rat genome (data flot shown).
More importantly, no matter what effects the remaining MNS genome had in the S
background in the congenic S.M strain, it definitely did flot influence BP because S.M2,
which was entirely derived from S.M, showed the same BP as that of S. This fact
indicates, without doubt, that the BP-lowering effect shown in S.M is entirely due to the
Chr.2 segment flot shared between S.M and S.M2. Therefore, at least one BP QTL has
to exist in the Chr.2 segment between D2Mit9 and Adh markers.
A region containing a BP QTL can be narrowed further by examining S.M5 and S.M6.
By comparing these substrains, one can reasonably conclude that a region containing a
BP QTL should be located in a minimum segment shared by both substrains, i.e.
between D2Ratl66 and D2MghÏO (roughly 15 cMs). In this case, the same region was
tested independently two times and tumed out to have a BP-lowering effect every time.
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In contrast to BP, heart rates of the ail the congenic strains are the same as that of the S
rat (p>O.49) when averaged at every 24 hours. This is striking when noticing that MAPs
of S.M5 and S are significantly different and MAPs of S.M2 and S are flot (Figure 2d),
whereas the heart rates of ail three strains were flot significantly different (Figure 3c).
These observations indicate that a QTL present in the chromosome region of interest
influences only blood pressure, flot heart rate. Thus, blood pressure and heart rate are
controlled independently by different genes.
Upon doser examinations, it appears that there could be a sizable difference in heart
rates between S and both S.M (Figure 3b) and S.M6 (Figure 3f) within an 24-hour
period. It is to be determined, however, if these differences within 24 hours could be
genetic because S.M5 had a similar heart rate as S (Figure 3d), whereas S.M6 had a
slower heart rate (Figure 3f). Both S.M5 and S.M6 shared a chromosome segment in
common (Figure 1). There are reports of genetic determinants for heart rates
independent of BP in both humans (16) and the spontaneously hypertensive rats (11).
Although S.M5 contained Atp]a] whereas S.M6 did flot, but both showed a BP effect
with a similar magnitude (Figure 2b and c). This fact would argue against the candidacy
of Atpla]. But since the possibility of an epistatic gene-gene interaction among
potential multiple QTL in the same region could flot be ruled out at this point, Atp]a]
could flot be excluded as a candidate QTL. A definitive proof wiÏl come from a
congenic strain involving a minimum chromosome segment containing the Atp]a]
locus.
For a more in-depth study of a BP QTL, especially when one attempts to study a time
course relationship, telemetry appears to be more appropriate, because it can provide
continuous measures for ail components of BP. Moreover, if diastolic and systolic
pressures are controlled differently, they might contain separate genetic determïnants
also. Telemetry is ideal for monitoring each separate component of BP and following it
with time. On the other hand, the BP measurements obtained by telemetry have an
environmental element flot present in tau cuff, that is the stress induced by surgery. It is
$2
reassuring, though, that both tau cuff (3) and telemetry (the present study) showed a BP
lowering effect for S.M.
The work of investigators using other hypertensive models has also shown that there us a
QTL in the same broad chromosome region either in linkage analysis (12, 14, 15, 17) or
using congenic strains (10). The QTL of interest appears to be common to most of the
hypertensive rat strains. By extrapolation, the QTL might be conserved in other
mammals potentially including humans. Although, our experiments put rats on 2%
NaC1, this setup was largely designed to hasten the expression of hypertension in a
shorter period of time than otherwise wouid have been without it. The sait sensitive
nature of the S rats may restrict the general applicability of other BP QTL discovered
from the S strain to different hypertensive strains.
Because the S.M2 substrain does not show a BP effect, the Agtr]b gene can not be
supported as a candidate for a BP QTL. Combining our previous sequencing analysis
(6), the Agtrlb gene does flot appear to be a candidate. The various resuits of linkage
analyses conducted in different crosses (2, 6, 8,) most likely reflected statistical artifacts.
Once again, our current work iflustrates the importance of the congenic approach to
either support or refute the resuits of linkage analyses.
The region containing the BP QTL in the rat shares a conserved synteny relationship
with a segment of mouse Chr.3, and segments of human CHR.1 and 4
(http ://www .welJ .ox . ac .uklrat mappingresources/Comparati ve maps/compa_map chr
02.html). A fine mapping of the QTL in question may further refine the exact portion of
the human chromosome with which it has a conserved synteny, and eventuaiiy help
unravel some of the genetic determinants in human hypertension. As the human and
mouse genome projects progress, genomic information obtained might also contribute to
the identification of the QTL in the rat.
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4.8 FIGURE LEGENDS AND FIGURES
Figure 1. Chr. 2 regions replaced in the original congenic strain and substrains,
and the QTL region rnapped. The Iinkage map is essentially the same as published
previously (4), which is based on an F2(S x MNS) population. Numbers to the ieft of
the linkage map are units in cM. The order of most of the loci on the map has been
initially determined by linkage using the MAPMAKER program, and then verified by
scoring crossovers during construction of congenic substrains. RH map refers to the
map based on rat/hamster radiation hybrids, in which units are in centiRays (cR). S.M
represent the original congenic strains S.MNS-Adh/D2Mit6 (3). S.M2, S.M5 and S.M6
are substrains that have been derived from S.M. Solid bars under congenic strain and
the substrains symbolize the S chromosome fragments that have been replaced by that of
the MNS rat. The entire region indicated by soiid bars andjunctions between the solid
and open bars are homozygous Mlvi on the map for ail the markers iisted in the
conesponding positions. Open bars on ends of solid bars indicate the ambiguities of
crossover breakpoints between markers. Junctions between solid and open bars as well
as ends of chromosome regions of interest in each strain are connected by dotted unes to
the marker positions on the map. Adh, alcohol dehydrogenase; Agtrlb, angiotensin
receptor type lB; Atp]al , NaK-ATPase ai; Camk2d, calmodulin-dependent protein
kinase II-delta; Cpb, carboxypeptidase B; Fgg, fibrinogen gamma; Gca, guanylyl
cyclase A/atri al natri uretic peptide receptor; Hsd3b, 3-hydroxysteroid
dehydrogenase/delta 5 i somerase; Nep, neutrai endopeptidase; PrÏr, prolactin receptor.
The rest of the markers are anonymous (http://waldo.wi.mit.edu/rat/public/). S.M2,
S.M5 and S.M6 are S.MNS-D2Mit6/D2Rat3O3, S.MNS-Nep/D2Mitl4, and S.IvINS
NeplGca respectiveÏy. S, the Dahl sait-sensitive strain.
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Figure 2. Comparisons in mean arterial (MAP), diastolic (DAP) and systolic (SAP)
pressures between the S.M, S.M2, S.M5 and S.M6 congenic strains, and the S
strain. Each time point on the graph represents an average of 24-hour readings. S, the
Dahi sait-sensitive strain. S .M, S .MNS-D2Mit6IAdh, S .M2, S .MNS-D2Mit6/D2Rat3O3;
S.M5, S.MNS-Nep/D2Mitl4; and S.M6, S.MNS-NeplGca strains respectively. Each
point on the 24-hour graph is an average of readings taken at every 1 hour (j, 1, and n) or
4 hours (k, m and o). a, b and c, MAP, DAP and SAP of S and S.M; d, e and f, MAP,
DAP and SAP of S, S.M2 and S.M5; g, h and i, MAP, DAP and SAP of S and S.M6; j
and k represent MAP readings of S and S.M in a 24-hour period averaged every hour
and every four hours respectiveiy; 1 and m represent MAP readings of S, S.M2 and
S.M5 in a 24-hour period averaged every hour and every four hours respectiveiy; n and
o represent MAP readings of S and S.M6 in a 24-hour period averaged every hour and
every four hours respectively. Error bars represent SEM.
Figure 3. Comparisons in heart rates between the S and congenic strains. The
difference in heart rates among S, S.M, S.M2, S.M5 and S.M6 are compared. Each time
point on the graph in a, c, and e represents an average of 24-hour readings. a,
comparing S (n=5) with S.M (n=5), p>O.47; c, comparing S (n=3), S.M2 (n=4), and
S.M5 (n=4), p>O.49; and e, comparing S (n=4) and S.M6 (n=7), p>O.3O. Along side
each graph for the 12-day period of measurements (left, a, c and e) are variations of
heart rates in a 24-hour period (nght, b, d and f) to show the hemodynamic variance
among the strains. Each point on the 24-hour graph is an average of readings taken at
every 4 hours. S, the Dahi sait-sensitive strain. For congenic strain designations, see
the legend for Figure 2. ElTor bars represent SEM.
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5.1 ABSTRACT
Our previous work demonstrated two quantitative trait loci (QTLs), C2QTL1 and
C2QTL2, for blood pressure (BP) located on Chromosome (Chr) 2 of Dahi sait-sensitive
(DSS) rats. However, for a lack of markers, the two congenic strains delineating
C2QTL1 and C2QTL2 couid flot be separated. The position of the C2QTLY was only
inferred by comparing two congenic strains, one having and another lacking a BP effect.
Furthermore, it was flot known how adjacent QTLs would interact with one another on
Chr 2. In the cuiTent investigation, first, a critical chromosome marker was developed
to separate two C2QTLs. Second, a congenic substrain was created to cover a
chromosome fragment thought to harbor C2QTL1. Finally, a series of congenic strains
were produced to systematically and comprehensiveiy cover the entire Chr 2 segment
containing C2QTL2 and other regions previousiy untested. Consequentiy, a total of
three QTLs were discovered, with C2QTL3 iocated between C2QTL1 and C2QTL2.
C2QTLY, C2QTL2 and C2QTL3 reside in chromosome segments of 5.7 centiMorgan
(cM), 3.5 cM and 1.5 cM respectively. C2QTL1 interacted epistatically with either
C2QTL2 or C2QTL3; whereas C2QTL2 and C2QTL3 showed additive effects to each
other. These resuits suggest that BP QTLs closely linked in a segment interact
epistatically and additively to one another on Chr 2.
Key words: hypertension, epistasis, additivity, comparative congenics, comprehensive
congenic coverage
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5.2 INTRODUCTION
Ever since the revelation of a quantitative trait locus (QTL) for blood pressure (BP) on
Chromosome 2 (Chr 2) of Dahi sait-sensitive (DSS) rats 1;2 Chr 2 seems to play a role
in the development of hypertension in several of the hypertensive strains 3-13• In our
initial work, two BP QTLs designated C2QTL1 and C2QTL2 were localized to regions
on Chr 2 of the DSS rat . C2QTL1 was found between the markers D2Rat3O3 and
D2Ratl66 6 and C2QTL2 was found between the markers D2RatÏ66 and D2Ratl3l .
However at the time, the position of C2QTL1 was soleiy inferred from comparing two
overlapping congenic strains, one having and the other lacking a BP effect 6 It was
uncertain whether this deduction was vaiid in iocalizing a QTL for a poiygenic trait.
Another issue was that C2QTL1 defined by S.Ml 6 and C2QTL2 defined by S.M5 and
S.M6 shared a chromosome region of ambiguity. As a resuit, it couid flot be ruled out
that there might be just one QTL instead of two in the Chr 2 region in question.
Subsequent to our original work on Chr 2 QTL localizations 1,2;5;6;14 another group
found several QTLs situated adjacent to one another in one Chr 2 segment of DSS rats
However, it was not clear how these QTLs couid act with reference to one another.
Based on these observations, two questions were addressed: are there truly multiple BP
QTLs in a Chr 2 segment of the DSS rat? If there are, how do they interact with
reference to one another in determining BP?
5.3 METHODS
5.3.1 Animais
Congenic strains, S.M, S.M1, S.M2, S.M5 and S.M6 and DSS strain are the same as
used previously 56 (Figure 1).
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5.3.2 Constructions of congenic substrains
S.M, S.M1, S.M5 and S.M6 5;6 were used to derive congenic substrains. The basic
design was to systematicaily and as completely as possible cover the entire Chr 2 region
of interest. The goal is to define each QTL unambiguousiy.
The procedure was similar to that published previousiy 15 In brief, rats of the DSS and
S.M (or $.M1 or S.M5 or S.M6) were used to derive congenic substrains (see the online
supplement for detail). In the end, the authenticity of each congenic substrain has been
estabiished by genotyping the markers for the region of interest, and 57 additionai
markers scattered throughout the rat genome (data flot shown). The chromosome region
homozygous MM for each congenic substrain is depicted by a soiid bar in Figures 1 and
2. New congenic substrains produced in the present work are: DSS.MNS-(D2Ratl83-
D2Chml 1 3)/Lt (abbreviated as C2S .M7), DSS .MNS-(D2Chm25-D2Mitl4)/Lt
(C2S .M8), DSS .MNS-(D2Chm25-D2Rat 13 1)ILt (C2S .M9), DSS .MNS
(D2Wox27IAdh)/Lt (C2S .M1O), DSS .MNS-(D2Chm5 1-D2Rat34 1)/Lt (C2S .M1 1) and
DSS.MNS-(D2Chm25-Fgg)ILt (C2S.M12).
5.3.3 BP measurernents
BP studies on the congenic strains were essentially the same as reported previousiy 56,15
21 In brief, male rats were weaned at 21 days of age, maintained on a iow sait diet
(0.2% NaCi, Harlan Teklad 7034) and then fed a high sait diet (2% NaC1, Harlan Tekiad
94217) starting from 35 days of age untii the end of the experiment. Telemetry probes
were implanted when rats were 56 days old (i.e. after 3 weeks of the high sait diet) with
their body weights between 250-320 grams. BPs for ail the strains were measured at
ieast at two different times to exclude seasonal as weii as environmentai influences.
Thus the BP data were pooled from separateiy reproducibie measurements for each
strain
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5.3.4 Statistical analysis
Repeated measures’ Analysis of variance (ANOVA) followed by Dunnett, (which
permits a correction for multiple comparisons and sample sizes), was used to compare a
parameter between 2 group as presented previously 5;6;15-21 During the BP comparison,
ANOVA was, first, used to analyze the data to sec if there was any difference among the
groups. If the difference is significant, then, the Dunnett test was followed to see which
group is different and how much significant from the DS$ strain.
The 2 x 2 ANOVA determines a QTL-QTL interaction (or a lack of it) by evaluating
whether the observed BP effect of a congenic strain combining two separate congenic
strains is significantly different from a predicted sum of BP effects from each individual
congenic strain.
5.4 RESULTS
5.4.1 A chromosome rnarker defining separate QTLs
The marker designated as D2Chm9O was instrumental in separating QTLs [Figure 1 and
Table 1 (see the online supplement for the detail as to how these markers were
generated)]. It came from the same supercontig containing Mine and is homozygous
MM for S.M, but SS for S.M1, S.M2, and S.M6 (Figure 1). Thus D2Chm9O effectively
separated S.M1 and S.M2 from S.M6. Consequently, there are definitively at least 2
different BP QTLs present (Figure 1). Because S.Ml had a BP 22 mmHg lower
(p<O.O3) than that of DSS, whereas S.M2 is different (p>O.82) from DSS by 2 mmHg,
C2QTL1 should be present between D2Rat3O3 and D2Chm9O (Figure 1). Since BP of
S.M6 was 48 mmHg lower (p<O.00l) than that of DSS, C2QTL2 should exist between
D2Chm9O and D2MghlO (Figure 1). BP of S.M (i.e. 120 mmHg) is flot different from
that of S.M6 (i.e. 122 mmHg) (p>0.5).
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5.4.2 Constructions of new congenic substrains to fine map multiple BP
QTLs
C2S.M7, C2S.M8, C2S.M9, C2S.M1O, C2S.M11 and C2S.M12 span around 5.7 cM,
11.5 cM, 8 cM, 28 cM, 1-2cM and 5.5 cM respectively.
Figure 3 shows the actual tracings of systolic (SAP), diastolic (DAP) and mean arterial
(MAP) of DSS and congenic strains by telemetry. For the simplicity of compansons
among the strains, averaged MAPs were shown at the bottom of Figures 1 and 2.
C2S.M7 was produced by targeting the chromosome segment between D2Rat3O3 and
D2Ratl66 of S.M1 (Figure 1). C2S.M7 exhibited a BP lower (p<O.03) than that of DSS
(Figures 2 and 3).
When C2S.M9 (Figure 2) were produced from S.M6 , its MAP of around 139 mmHg
was 31 mmHg lower (p<O.O2) than that of 170 mmHg of DSS rats (Figure 2). This
Towering in BP could only explain about 65% (i.e. 3 1/48) of that observed in S.M6 (
i.e. 170-122 = 48 mmHg), suggesting that there might be another QTL, C2QTL3, that
would have an additive BP effect to C2QTL2. To prove this prediction, a ncw congenic
substrain, C2S.M11 (Figure 2), was constructed specially targeting the sub-segment in
S.M6 none-overlapping with C2S.M9 (Figures Ï and 2). Indeed, MAP of C2S.M11 was
around 147 mmHg (Figures 2 and 3), which was lower (p<O.03) than that ofDSS.
From C2S.M9, C2S.MÏ2 was produced (Figure 2) and its BPs were flot different
(p>0.3) from those of DSS (Figures 2 and 3). As a resuit, the interval for C2QTL2 can
be further narrowed to the section non-overlapping between C2S.M9 and C2S.M12 by
subtracting the segment shared between them (Figure 2).
The genes for the soluble subunits Œ (Gucyla) and f3 (Gucylb) of guanylate cyclase 1
are located in the chromosome fragment in C2S.M12 (Figure 2), which had a BP not
different (p>O.3) from that of DSS.
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5.4.3 Epistatic and additive QTL-QTL interactions
Figure 4 summarizes the relationships among the three C2QTLs, assuming that one
QTL was involved in cadi QTL interval. A 2 x 2 factorial ANOVA 22 indicated that
there is an epistatic interaction (p<0.O3) between C2QTLY and a combination of
[C2QTL2 and C2QTL3] (Figure 4a). This interaction can be viewed in another way.
That is: S.M (Figure 1), which harbors three QTLs, C2QTL1, C2QTL2 and C2QTL3,
possessed a similar BP (i.e. 120 mmHg) as that of S.M6 (i.e. 122 mmHg), which
contained only two QTL5, C2QTL2 and C2QTL3 (Figure 1). The BP effect of C2QTL1
was apparently masked when combined with C2QTL2 and C2QTL3.
C2QTL3 and C2QTL2 appear to act additively to each other, because a 2 x 2 factorial
ANOVA demonstrated that there is no epistatic interactions between them (p interaction
>0.5, Figure 4h). In other words, a combined BP effect of C2QTL2 and C2QTL3 is
greater than each of the two QTLs acting alone.
5.5 DISCUSSION
Major findings from the current studies are (a), a comprehensive and systematic
congenic coverage unraveled multiple QTLs closely linked in a segment on DahI rat Chr
2. (b), Certain of these QTLs demonstrated epistatic interactions, while others exhibited
additive effects.
5.5.1 Comprehensïve congenic coverage divulging multiple BP QTLs in a
closely linked region
Ail the available markers in the rat data base for the region between D2Rat 166 and Mine
were tested, but, none was either homozygous SS or Mlvi for S.M1 and S.M6 (Figure 1).
Therefore, potential overlaps could not be ruled out between the lower segment for
C2QTL1 6 and the upper segment for C2QTL2 (Figure 1). Two approaches of proving
that C2QTL1 and C2QTL2 are separate genes were that a marker between D2Ratl66
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and Mme shouid be 55 for both S.M1 and S.M6; andlor non-overlapping congenic
strains separateiy covering C2QTL1 and C2QTL2 would each show a BP effect.
Indeed, the new marker, D2Chum9O, turned out to be 55 for S.M1 and S.M6 (Figure 1).
Moreover, both C2S.M8 and C2S.M9 are cleariy separate from C2S.M7 (Figure 2), and
ail three showed BP effects (Figure 2). Combining both sets of evidence, C2QTL1 and
C2QTL2 ïndisputably represent distinctive genetic loci.
In addition to C2S.M7, C2S.M$, and C2S.M9, congenic strain C2S.M1l (Figure 2) also
showed a BP significantiy lower (p<O.O3) than that of DSS (Figure 3). In contrast,
C2S.M1O and C2S.M12 (Figures 2 and 3) had BPs flot statistically different (p>O.3)
from that of DSS (Figure 3). Since congenic strains C2S.M7, C2S.M9, and C2S.M11
unequivocafly do flot overlap in the chromosome segments that they cover (Figure 2)
and ail showed BP effects, consequently, three separate QTLs, C2QTL1, C2QTL2 and
C2QTL3, must be Iocated in C2S.M7, C2S.M9, and C2S.M1l respectively. C2QTL1,
C2QTL2 and C2QTL3 reside in intervais of 5.7, 3.5 and 1.5 cMs respectively.
Because C2S.M1O and C2S.M12 as ‘negative’ controis did flot manifest significant
alterations in BP from DSS, the BP effects of the three QTLs observed could not be due
to the genetic background in congenic strains C2S.M7, C2S.M9, and C2S.M11. It is a
QTL that is responsible for lowering BP in each congenic strain.
For a iack of congenic strain specificaliy made for the fragment between D2Chm57 and
D2Wox27 (Figure 2), it can flot be ruied out that an additional QTL could stili exist in
that region.
Our resuits are consistent with those of other investigators 3;7;8, which showed the
existence of several BP QTL5 in similar regions. Specifically in comparing our current
resuits with those of Garrett and Rapp ‘, several features are evident. First, MNS and
Wistar Kyoto (WKY) strains may or may not share the same aileles at each QTL on Chr
2. For exampie, C2QTL1 seems unique to the DSS and MNS contrast. Second,
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C2QTL2 and C2QTL3 shared the same chromosome segment with QTL1 and QTL2 in
Garrett and Rapp , implying that the same QTL alleles could be in common between
MNS and WKY. Third, the C2QTL3 region in our current work is now small enough
(i.e. 1.5 cM) for positional cloning to identify the gene. Finally, our telemetry affords
more accurate measurements to assess a QTL effect and QTL-QTL interactions. In a
nutshell, our cunent work fine mapped the three C2QTLs and presented evidence for
both epistatic and additive QTL-QTL interactions among them.
5.5.2 Epistatic and additive QTL interactions among C2QTL1, C2QTL2
and C2QTL3
From Figure 4, it is apparent that C2QTL1 is epistatic to either C2QTL2 or C2QTL3. It
is unknown if the interaction was between C2QTL1 and C2QTL2, or between C2QTL1
and C2QTL3. Mechanistically, it is probable that C2QTLÏ belongs to the same
pathway/cascade as either C2QTL2 or C2QTL3 23;24 Increasingly, epistasis in
determining BF 2;20;22;25 has been recognized as an important organizational hierarchy
among BP QTL5 23;24 not simply a background genetic noise.
It wilI be worthwhile to ascertain with which of the two QTLs, i.e. C2QTL2 or
C2QTL3, C2QTL1 interacts epistatically. One way to accomplish this task is to make
‘double’ congenic strains between both C2QTL1 and C2QTL2, and C2QTLY and
C2QTL3, much as S.M6 being for C2QTL2 and C2QTL3. As these three QTLs are
located in close proximity on the same chromosome (Figure 2), any ‘double’ congenic
strain as such will require a crossover between two closely linked markers. So far, no
such crossovers have been achieved (data not shown). Another way to study these
epistatic interactions is to construct ‘double’ congenic strains between a congenic strain
from a different chromosome and every one of the single congenic strains harboring the
three QTL5 on Chr 2. In this case, no chromosome crossovers are required so that a
production of such a ‘double’ congenic strain is practically achievable. This line of
work is ongoing.
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The phenomenon of additive QTL interactions between C2QTL2 and C2QTL3 is flot an
isolated instance. Several BP QTLs adjacent to one another acting additively have also
been detected on another chromosome using congenic strains 15 In a mechanistic sense,
it is possible that QTLs in an additive relationship belong to different pathways/cascades
23;24
5.5.3 Perspective
There are three BP QTLs closely linked in a chromosome segment of 19.6 cM of the
DSS rat in contrast to the MNS rat. C2QTL1 interacted with either C2QTL2 or
C2QTL3 epistatically; whereas C2QTL2 and C2QTL3 seemed to be additive in
affecting BP. By extrapolation, the identifications of these QTLs and how they interact
with one another could have an impact on the revelation of mechanisms goveming
certain forms of human essential hypertension. The chromosome segment harboring the
three QTLs has a conserved synteny with a fragment of Chr 3 of the mouse and with
segments of human CHRs 3 and 13 (C2QTL1), CEWs 1 and 4 (C2QTL2) and CHR 3
(C2QTL3) (http:IIwww.ncbi.n1m.nihrovI). The newly available rat genome
information 26 will no doubt be helpful in positional cloning of these C2QTLs 23;27
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5.7 FIGURE LEGENI)S, FIGURES AND TABLES
Table 1: Newly generated polymorphic Chr 2 markers:
Footnote to Table 1: DSS, the Dahi sait-sensitive strain; MNS, the Milan normotensive
strain strain; bp, base pairs; Supercontigs are those obtained from blasting an existing
marker on the map to the rat genome database at
http://www.ncbi .nl m .nih.ov/genomc/seg/RnB1ast.html. Only p01 yrnorphic markers
used in octr present work are Iisted. Under condition: P represents polyacrylamide and
A represents agarose gel electrophoresis.
Rat Supercontig Primer sequences (5’ 3’) Size Temp Condition Polymorphism
(Bp) (°C) (PorA) arnong
arer rat strains
D2Chum24 NW047625 TTCGGTrGTTGAGACCCATT 245 60 A DSS<MNS
GCCAGAGGTCGAGTTCAAAG
D2Chum25 NW_047625 GAGAGGGATATAACATGGACAGG 244 60 A DSS>MNS
CCACTTTCATTGCTFCTTTGG
D2Chum33 NW_047625 AGGCAGAGTTGGACGAAGAA 209 60 A DSS>MNS
TGCAGCTCAACCAGAAAATG
D2Chum46 NW_047625 TTCCTCCCTTGCCCTACTCT 204 60 A DSS<MNS
CACCAGGTGAAACTCCCACT
D2Chum5 1 NW_047625 ACTTCGCAAGCATTGGAAAC 227 60 A DSS>MNS
CCCCTTTTTCTCTCCCAACA
D2Chum57 NW_047627 CTACTGGAAACAGCCCCATC 225 60 A DSS<MNS
GGGGGTGTTTATTTTTGCAT
D2Chum9O NW_047625 TTGGAGTTCATTAAGCAACACAG 242 60 P DSS>MNS
CCTTCTGGAAAAAGGTAAACCA
D2Chuml 13 NW_047625 TGTGGGTGTGGGTGTGTATC 248 60 A DSS<MNS
TGGCCCAAATACTTCCTGA
D2Chuml22 NW047625 GTGTCACAGAGCAGCAGGAA 197 60 A DSS<MNS
GGTGGAAAGGTTGTTGAGGA
D2Chum225 NW_047625 ACAAGCAAGAAGGCACCACT 168 60 A DSS<MNS
GCCTGTGGAGAGAAGTGACC
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Figure 1. Separations of two congenic strains by a critical new chromosome
marker. The iinkage map is essentiaily the same as published previously 1;5;6;2$ which
is based on an F2(S x MNS) population. Numbers to the left of the linkage map are
units in cM. RH map refers to the map using rat/hamster radiation hybrids, in which
units are in centiRays (cR). Numbers on the RH map are arbitrary units descending
from the top of the chromosome. Solid bars under congenic strains symbolize the DSS
chromosome fragments (i.e. in an open bar) that have been replaced by that of the MNS
rat. Hatched bars on ends of solid bars indicate the ambiguities of crossover breakpoints
between two markers. The rest of Chr 2 and the rest of the congenic genomes were
homozygous SS. Adh, alcohol dehydrogenase; Agtr]b, angiotensin receptor type lB;
Atp]a], NaK-ATPase OEl; Caink2d, calmodulin-dependent protein kinase II-delta;
Fgg, fibnnogen gamma; Gca, guanylyl cyclase A/atrial natriuretic peptide receptor;
Mine, membrane metailo-endopeptidase (neutral endopeptidase, enkephalinase); Prir,
prolactin receptor. D2Chm9O and the rest of the markers are anonymous either from our
current (Table 1) and previous 28 work, and from the rat genome data bases
(http:Ilwww.ncbi .n Im.ni h. gov/genome/seg/RnB] ast.html). DSS, the Dahi sait-sensitive
strain. Congenic strains were as foiiows: S.M, DSS.MNS-(D2Mit6-Adh)ILt; S.M1,
DSS .MNS-(D2Mit6-D2Ratl66)/Lt; S .M2, DSS .MNS-(D2Mit6-D2Rat3O3)ILt; S .M5,
DSS .MNS-(Mme-D2Mitl4/Lt) and S .M6, DSS .MNS-(Mme-D2Ratl3 1 )[Lt. BPs of
these strains were reported previously 5;6 MAP refers to the averaged mean arterial
pressure during the period of measurement for each strain. The localization of C2QTLÏ
is shown. The QTL region indicated that the interval initially thought to harbor onÏy
C2QTL2 actually contains C2QTL2 and C2QTL3 (Figure 2).
Figure 2. Mapping of multiple BP C2QTLs. Chr 2 map and depictions of new
congenic substrains are essentially the same as that for Figure 1. The regions harboring
the QTL5 for BP have been enlarged for better presentations. Solid bars under congenic
substrains symbolize the DSS chromosome fragments (i.e. an open bar) that have been
replaced by that of the MNS rat. Hatched bars at ends of solid bars represent the
segments of crossover ambiguity between two markers. The entire region indicated by
solid bars and junctions between the solid and open bars are homozygous for MNS, i.e.
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MM, on the map for ail the markers iisted in the colTesponding positions. The rest of
Chr 2 and the rest of the congenic genomes were SS. DSS, Dahi sait-sensitive strain;
DSS .MNS-(D2Ratl $3-D2Chm 11 3)/Lt (abbreviated as C2S .M7), DSS .MNS
(D2Chm25-D2Mit 14)/Lt (C2S .M8), DSS .MNS-(D2Chm25-D2Ratl 31 )/Lt (C2S .M9),
DSS .MNS-(D2Wox27/Aclh)/Lt (C2S .M1 O), DSS .MNS-(D2Chm5 1-D2Rat3 $)fLt
(C2S.M1 1) and DSS.MNS-(D2Chm25-Fgg)/Lt (C2S.M12). C2Chm markers are given
in Table 1. For explanations of MAP comparisons and most of the marker designations,
see the legend for Figure 1. Gucyla and Gucy]b are the soluble subunits Œ and f3 of
guanyiate cyciase 1 genes respectiveiy. They have been excluded as candidate genes for
a C2QTL because C2S.M12 did flot exhibit a BP effect. The placements of C2QTL1,
C2QTL2 and C2QTL3 were indicated by brackets to the right.
Figure 3. Comparisons of BPs between congenÏc substrains, and the DSS strain. a,
d, g, j, m: systolic arterial pressures (SAPs), b, e, h, k, n: Diastoiic arteriai pressures
(DAPs), and c, f, i, 1, o: mean arterial pressures (MAPs). Error bars represent SEM. n
refers to the number of rats. BP response pattems such as diumai variations among ail
the congenic strains were flot different (data flot shown). BPs of each strain were
measured, at least, during two different time periods, and then pooled to produce the
final BP readings. For the simplicity of presentation and comparison, only a 24-hour
average of BP is taken as one data point on the graph for each strain. DSS, Dahi sait-
sensitive strain; For designations of the rest of the strains see the iegend for Figure 2.
Figure 4. Epistatic and additive ïnteractions among C2QTL1, C2QTL2 and
C2QTL3: The left three columns in (a) and (b) represent differences in mean arteriai
pressure (MAP) between a congenic and DSS strains, i.e. BP lowered by a congenic
strain. The iast coiumn to the right in (a) and (b) indicates a ‘predicted’ value of MAP
iowered by combining different C2QTL5. The BP effect of C2QTL1 is represented by
congenic strain S.M1 (Figure 1) or C2S.M7 (Figure 2); the BP effect of C2QTL2 is
represented by congenic strain C2S.M9 (Figure 2); the BP effect of C2QTL3 is
represented by congenic strain C2S.M1 1 (Figure 2); the BP effect of [C2QTL2 and
C2QTL3j is represent by congenic strain S.M6 (Figure 1); and the BP effect of
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[C2QTL1 and C2QTL2 and C2QTL3] is represented by congenic strain S.M (Figure 1).
p indicates a significant QTL-QTL interaction or no interaction as pefformed by 2 x 2
factorial analyses 22 a), The ‘observed’ BP effect of one congenic strain combining
[C2QTL1 and C2QTL2 and C2QTL3] is different (p interaction <0.03) from a
‘predicted’ sum of BP effects from an individual congenic strain containing [C2QTL2
and C2QTL3] plus another individual congenic strain containing only C2QTL1. Thus,
there is a QTL-QTL interaction between C2QTL1 and [C2QTL2 and C2QTL3J. b), The
‘observed’ BP effect of one congenic strain combining C2QTL2 and C2QTL3 is not
different (p interaction >0.5) from a ‘predicted’ sum of BP effects of C2QTL2 +
C2QTL3. Thus, there is no QTL-QTL interaction between C2QTL2 and C2QTL3.
Congenic strains
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6.1 ABSTRACT
Vascular hyperpiasia may be involved in the remodeling of vasculature. It was
unknown if there were genetic determinants for aortic smooth muscle celi number
(SMCN) and, if yes, whether they acted independently of those for blood pressure (BP).
To unravel this issue, we utilized congenic strains previously constructed for BP studies.
These strains were made by replacing various Chromosome 2 segments of the Dahi sait-
sensitive (S) rat with those of the Milan normotensive rat (IVINS). We measured and
compared SMCN in aortic cross sectional areas and BPs of these strains. Consequently,
a quantitative trait locus (QTL) for SMCN was localized to a chromosome region not
containing a BP QTL, but harboring the locus for the angiotensin II receptor AT1B
(Agtr] b) . Agtr]b became a candidate for the SMCN QTL because a) two significant
mutations were found in the coding region between S and ail congenic strains
possessing the MNS alleles and b) contractile responses to angiotensin II were
significantly and selectively reduced in congenic rats harboring the MNS alleles of the
SMCN QTL as compared to S rats. The current investigation presents the first une of
evidence that a QTL for aortic SMCN exists, and it acts independently of QTLs for BP.
The relevant congenic strains developed therein potentially provide novel mammalian
models for the studies of vascular remodeling disorders.
Key words: functional genomics, Dahi sait-sensitive rats, Milan normotensive rats,
aortic hyperpiasia, vasoreactivity, congenic strains
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6.2 INTRODUCTION
Hypertrophy andlor vascular hyperpiasia may contribute to the elasticity/rigidity of the
blood vessel, and peripheral vascular resistance. Although, cardiac hypertrophy and
hypertension were sometimes associated, there were indications that genes for BP and
left ventricular hypertrophy (LVH) could be separated in hypertensive models 1,2 LVH
can be deterrnined by genes from normotensive rats, independently of hypertension .
As for a relationship between hypertension and hyperpiasia, the initial evidence
indicated that the cultured aortic smooth muscle cells (SMC) proliferated faster (i.e.
hyperplasia) in the spontaneously hypertensive rats (SUR) than those in the Wistar
Kyoto rats (WKY) These findings suggested a link between hypertension and the
SMC proliferation. Since then, a large body of evidence lias been accumulated on their
associations 6-11 Based on these observations, one would expect that a higher SMC
proliferation might coiielate with a higher BP. Nevertheless, there was one genetic
study reporting that hypertension was not associated with the growth of skin fibroblast
in a F2 cross between SUR and WKY 12 This is not surprising because an association
between BP and the SMC growth in these two strains could simply be accidental not
causal, one way or the other.
Up to date, it remained unclear whether or not there are QTL5 determining vascular
SMC number and, if yes, whether or not mechanisms determining hypertension and
vascular hyperpiasia could be separated. Our cunent goal is to discover QTLs
controlling vascular SMC number regardless of, or unprejudiced by, its association or
dissociation with BP.
The power and utility of genetic analyses are evident in finding causal genes for
vascular hyperpiasia. The beauty of the genetic approach lies in its objectivity, i.e., one
is flot biased towards predicting an outcome based on a preconceived notion linking two
associated phenomena, e.g. hypertension and hyperplasia. Nor are we biased towards
the perception that hyperplasic alleles of a QTL, if it existed, had to corne from a
hypertensive strain, but flot from a normotensive strain. If hypertensive alleles of a QTL
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for BP could originate from a normotensive strain, and vice versa 13,14 one can expect
that SMC-increasing alleles of a QTL could originate from a normotensive strain.
Ever since the revelation of a QTL for BP in Dahi sait-sensitive (S) rats 15,16 rat Chr 2
appears to play an important role in the development of hypertension in several of the
hypertensive strains 17-27 In the process, a number of congenic strains have been
developed that cover various regions of Chr 2 of S rats 28,29 Taking advantage of these
resources, some questions couid be addressed regarding QTLs for hyperpiasia.
Specifically (a), is there a QTL for vascular hyperpiasia, and particularly for aortic
smooth muscle celi number (SMCN) in S rats? If yes, does it act independently of
blood pressure? And (b), if there is a QTL specific for SMCN, can any gene be
supported as a candidate?
In the present studies, BPs of certain congenic strains were compared along with their
respective indices of vascular SMCN, and vascular, cardiac, and renal weights, and the
intemucleosomal DNA fragmentation, an indicator of apoptosis. Additionally, when a
candidate gene was found in the region containing the QTL for SMCN, sequencing
would be conducted to detect significant mutations that could have the potential to alter
the expression or/and the function of the gene.
6.3 METHODS
6.3.1 Animais
For the sake of easy distinctions for congenic strains specifically made for Chr 2, a
prefix of C2 is added in front of congenic designations. Thus the congenic strains
previously utilized 28,29 S.M, S.M1, S.M2 and S.M6, are re-designated as C2S.M,
C2S.M1, C2S.M2 and C2S.M6 respectively (Figure 1).
6.3.2 Marker development
We examined ail the available markers in the rat database for the region between
D2Ratl66 and Mine (Figure 1). But none of them was either homozygous SS or Mlvi for
C2S.M1 and C2S.M6. Therefore, potential overlaps could flot be ruled out between the
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lower segment for BP C2QTL1 29 and the upper segment for BP C2QTL2 28 This
ambiguity called into question whether or flot BP C2QTL1 and BP C2QTL2 were
separate or merely represented the same QTL, but under the influence of a different
background.
To prove that BP C2QTLÏ and BP C2QTL2 are separate genes, one had to find a
marker between D2Ratl66 and Mine that is SS for both C2S.M1 and C2S.M6. For this
purpose, we employed the rat genome data base. Supercontigs located in Chr 2 region
between D2Ratl66 and Mme were first identified by blasting them at the website,
http:Ilwww.ncbi .nlm.nih.gov/genome/segfRnBlast.html. From such a supercontig,
regions containing microsatellites were searched, and when found, were used to design
markers for genotyping rats based on PCR. These new markers were designated with
D2Chm prefixes, which represent the Centre Hospitalier de l’Université de Montreal
(CHUM). Consequently, a series of markers were generated. One particular marker
designated D2Chm90 was polymorphie and located in the region of interest (Figure 1).
6.3.3 BP studies and tissue extractions
BP studies on the congenic strains were reported in detail previously 28,29 In brief, male
rats were weaned at 21 days of age, maintained on a low sait diet (0.2% NaC1, Harlan
Teklad 7034) and then fed a high sait diet (2% NaC1, Harlan Teklad 94217) starting
from 35 days of age until the end of the experiment. Telemetry probes were implanted
when rats were 56 days old (i.e. after 3 weeks of the high sait diet) with their body
weights between 250-320 grams. The BP measurements lasted until the time of
sacrifice.
Rats were sacnficed by decapitation 30 days after the commencement of their BP
measurements, i.e. at 14 weeks of age. The organs of interest (see the following
sections) were removed, cleaned carefully from surrounding adventitial connective
tissues and fat, blotted to remove excess blood, and weighed immediately. To minimize
any potential inconsistency in the collection, one person was designated for harvesting
one particular organ and also for the subsequent dissections into sub-sections of interest.
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The whole heart was then dissected into the left ventricle plus the septum, and into right
ventricle. The weight of each section was then recorded and corrected for the body
weight of the respective animal. The dissection was according to a previously published
procedure 30,31
6.3.4 Measurement of aortic cross sectional areas (CSA)
The following procedure was done essentially according to that previously published 32
The thoracic aorta was isolated from the diaphragm to above the first intercostal artery
and cleaned of adherent adventitial tissue and fat. A 3-mm-long ring of aorta was cut
between the third and fourth intercostal arteries. The aortic rings were immerse-fixed in
4% parformaldehyde overnight and processed according to routine histological
procedures for morphological examinations in parafin-embedded tissues. The fixation
of aortas was done in non-pressure-controlled conditions. The aortic endothelium of the
remaining aorta segments was removed by scrubbing the intimal surface with a cotton
tïp applicator. The aortic media was immediately snap frozen in liquid nitrogen and
kept at —80°C until further processing for DNA extraction.
The medial cross-sectional area was evaluated in 5-m-thick, hematoxylin-eosine
stained sections of aorta. Photomicrographs of the aortic sections were taken at 400x
magnification, digitalized, and analyzed using the public domain Nifi Image program
1.61 (developed at the National Institute of Health and available on the Internet at
http://rsb.info.nih.gov/nih-image/). Two independent measurements of each tissue
section were conducted to ensure the reproducibility of the image analysis.
6.3.5 Determination of vascular SMCN
The following was done essentially according to the procedure previously published
Briefly, three consecutive sections (5 tm thickness) were obtained from aortic rings
sectioned perpendicularly to the longitudinal axis of the vessel. Tissue sections were
stained with hematoxylin, photographed, and printed at a final magnificatlon of 400X.
In the top section, an area, au, of vessel wall was delineated by two parallel lines
approximately perpendicular to the wall edges. A disector was defined as the three
122
dimensional probe bounded by au and the top surface of the “bottom” section. The
disector has volume vu = au X bu, where au is the area of the disector and hu is the height
of the disector. The term bu is obtained by the following equation h = (s- 1) X t, where s
is the number of serial sections and t the average section thickness. Within au, the
number of nucleus profiles, nt, was determined and in the subsequent sections, each of
the n nuclei was followed and marked. In the final section, the number of nuclei still
present was determined, nb. The number u = (nt-nb) is then the number of “downward
pointing” nucleus ends within the disector when counting from top to bottom.
Binucleate SMC account for less than 0.5% of the SMC in the thoracic aorta of
hypertensive rats Therefore, on the assumption that each celi contains only one
nucleus, an estimate of celi numerical density, N, is given by N = nul VU. The number
of ceils per unit vessel length then was estimated from a1 X N, where a1 is the medial
cross-sectional area determined with the image analyzer as described above.
6.3.6 DNA content and apoptosis
The remaining aortic media was pulverized in liquid nitrogen. The total tissue DNA was
extracted and quantified as described previously To quantify the degree of
intemucleosomal DNA fragmentation, a hallmark of apoptosis (programmed celi death),
the 3’OH ends in the extracted DNA were radiolabeled using 32P-dNTP and terminal
deoxynucleotidyl-transferase. DNA was separated by gel electrophoresïs, blotted, and
radioactivity incorporated in the small fragments (150 to 1500 bps) was quantified using
a Phospholmager as described previously 36•
6.3.7 Vasoreactivity studies
Vasoactive responses to angiotensin II (Angil) and phenylphrine (PE) were examined as
described previously in rings of thoracic aorta isolated from of S and C2S.M2
implanted or not with a telemetry probe. Briefly, rats were killed by exposure to C02
and freshly-isolated vessels without adventitial adipose and connective tissue or
endothelium were cut into 3-mm-long rings to be placed at 37°C in organ chambers
filled with oxygenated Krebs solution containing in mM: dextrose, 11; NaCI, 117.5;
MgSO4, 1.18; KH2PO4, 1.2; NaHCO3, 25; KCÏ, 4.7; CaC12, 2.5. Isometric contractions
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were measured with the use of isometric force transducers (Harvard Apparatus Canada)
and a digitalized data acquisition system (Model MPYOO, Biopac System, Harvard).
Rings were equilibrated under a passive tension of 1 g and then challenged with 40
mmolIL KCI to document receptor-independent contractility. Tissues were also
stimulated with cumulative concentrations of PE (1 — 100 mmol/L) and AnglI (300
pmol/L to 300 mol/L). Separate sets of rings were used to measure contractile
responses in the presence or absence of L-NAME (100 molIL). The integrity of the
endothelium was evaluated on the plateau of PE-induced maximal contraction by
measuring the relaxant response to Ach (1 /Lmol/L). In a subset of tissues, Angil
induced contractile effect was also evaluated in the presence of losartan (75 nmol/L).
6.3.8 Statistical analysis
In BP analyses, repeated measures’ analysis of variance (ANOVA) followed by
Dunnett, (which permits a correction for multiple comparisons and sample sizes), was
used to compare a parameter between 2 group as presented previously 28,29 During the
comparison, ANOVA was, first, used to analyze the data to see if there was any
difference among the groups. If the difference is significant, then, the Dunnett test was
followed to see which group is different and how much significant from the S strain. If
the difference is not, then, no Dunnett test followed. In functional vasoreactivity
studies, data from S and C2S.M2 were compared using unpaired Student t test using
Prism 4.0 (GraphPad Software).
6.4 RESULTS
6.4.1 Localization of a QTL for vascular SMCN ïndependent of BP QTLs
The marker, D2Chm9O, is important (Figurel). It came from the same supercontig,
NW_043524, containing lime and is homozygous MM for C2S.M, but SS for C2S.M1,
C2S.M2, and C2S.M6 (Figure 1). Thus D2Chm9O effectively separated C25.M1 from
C2S.M6.
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The most informative strain is C2S.M2 (Figure 1), which had no effect on BP (reference
17 and summarized at the bottom of Figure 1) and had the same cardiac, left ventricular
and renal weights as S (Figure 2 a and b), but showed higher SMCN (Table 1). In fact,
aortic SMC counts of both C25.M1 and C2S.M2 were higher than that of the S strain
(p<O.O39). In contrast, SMC counts of the C2S.M6 and C2S.M strains were not
different from that of the S strain (Table Ï).
Figure 2c shows comparisons of aortic cross sectional areas (CSAs) between a congenic
and the S strain. C2S.M6 had smaller CSAs than S (p<O.006). CSAs (Figure 2c)
showed the same tendency as the SMC counts (Table 1). Both C2S.M1 and C2S.M2
had slightly larger, although flot significantly different, CSAs than S.
Figure 2 also shows comparisons of cardiac and renal weights corrected for body
weights among the strains. Kidney weights in C2S.M1, C2S.M6 and C2S.M were lower
(p<O.O3) than those of the S rats; whereas these of C2S.M2 were not different from
those of the S rats (Figure 2 a and b). Cardiac and left ventricular weights were only
significantly lowered in C2S.M and C2S.M6 (p<O.O3), but flot in C2S.M1 strains
(P>O.IO). Table 2 shows assessments of DNA content and DNA fragmentation indices
in both cardiac ventricles and aortas.
In terms of the DNA fragmentation indices and DNA contents comparing various
strains, a possible relationship between apoptosis (or DNA synthesis) and hypertension
or aortic SMC number remains to be investigated further. There was a suggestive
correlation between tissue weights and the DNA content in both ventricles (Table 2).
Moreover, although the DNA fragmentation suggested a tendency to be inversely
correlated with the DNA content in the left ventricle, with a significant decrease in DNA
content in the C2S.M and C2S.M6 strains as compared to the S strain. In the right
ventricle, the DNA fragmentation was significantly increased in the C2S.M strain only.
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6.4.2 The angiotensïn-receptor AT1B (Agtrlb) gene as a candidate for the
SMCN QTL:
In previous pharmacological studies, we observed that AT1 not AT2 receptors were
involved in the SMC growth 38,39, implying that AT1 receptors might be important in
mediating the SMC proliferation. There are two types of AT1 receptors, ATÏA and
AT1B, encoded by Agtr]a and Agtr]b genes respectively. In our congenic strains, the
Agtrla gene on Chr 17 40 was the same as s 28,29,41 but the Agtr]b on Chr 2 (Figure 1)
was different in that it contains the alleles from the Milan normotensive strain (MNS)
(Figure 1). Because it is located in the chromosome region harboring the SMCN QTL
(Figure 1), Agtr]b could be conceived as a candidate gene for the SMCN QTL. We
reasoned that to qualify Agtrlb to be the candidate gene, it had to contain significant
mutations that could potentially resuit in differences either in its function or in its level
of expression between S and congenic strains trapping the SMCN QTL.
Mutational evidence supporting Agtr]b as a candidate gene of the SMCN QTL: Indeed,
when Agtr]b genes were cloned and sequenced, several nucleotide mutations were
detected in its coding region. Two of these mutations were of special interest in that
they were found in MNS, C2S.M, C25.M1, and C25.M2, but were different from those
in C2S.M6 and S, which had the same nucleotides. These two nucleotides resulted in
significant changes in amino acids. One of T to C change at nucleotide position 6
caused a change of (aliphatic) isoleucine to (hydroxyl) threonine at amino acid position
2. Another nucleotide of A to G change at nucleotide position 118 resulted in a
significant change of (sulfuric) methionine to (aliphatic) valine at amino acid position
20. The nucleotide positions were numbered from the sequence coding for the first
amino acid as given previously 42 These mutations support functional implications of
Agtr]b as the candidate for the SMCN QTL (Figure 1), since C25.M, C2S.M1, and
C2S.M2 possess MNS alleles at Agtrlb (i.e. C at position 6 and G at position 118);
whereas C2S.M6 possesses S alleles at Agtrlb (i.e. T at position 6 and A at position
118).
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Functional evidence supporting Agtr]b as a candidate gene of the SMCN OTL: If the
mutations found in Agtr]b were truly significant, one is expected to observe functional
differences between the MNS Agtr]b and S Agtrlb genes.
For the subsequent functional study, C2S.M2 was chosen because it carnes a smaller
chromosome interval of MNS than C2S.M1 (Figure 1). In our work, contractile
responses to Angli were documented in rings of aorta isolated from C2S.M2 and S rats.
The analysis indicated that contractile responses were flot different whether a telemetry
probe had been implanted (N=6/strain) or flot (N=6-7lstrain) and the data were therefore
pooled for each strain. As shown in Table 3, contractile responses to AngIl were
significantly reduced in C2S.M2 rats as compared to S rats, without a significant change
in apparent receptor affinity. The contractions induced by AngIl were AT1 receptor
dependent since they were significantly inhibited (>90%) in the presence of losartan
(data not shown). In contrast, there was no inter-strain difference in the contractile
responses to phenylephrine (aiphai-adrenergic agonist) or KC1 (receptor-independent
contractile stimulus) (Table 3). Similar conclusions were reached with tissues
challenged in the presence or absence of the NO synthase inhibitor L-NAME (Table 3).
Thus, the hyperplasic aorta from C2S.M2 rats exhibited a selective decrease in Angil
induced, ATÏ receptor-dependent contractility as compared to S rats.
6.5 DISCUSSION
Major findings from the current studies are (a), there is a QTL(s) determining vascular
smooth muscle cell number (SMCN) which acts independently of QTLs for blood
pressure. (b), The Agtr]b is a candidate for such a QTL based on two lines of evidence,
gene mutations and their functional consequences. That is to say that significant
nucleotide differences resulted in functional differences in Agtrlb between the S strain
and the congenic strain carrying Agtr]b alleles from MNS. The significant functional
correlates were shown in vasoreactivity studies.
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6.5.1 A QTL for the vascular SMCN functions independently of QTLs for
hypertension
C2S.M1 had a BP lower than S [Figure 1 and reference 29 but had more aortic SMCN
(Table 1). In contrast, C2S.M2 had the same BP as S [Figure 1 and reference 29 but
showed SMCN similar to those of C2S.M1 (Table 1). This fact clearly indicates that
these genetic determinants for BP and aortic SMCN act independently of each other.
Upon examining the chromosome interval on the map, the QTL for the aortic SMCN
should be present in the chromosome fragment shared between C2S.Ml and C2S.M2,
which is between Prir and D2Rat3O3 markers (Figure 1). In contrast, BP C2QTL1
exists in the segment flot shared between C25.M1 and C2S.M2, i.e. between the
D2Rat3O3 and Mme markers (Figures 1). It is noted that the QTL for the vascular
SMCN acts independently, also, of cardiac, left ventricular, and renal hypertrophy,
because C2S.M2 had the same cardiac, left ventricular and renal masses as S (Figure 2a
andb).
By the use of two congenic strains, a stringent genetic testing, aortic SMCN and BP
have different genetic, and possibly physiological, bases. Although MNS rats per se
were flot directly analyzed for SMCN, C2S.M6 served effectively as a negative control,
because it contained a small segment from the MNS strain flot including the region
delineated by Prtr and D2Rat3O3 markers (Figure 1). Since C25.M6 has no
hyperpiastic effect, whereas C2S.M1 and C2S.M2 do (Table 1), the effects to increase
SMCN in C2S.M1 and C2S.M2 have to be attributed to the QTL residing in the
PrÏr/D2Rat3O3 segment, not to any MNS genetic background. The MNS rat would flot
be a good control, because it differs greatly from the S genome on the rest of the
chromosomes and because it gives no information on the effects of genome changes
during the congenic construction
Because SMCNs were slightly different (Table 1) between C2S.M1 (170 ± 11) vs
C2S.M2 (134 ± 21), a possibility can not be ruled out that there could be another QTL
for SMCN in the region of BP C2QTLÏ (Figure 1). In that case, the same QTL could be
responsible for both BP and SMCN.
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It is noteworthy that the alleles to increase SMCN corne from MNS, which is
normotensive. Nonetheless, it is flot surprising that MNS QTL alleles cause SMCN to
increase, whereas S QTL alleles decreased SMCN. In an independent study, Lewis rats,
a normotensïve strain, actually carry BP-increasing alleles in comparison with S at a
QTL on Chr 3, although the overail BP of the Lewis strain is considerably lower than
that of the hypertensive S strain 14 This fact indicated that the BP-increasing QTL
alleles in Lewis were hidden and were only unveiled by isolating the region harboring it
from the rest of the Lewis genome by congenic strains. Therefore, our present and
other studies further demonstrated the power and necessity of genetic dissections of
individual QTLs using congenic strains.
The detection of BP C2QTLÏ added a further proof for the power of congenic approach.
In linkage analysis, there was no indication that a QTL existed in the region around
C2QTLÏ 46,47• It is only after the isolation of a segment by using a congenic strain
(C2S.M1) that BP C2QTL1 was found 29 This phenornenon is due, probably, to
epistatic gene-gene interactions among other things and indicates that the effect of
the genetic background impacted by other QTLs affecting the same phenotype may need
to be removed for the manifestation of a QTL for SMCN (Figure 1).
It is also of note that C2S.M strain included the chromosome segment contained in
C2S.M1 and C2S.M2 (Figure 1), and yet, C2S.M did not show hyperplasia (Table 1).
This phenomenon can be explained by the following. There could be another QTL or a
modifying gene present in the segment in C2S.M but lacking in C2S.Ml, i.e. between
D2Ratl66 and Adh that would have a hypoplasic effect. When combined, the overall
effect would be hypoplasic. There was an example of this epistatic interaction between
two QTL5. When BP-lowering alleles at one QTL was experimentally put together with
BP raising alleles at another QTL, the combined effect was the same as that of the BP
lowering alleles on Chr 14 This fact indicates that these QTL5 do flot act alone, but in
a hierarchical relationship with each other in controlling the overail BP. The same
principle could be applied to the genetic determinants of SMCN.
129
As to the mechanisms for increasing SMCN, there are two possibilities. The QTL could
either favor the SMC proilferation or reduce the SMC death. The present data showing
an inverse relationship between DNA fragmentation and SMCN (Table 2) suggest a
possible role for reduced apoptosis. Defining the relative contribution of these cellular
mechanisms, however, is worthy of further investigations.
6.5.2. Agtrlb is a candidate gene for a SMCN QTL
It is noted that Agtr]b is present in the region containing the QTL for SMCN (Figure 1).
Interestingly, we detected two nucleotide differences leading to significant changes in
amino acids in congenic strains possessing MNS Agtrlb alleles (i.e C2S.M, C2S.M1,
and C2S.M2), and that possessing S Agtrlb allele (i.e. C2S.M6) (see the result section
for detail). The presence of these mutations in Agtr]b corresponding to the location of
the QTL provides a possible mechanism for increased SMCN, because the pro-growth
and anti-apoptotic effects of AT1 receptors on SMC are well known
The mutations found in Agtr]b could have functional roles in controlling SMC
proliferation. As an initial investigation of this issue, we chose to measure contractile
responses to Angli since this is a proximal marker of receptor function. Surprisingly,
we observed that responses to Angli were reduced in C2S.M2 vs S rats. We speculate
that a prior AT1 receptor activation in vivo may have resulted in receptor desensitization
in the aortic tissue isofated from C2S.M2 rats. Such a negative effect of in vivo receptor
activation on the vascular sensitivity ex vivo seems reminiscent of hypertensive human
and rat arteries, where an enhanced local expression of endothelin resulted in a selective
attenuation of contractile responses to endothelin in tissues stimulated ex vivo 50•
Altematively, the altered responses to Angil may be an epiphenomenon. In vitro studies
with cultured SMCs are needed to better define the functional conelates of the
mutations in Agtrlb and its significance for the SMC proliferation.
Another way to validate if Agtrlb would remain a good candidate gene or flot for the
SMCN QTL is by fine congenic mapping. If Agtr]b is the SMCN QTL, no matter how
small the region harboring the QTL is minimized to (e.g. 100-200 kb), Agtrlb should
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aiways be included in the same region, and this congenic substrain should also have an
effect on SMCN. Alternative, Agtr]b could simply be a marker indicating the approximate
location of the QTL for SMCN. The inducible form of the nitric oxide synthase (Nos2) is
a case in point. Nos2 was located in a broad region containing a QTL for BP initially, but a
fine mapping ruled it out as a QTL because a congenic strain harboiing it did flot show a
BP effect ‘. Furthermore, fine congenic mapping will also test the possibility if there
are multiple QTL5 for SMCN present in the interval between Prir and D2Rat3O3.
In summary, a major finding in the present work is that there is a QTL(s) for vascular
SMCN that acts independently of hypertension. This discovery has laid the foundation
for the identification of the QTL and will lead to revelations of its underlying
physiological mechanisms regulating of vascular remodeling independently of BP.
Agtrlb is a candidate gene worthy of further investigations to be the SMCN QTL by
fine mapping and in vitro functional assays. Utilizing the same strategy of fine congenic
mapping and comparative congenic mapping of BP QTL5, the QTL(s) for SMCN can
and will be localized to a smaller interval for candidate cloning (i.e. Agtr]b), or if not,
then positional cloning.
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6.8 FIGURE LEGENDS, LEGENDS AND TABLES
Figure 1. Mapping of a QTL for vascular SMCN independently of BP QTLs. The
linkage map is essentially the same as published previously 16,5255 which is based on an
F2(S x MN$) population. Numbers to the left of the linkage map are units in cM. RH
map refers to the map using rat/hamster radiation hybrids, in which units are in
centiRays (cR). Numbers on the RH map are arbitrary units descending from the top of
the chromosome. Solid bars under congenic strains symbolize the S chromosome
fragments that have been replaced by that of the MNS rat. The entire region indicated
by solid bars andjunctions between the solid and open bars are homozygous for MNS,
i.e. MM, on the map for ail the markers Iisted in the corresponding positions. Open bars
on ends of solid bars indicate the ambiguities of crossover breakpoints between markers.
Adh, alcohol dehydrogenase; Agtr]b, angiotensin receptor type lB; Atplal , NaKt
ATPase cd; Canzk2d, calmodulin-dependent protein kinase II-delta; Fgg, fibrinogen
gamma; Gca, guanylyl cyclase Alatrial natriuretic peptide receptor; Mine, membrane
metallo-endopeptidase (neutral endopeptidase, enkephalinase); PrÏr, prolactin receptor.
D2Chm9O is a newly produced marker. Primers used are forward 5’-
TTGGAGTTCATTAAGCAACACAG-3’, and reverse, 5’-
CCTTCTGGAAAAAGGTAAACCA-3’. The rest of the markers are anonymous. S,
the Dahi sait-sensitive strain. Congenic strains were as follows: C2S.M, S.MNS
(D2Mit6-Adh)/Lt; C25 .Ml, S .MNS-(D2Mit6-D2Ratl66)/Lt; C2S .M2, S .MNS
(D2Mit6-D2Rat3O3)/Lt; and C2S.M6, S.MNS-(Mme-D2Ratl3l)/Lt. MAP refers to the
averaged mean arterial pressure during the period of measurement for each strain 28,29
ANOVA with the Dunnett’s correction compares MAPs between S and each of the
congenic strains. The placement of the QTL specifically for SMCN is indicated by a
bracket. So are these for two BP C2QTL1 and BP C2QTL2.
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figure 2. Comparisons of cardiac and renal parameters and cross sectional areas
of aortas between the congenic and the S strains. The number of rats for each strain
in the comparisons is as follows: for (a), C2S.M (n=5), C2S.M1 (n=9), C2S.M2 (n=1O),
C2S.M6 (n=5), S (n=Ï Ï); for (b) C2S.M (n=5), C25.M1 (n=5), C2S.M2 (n=ÏO),
C2S.M6 (n=5), S (n=7); and for (c), C2S.M (n=5), C25.M1 (n=$), C2S.M2 (n=8),
C2S.M6 (n=4), S (n=1O). HW, heart weight; LVW and RVW, left and right ventricular
weight; KW, lddney weight; LKW and RKW, left and right lddney weight; BW, body
weight; CSAs, cross sectional areas of aortas; mg, milligram; g, gram. HW, LVW,
RVW, KW, LKW and RLW were corrected for BW. For congenic strain designations,
see the legend for figure 1.
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Table 1: Comparisons in aortic smooth muscle celi numbers (SMCN) between the
congenic and the S strains.
Strains SMC number (SMCN)
n (ce1ls/im) p
C2S.M 5 58±9 0.275
C2S.Ml 8 170± 11 <0.0001
C2S.M2 8 134±21 0.039
C2S.M6 4 71 ± 4 0.775
S io 90±4
Footnotes to Table 1: p, ANOVA comparing the S with a congenic strains with Dunnett
corrections; SEM, ± standard error of the mean. SMC, smooth muscle ceils; n, number
of rats. For congenic strain designations, see the legend for Figure 1. Rats for each
strain were taken from multiple litters, and any potential litter effect among litters of the
same strain were found flot to be significant.
n
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Table 2: Comparisons in cardiac and vascular parameters between congenic and S
straïns.
Aortic Cardiac
Left Ventricle Right Ventricle
Strains DNA Frag. DNA DNA Frag DNA content DNA Frag
Index content Index (JWg) Index
(arb units/pixel/ (igJg) (arb units/ (arb units/
tg DNA) pixel4tg DNA) pïxel4tg DNA)
C2S.M
5 36±9 3.0±0.2 83±10 1.13±0.05 83±10
0.0015 0.005 0.075 0.114 <0.0001
C2S.M1
4 0.23 ± 0.06 5.0 ± 0.5 6 ± 5 0.50 ± 0.09 3 ± 1
[ 0.291 0.833 0.075 0.114 0.878
C25.M2
5 6±2 5.0±0.5 8±1 1.2±0.09 7±2
—r 0.784 0.331 0.075 0.114 0.999
C2S .M6
5 6±1 3.7±0.3 249± 170 1.1±0.2 4±1
0.711 0.045 0.075 0.114 0.909
11 8±5 5.8±0.6 16±7 1.1±0.1 8±3
Footnotes to Table 2: p, ANOVA comparing the S with a congenic strains with Dunnett
corrections, which take into account multiple group comparisons and differences in
sample sizes; SEM, ± standard error of the mean; DNA content in the aorta is calculated
as microgram (jig) of DNA per millimeter (mm) of aorta conected for BW (g). DNA
content in the ventricle is calculated as jig of DNA corrected for BW. DNA
fragmentation (Frag) is calculated in arbitrary units per pixel unit area per tg of DNA.
For detail, see the ‘Method’ section. For congenic strain designations, see the legend for
Figure 1. P values for the DNA fragmentation index of the left ventricle and for the
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DNA content of the right ventricle were given uniformly among the strains because
ANOVA was flot significant among the strains. Consequently, no further analysis was
necessary.
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Table 3: Comparisons in contractile responses to KC1, angiotensin II and
phenylephrine between congenic strain C2S.M2 and S strain.
n KC1 Phenylephrine Angiotensin II
(g) Emax (%KC1) 10g EC50 Emax (%KCY) log EC50
Control
5 12 1.59±0.11 104.06±4.70 7.26±0.06 34.85±2.94 8.22±0.26
C2S.M2 13 1.62±0.09 100.16±5.63 6.96±0.17 19.33±3.67** 7.86±0.27
L-NAME
(100
ttntoÏ/L)
S 12 1.39 ± 0.06 141.72 ± 7.73 7.60 ± 0.05 50.61 ± 5.29 7.92 ± 0.36
C25.M2 13 1.60 ± 0.12 143.03 ± 6.62 7.41 ± 0.16 26.63 ± 4.00 t 7.20 ± 0.31
Footnotes to Table 3: Paired sets of aortic rings with endothelium were stimulated in the
presence or absence of L-NAME. For each strain, data from rats implanted (n=6/strain)
or flot implanted (n=6-7lstrain) with a telemetry probe were flot significantly different
(data flot shown), and were pooled. Resuits are expressed as mean ± SEM. ** p<O.O1 vs
corresponding S group; t p<O.001 vs coffesponding S group by unpaired Student t-test.
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CHAPTER 7
DISCUSSION
7.1 Effect of the chr. 2 congenic strains on heart rate
In chapter 4, we showed that the congenic strains $.M, S.M5 and S.M6, ail of which
having a BP lowering effect, had no effect on heart rate (HR) when averaged at 24
hours. From these observations, we concluded that blood pressure and heart rate are
controiied independentiy by different genes. However, some issues regarding the effect
of these congenic strains on HR remain to be discussed.
7.1.1 Circadian rhythms in TIR and BP
It has been well described that mammals are submitted to an internai dock that is
responsible for controlling circadian rhythms of behavior, physiology and metabolism,
including 24hr variations in BP and I. 206 In the transgenic rat TGR(mREN2)27, an
additional copy of the mouse renin gene ieads to overactivity of the renin-angiotensin
system.207 The TGR(mREN2)27 is characterized by hypertension, hypertensive end
organ damage and inverse circadian BP pattems 207 Consequently, one can wonder if
the HR effect in S.M, S.M5 and S.M6 may be masked by displaced circadian rhythms?
Upon doser examination of the HR curves within a 24 hour period, we noticed a
lowering of the heart rate (HR) in both S.M and S.M6, when compared to the DSS rat.
However, the timing circadian pattem did flot deviate from what we expected, reaching
the highest values during the nighttime.
It has been previously shown that in the DSS rat fed a high sait diet, there is an increase
in the amplitude of the circadian BP variations, but no shift in the timing of the BP peak
is observed. 20$ Similarly, when the TGR(mREN2)27 is submitted to sait loading, the
amplitude of the circadian MAP fluctuation is increased, without affecting the circadian
timing of the peak MAP. 209 In our congenic strains, despite a normal pattem of
circadian variation, we cannot exciude the possibility that the amplitude of the circadian
variations may hinder the statistical revelation of a significant difference between the
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TIR in S.M and S.M6 when compared to DSS. For a more definitive analysis of the TIR,
ït would be interesting to: 1) increase statistical power by measuring more animaIs, 2)
compare the congenic strains to the DSS at specific time points during the days and
night rather than averaging data for 24 hours.
7.1.2 Localization of a TIR QTL
If S.M and S.M6 congenic strains have in fact a lower HR than D$S, where would the
HR QTL map? Both S.M5 and S.M6 are congenic substrains derived from the original
congenic strain, namely S.M. From S.M, a first crossover event in the region between
D2Ratl66 and Nep resulted in the creation of a first substrain (data flot shown).
Subsequently, crossovers between D2Mitl4 and D2Wox37 and between Gca and
D2MghlO resulted in S.M5 and S.M6, respectively. From the familial history of the
strains, we cari conclude that the ambiguous regions in S.M5 and S.M6 are identical.
Hence, the MM region in S.M6 is entirely encompassed by the MM region of S.M5.
For this reason, the genetic determinants that are responsible for the TIR lowering in S.M
and S.M6, but not in S.M5, could flot be Ïocated in the region between D2Ratl66 and
Nep.
Given that the Mlvi region in S.M5 encompasses completely the MM region of S.M6,
how could we explain the presence of a HR effect in S.M and S.M6, but not in S.M5?
The study of epistatic interactions may provide an explanation for this apparent
discrepancy. In chr. 1 and chr. 10 congenic strains carrying SFW alleles on a WKY
background, it was showed that only the chr. 10 congenic strain had a significant
increase in BP. 210 When taken individually, the $HR chr. 1 congenic strain showed a
slight increase in BP that was not sufficient to reach statistical significance. 210
However, in a double congenic strain combing the chr. 1 and chr. 10 SUR regions, the
BP effect was higher that the sum of the chr. 1 and chr. 10 QTLs when taken separately.
210 In this case, the full expression of the BP effect was conditional to the presence of
SUR alleles on both, chr. 1 and chr. 10. The TIR effect observed in S.M6, but flot in
S.M5, may also be explained by epistatic relationshïps between QTLs. In effect, it is
possible that the combination of genetic factors present in S.M5 is not favorable to the
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expression of a HR QTL, whereas the genetic environment is more favorable in S.M6.
This issue could be resoÏved by the construction of congenic substrains in which the
Mlvi region is smaller and therefore less likely to contain more than one genetic factor
influencing the cardiovascular system.
7.2 QTL-QTL interactions
The use of congenic strains have revealed the presence of BP QTLs on Chr. 1, 3, 5, 7,
8, 9, 10, 12, 13, 15, 16, 17, and 18 of the Dahl rat 211 Given the number of QTL
identified in the Dahi rats, it will be interesting to investigate how these QTLs relate to
one another, how they interact. By definition, an additive relationship between two
QTL occurs when the sum of the BP effects of each QTL taken individually is equal the
BP effect of a congenic strain containing both QTL. In contrast, an epistatic relationship
occurs when the individual QTL BP effect are not equal to that of a congenic containing
both QTLs. To further describe the relationships between the different BP QTL, an
approach was proposed to assemble the QTL without knowing the physiological role
that each gene plays. 211 Using this strategy, one can hypothesize that the QTLs
demonstrating an additive relationship might be part of different physiological
pathways, whereas the QTLs that interact epistatically might be involved in the same
physiological pathway or cascade.
In Chapter 5, we have shown that the Dahl rat Chr. 2 contains at least 3 BP QTL, and
that C2QTLÏ is epistatic to either C2QTL2 or C2QTL3. At this point, we were not able
to determine if C2QTL1 was epistatic to C2QTL2 or to C2QTL3. In addition, the
C2S.M strain encompassing C2QTLÏ, C2QTL2 and C2QTL3 also includes regions that
were not tested individually for the presence of QTL (region between D2Chm225 and
D2Mco8, and the segment between D2Chm57 and D2Wox27). It is possible that these
regions hide more BP QTLs.
To resolve these issues, we propose to construct double congenics. As mentioned in
chapter 5, the construction of double congenic strains for rat chr. 2 requires a
recombination event between two closely linked loci. This concept can be illustrated
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with the following example: the production of a double congenic strain for C2QTL1 and
C2QTL3. The first step to obtain such a strain is to cross the C2QTL1 congenic
(C2S.M7) to the C2QTL3 congenic (C2S.M7). The progeny obtained,
F1(C2S.M7XC2S.M11), will be heterozygous at the C2QTLÏ locus and at the C2QTL3
locus. (Figure 6a). Figure 6h illustrates the outcomes of the meiosis of
F1(C2S.M7XC2S.M1 1) if no crossover event occurs between the C2QTL1 locus and the
C2QTL3 locus. In this case, the gametes obtained carry either the MM allele for
C2QTL1 with the SS allele for C2QTL3 or the SS allele for at QTL1 with the MM allele
at C2QTL3. The progeny obtained from such gametes will bear the Mlvi allele at
C2QTL1 or at C2QTL3. In contrast, if a cross over event occurs between C2QTL1 and
C2QTL3 (figure 6c) loci, 25% of the gametes obtained will bear the MM alleles at both
loci. Brother sister mating of rats obtained from these gametes will resuit in a rat
homozygous MM at C2QTL1 and C2QTL3 loci. The frequency with which
recombination occurs between two given loci is dependent on the distance separating
those loci, but also on the intrinsic properties of the sequence. 114 So far, we have flot
been able to obtain crossovers between C2QTL1 and C2QTL3 or between C2QTL3 and
C2QTL2.
In this context, one could believe that it would be more practical to compare directly
F1(C2S.M7XC2S.MÏ1), which is heterozygous at C2QTL1 and at C2QTL3 loci, to
heterozygotes for C2QTLÏ or C2QTL3 only. However, the study of heterozygotes is
complicated by the presence of dominant and recessive alleles. For example, the BP of
C2S.M7 rats heterozygous at the C2QTL1 locus is not significantly different from that
of C2S.M7 rats that are homozygous Mlvi at the C2QTL1 locus (data flot shown). This
implies that for the C2QTLÏ locus, the MNS allele is dominant over the DSS allele. In
effect one copy of the MNS allele at C2QTLÏ is sufficient for the heterozygote to
display the same BP effect as the homozygote. The opposite situation is observed for
C2S.M1l heterozygous rats which have the same BP as DSS. For this reason,
heterozygous congenic strains may flot be suitable for the study of QTL-QTL
interactions.
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a C2S.M7 C2S.M1 1 F1(C2S.M7XC2S.M1 1)
Rat
chr.2
b F1(C2S.M7XC2S.M1 1) Meiotic products(gametes)
c F1(C2S.M7XC2S.M1 1) Meiotic products(gametes)
Figure 6 Construction of double congenic strains for rat chr. 2. Grey and black bars
indicate the region coming from the MNS strain in the C2QTL1 and C2QTL3 congenic
strains, respectively. White bars represent the DSS genetic background. a- Breeding of
C2S.M7 and C2S.M1 1 congenic strains. b- and c- Generation gametes from the meiotic
division in F1(C2S.M7 X C2S.M11) rats when no recombination occurs between
C2QTL1 and C2QTL3 loci (b) or when a recombination event occurs between C2QTL1
and C2QTL3 loci (c). Refer to text for detailed expalnations.
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7.3 QTL for SMC number implicating the AT1B gene as a candidate
7.3.1 Model for regulation of SMC number independently of BP
In chapter 6, we reported that the congenic strain C2S.M2 had an significant increase in
SMC number in the thoracic aorta when compared to the DSS rat. This increase in
SMC number was accompanied by a slightly higher but non-significant increase in the
cross sectional area of the aorta. It is of importance that we didn’t observe any BP effect
in C2S.M2, despite the increase in SMC number. Several hypotheses can be emitted to
explain the absence of a relationship between hyperplasia and B? in the C2S.M2
congenic rat.
First, the increase in peripheral resistance that has been associated with essential
hypertension is explained mainly by the remodeling of small arteries and arterioles. 48
At this point, we cannot extrapolate about the structural reorganization of the resistance
arteries, if any. It is possible that the hyperplasia is restricted to the large arteries. In
this case, no increase in peripheral resistance is expected. It would be interesting to
study the structural characteristics of the resistance arteries as well.
Second, in large arteries such as the aorta, remodeling is characterized by outward
hypertrophy of SMC that resuits in a thicker wall without a reduction in the size of the
lumen. It is possible that the increase in SMC number is compensated by an increase
in the lumen of the artery. The measurement of the SMC number and of the CSA of the
artery give information about the wall thickness only. At this time, we have no
information about the media:lumen ratio of C2S.M2 and DSS aortas. As hypertension
progresses, the outward hypertrophy will be accompanied with an increase in arterial
stiffness that is mainly due to an increase in collagen content. 212 From hemodynamic
studies, BP is known to be composed of a steady component (MA?) and a pulsatile
component, the pulse pressure (PP). Pulse pressure is determined by the stiffness of the
large arteries and the wave reflexion, whereas MAP is influenced by the resistance
vessels. 213 If the hyperplasia in the aorta of the C2S.M2 strain were accompanied with
an increase in the rigidity, we would observe a difference in the PP which is determined
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by the response of the vessel to ventricular ejection. Because of its pulsatile nature, PP
varies along the arterial tree, which makes its measurement difficult.
Finally, the contraction state of the vesse] is flot only influenced by its structural
characteristics but it also depends on its the contractile properties. It is possible that the
structural changes we observe in the aorta of C2S.M2 are compensated for by changes
in contractile properties of the SMC.
7.3.2 Agtrlb as a candidate gene for SMC number QTL
In looking at the molecular mechanisms responsible for the increase in SMC number in
S.M2, Agtrlb was proposed as a candidate gene based on its localisation in the QTL
region. This candidate is validated by the presence of two nucleotide substitutions
resulting in significant amino acid changes in the MNS sequence when compared to that
of DSS. Furthermore, the contractile responses to Ang II were significantly reduced in
C2S.M2 when compared to DSS. Given that C2S.M2 had a higher SMC number than
DSS, one could expect an increase in contractility in that vessel rather than the decrease
we observed.
In chapter 6, we proposed that the decrease in contractility observed in aortic rings from
C2S.M2 may be a resuit of prior receptor desensitization in vivo. It is well recognized
that G-protein-coupled receptors (GPRs) undergo agonist-induced desensitization as a
mechanism to tum off the signal resulting from ligand-receptor interaction. 214 The
mechanisms for desensitization of the family of GPRs involve three levels of
inactivation: 1) rapid inactivation following agonist-induced phosphorylation due to the
uncoupling of the G protein from the receptor, 2) internalization of the receptor and, 3)
targeted degradation of the intemalized receptor by lysosomes. 214 Even though
lysosomal degradation has been demonstrated in some cases, it is more frequent for the
receptor to be recycled at the ceil surface. 214 GPRs can be phosphorylated by the GPR
protein kinases (GPK5) and by the second messenger-activated kinases such as PKC and
PKA.215 In bovine adrenal glomerulosa celis, it was demonstrated that binding of Ang II
to AT1A receptor induces the phosphorylation of the receptor. 215 Specifically, agonist
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induced desensitisation of AT1A involved a serine/threonine rich segment of the carboxy
terminal intracellular region of the protein. 216
7.3.3 further implication ofAgtrlb as a candidate gene for the SMC
number QTL
To further implicate Agtrlb in the regulation of SMC number in S.M2, we proposed the
congenic strategy as a way to progressively narrow down the region of interest around
Agtr]b. An alternative genetic approach to validate Agtrlb as a candidate gene for the
SMC number QTL would be to generate a transgenic strain by inserting the normal copy
of Agtrlb (from DSS rat) in the C2S.M2 strain. If Agtr]b is responsible for the SMC
number phenotype, we would expect the transgenic strain to have the same SMC
number as DSS.
Molecular approaches are also available for confirming the role of the Agtri b mutations
on the receptor function. By comparing cultured SMC from DSS and from C2S.M2,
one could study the effect of the mutations on the receptor affinity for Ang II, and on the
activation of downstream signal transduction pathways. For example, it would be
interesting to compare the activity of PLC, PLD and PLA2, which are known target of
the activation of AT1B by Ang 217 Since the amino substitutions we identified are at
position 2 and 20 of the protein, they are located in the extracellular amino terminal
domain of the protein. 217 It is also possible that changes in this position affect the
interaction between Ang II and the ATÏB receptor.
7.4 The next step: from a region to a gene
The congenic strategy described in the current work has allowed us to narrow down the
regions of interest for the chromosome 2 BP QTL to 3 non-overlapping regions:
C2QTL1, C2QTL2, and C2QTL3. The next question one can ask is: what are the genes
in these regions of interest that are responsible for the blood pressure differences
observed between the congenic and the parental strain?
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7.4.1 Identification of functional and positional candidates
Identification of the gene responsible for the BP effect of the congenic is the next task to
achieve. This step will be facilitated by the bioinformatic tools available at National
Center for Biotechnology Information (NCBI) (http ://www.ncbi .nlm.nih. goy!) which is
a gate to access genomic data generated by a worldwide effort to sequence the genomes
of human and model organisms. From the list of genes generated, two types of
candidate genes are obtained: functional and positional candidates. Functional
candidates are genes that are already known to be involved in the cardiovascular system.
For example, the QTL2 region includes the gene coding for the atrial natriuretic peptide
receptor A (Gca) and the QTL3 region includes the gene coding for neutral
endopeptidase (Mme). Positional candidates are candidates based on their position in
the genome, maldng no assumption on their function.
7.4.2 Identification of sequence polymorphisms
For a given functional or positional candidate gene to be involved in BP regulation, the
hypertensive (DSS) and normotensive control strain (MNS) could differ in their coding
sequences or in their expression levels. The angiotensin receptor gene Agtr]b is a
candidate genes for the QTL for vascular SMC number on rat chr 2. Sequencing of the
coding region of the gene has revealed non-synonymous mutations between the DSS
and the MNS rats. Identification of the genes responsible for the BP effects observed in
C2QTL1, C2QTL2 and C2QTL3, will require us to undertake systematic sequence and
expression level comparisons between DSS and the MNS rats for ail the functionai and
positional candidate genes located in the QTL region. A variation between those
contrasting strains could indicate a gene responsibie for the BP variations.
7.4.3 Demonstrating the causative link between a variant and the BP effect
Identification of a functional or positional gene variant is necessary but not sufficient to
provide a definitive evidence of the contribution of a gene to the genetic basis of
hypertension. During the selection process of geneticaiiy hypertensive and
normotensive rats, a series of differences unrelated to the blood pressure phenotype
were also selected and fixed. The end result is that two contrasting strains of rat might
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exhibit polymorphisms at loci involved in BP control and at loci unrelated to BP control.
In this case, how can we differentiate between the genetic variations involved in BP
regulation and the polymorphisms randomly selected and fixed along the way? The
burden of proof is to demonstrate that the variations in the candidate gene are actually
the cause of the BP effect.
The preferred approach to solve this issue will depend on the type of variation
identified. A polymorphism affecting the expression levels of a gene could be resolved
by transgenic rescue experiments. For example, if a candidate gene was found to be
downregulated in the hypertensive strain when compared to the normotensive control,
inserting additional copies in the hypertensive rat by mean of transgenic technology
would be expected to have a BP lowering effect. In cases where the regulatory regions
allowing a temporal and regional regulation of the gene expression are flot known,
bacterial artificial chr (BAC) constructs can be used as a transgene. Due to their large
size, they offer the advantage of protecting the gene of interest from positional effect of
the region surrounding the insertion site and ensure that the cis regulatory elements are
also included in the transgene. Interestingly, a variation of the classical transgenic
strategy, where the transgene is overexpressed, can be used to silence a gene of interest.
A transgenic rat une expressing an antisense RNA targeted against the 5’ region of the
angiotensinogen mRNA resulted in an animal deficient in brain angiotensinogen. 218
This approach may be especially beneficial for the rat model since the knock out widely
used in the mouse is not yet available in the rat.
7.5 Identification of causative genes for complex trait: is it possible?
There are examples in the literature where positional identification of genes responsible
for complex diseases was achieved using the classical positional cloning approach.
Rheumatoid arthritis is a complex trait for which linkage analysis had demonstrated the
presence of a major QTL on rat chromosome 12. Fine mapping using congenic strains
lias allowed researchers to reduce the region of the QTL to a 300 Kb interval containing
only two genes. Sequence analysis of the two positional candidates revealed several
polymorphisms in the coding sequence of the gene Ncfl. This gene codes for a
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component of the NADPH oxidase complex. Differences in enzyme activity associated
with that polymorphism were associated severe destructive arthritis. 219 A susceptibility
gene for rat type 1 diabetes mellitus was identified in the Komeda diabetes-prone (KDP)
rat using a similar positional cloning approach. In this case, the region was narrowed to
a 3.1cM region on rat chr. 11 containing two genes. One of the genes did flot show
sequence or expression levels variations in the KDP rat. The other gene, Cblb,
contained a non-sense mutation changing an arginine to a stop codon and leading to a
protein tmncated by 448 amino acids. Transgenic rescue with a wild type Cbtb was
sufficient to rescue the KDP phenotype.22° Hence, the use of a traditional positional
cloning strategy can lead to the identification of single genes involved in the genetic
determination of complex traits.
7.6 Alternative strategîes to identify genes for complex traits
7.6.1 DNA Microarrays
The current work has demonstrated how powerful the congenic strategy is to break
down the complex traits and refine the position of the regions of interest to regions
reaching less than 2 cM. However, the limit of the congenic approach to reduce the
region of interest using substrains is the distance between the two closest recombination
events. 124 Depending on the gene density of the region of interest, even a very small
QTL region may contains an important number of genes. For example, we estimated
that BP QTL3, which is less than 1.5 cM, corresponds to 9 Mb, a region containing
roughly 80 known and predicted genes according to the national center for
biotechnology information (NCBI) (unpublished results). From this observation, one
can ask whether the strategy we use is capable of narrowing the candidate to a single
gene, or whether we need complementary approaches to achieve this task.
Successful positional cloning of the Cd36 gene for insulin resistance combined the
congenic and the microaffays technologies. The search for the genetic basis to insulin
resistance started with the identification of a highly significant linkage peak for glucose
and fatty acid metabolism, hypertriglyceridaemia, and hypertension close to the
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telomere of rat chr 4 in F2 populations issued from a SHR X WKY cross and from a
SI-W X BN cross. 221 Subsequently, the QTL was confirmed by congenic strains in
which part of the SHR chr. 4 region were repiaced by the homologous region from the
BN. 222 The molecular identification of the gene responsible for the difference in insulin
dependence between the congenic and the SI-W rat was achieved with the use of DNA
microarrays rather than with a traditional positional cloning approach. Three clones
encoding rat Cd36 showed reduced hybridization signais in the SHR when compared to
BN control and mapped to the region of interest on rat chr. 223 The transgenic
expression of Cd36 in the SHR ameliorates insulin resistance and lowers serum fatty
acid. 224
The successful identification of Cd36 as a candidate gene for insulin resistance lead the
way to a new strategy of positional cloning. Since the congenic approach may not be
sufficient to reasonabiy narrow down the number of candidates to study, the microarray
technoiogy may be a powerful complement to identify the genes of interest. Some of
the pitfalls that have been associated with large scale analysis of expression pattems is
the number of candidates obtained and the quantity of data generated. In effect, when
comparing cDNA expression ievels in the BN and the SHR, it is expected that 1% of the
genes tested will be differentially expressed, ieading to hundreds of genes to further
study. 225 Some of these differentiaiiy expressed genes may be responsible for
physiological differences between the strains that are flot relevant to BP controi. A
congenic strain is geneticaily identical to the recipient strain except in the region coming
from the donor strain. Combining congenic strain mapping to microarray technology
allows one to iimit the differentiaily expressed candidates to those that are located in the
region of interest of the congenic. The success of this strategy is however hïghiy
dependent on the choice of the organ to study and the point in time at which the
comparison is made. 225
7.6.2 Importance of intermedïate phenotypes
The construction of a map for cardiovascular function using more than 239
cardiovascular and renal intermediate phenotypes has highuighted the possibilities of
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such an approach to study complex traits. 226 Linkage and association studies would
gain statistical power by using intermediate phenotypes rather than Ïooldng at the blood
pressure only. Since hypertension shows a complex and diverse pathophysiology, it is
possible that populations studied are composed of an admixture of several sub-types of
hypertension involving different causative genes. In this case, using intermediate
phenotyping and classifying the population according to the type of hypertension they
have may help to group individuals likely to have the same genetic defect and gain
statistical power. The lack of detailed phenotyping may explain the highly contradictory
results obtained from the numerous association and linkage studies aiming at assessing
candidate genes.
7.7 Clustering of functionally related QTL
In the cuiTent work, we have shown that the original region of interest on rat chr. 2
contained at least 3 separate blood pressure QTLs in addition to a QTL for smooth
muscle ceil number. Using a similar fine mapping strategy, we have shown that the rat
chromosome 10 contained at least 3 BP QTLs. 167,227 Therefore, it seems that
functionally related QTLs have the tendency to cluster in certain chromosomal regions.
The murine systemic lupus erythematosus (SLE) susceptibility locus is an example of
functionally related genes cluster. 228 It was demonstrated that the genes stela, sÏe]b
and slelc contained within a 7 cM segment of mouse chr. 1 can each independently
cause a loss of tolerance to nuclear antigen ah contributing distinctly to the SLE
pathogenesis. 228 was concluded that they are part of a functionally related cluster of
genes. 228 A similar phenomenon was described for hypertension. In effect, a genome
wide scan of 239 cardiovascular and renal phenotypes in a F2 (BN X DSS) population
revealed the presence of aggregates composed of 6 or more QTL on chr 1, 2, 3 and 18 of
the rat. 226 From these finding, we can predict that further systemic coverage and fine
mapping of the chr. 2 regions of interest may lead to the discovery of additional
cardiovascular related QTLs.
The biological significance of the clustering of functionally related traits remain to be
investigated. It was proposed that clustering may be the result of functional and
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evolutionary pressures since clustered loci tend to belong to the same functional
pathway such as it is the case for the loss of tolerance to nuclear antigen for the Ste]
cluster. 226 The chr. 2 region of interest studied in this thesis presents an additional
evidence in favour of this hypothesis since the genes coding for several components of
the atrial natriuretic peptide pathway are located in adjacent chr. 2 regions. These
functionally related loci include the gene coding for the receptor for the atrial natriuretic
peptide (Gca), and the gene coding for the metallo-endopeptidase (Mine).
7.7.1 Implications of gene clustering and interactions on QTL detection
Even if the biological signification of the clustering of functionally related genes
remains hypothetic, this observation has important consequences on experimental design
for future genetic studies. Knowing that certain regions of the genome are more
concentrated in genes involved in cardiovascular regulation, it is important to proceed to
fine mapping of the QTLs. In effect, the current work shows that so far, the original
region of interest contained more that one QTL for blood pressure and it is not
impossible that further dissection of the C2QTL1, C2QTL2 and C2QTL3 regions lead to
identification of additional QTLs. We have demonstrated that the C2QTL1 is epistatic
to either C2QTL2 or C2QTL3. Such an epistatic interaction imply that comparing the
magnitude of the blood pressure lowering in congenic strains is not reliable for
evaluating the number of QTL in a given region. In effect, in this particular case, the BP
lowering effect of C2QTLI was hidden by that of C2QTL2 or C2QTL3. Furthermore,
since QTLs involved in the same pathways have been shown to cluster 228 and given that
we propose that the mechanistic behind epistatic interaction involves genes in the same
biological pathways, it is highly probable that clusters of genes show epistatic
interaction. In this regard, it is essential to proceed with the fine mapping work even if
the region identified contains interesting candidate genes. Fine mapping should be
performed to narrow down the region of interest to the maximum possible given the
limitation of the recombination events between two close loci.
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7.8 The animal model : background effect
7.8.1.1 Residual background
From a theoretical point of view, after the eight backcrosses required for the
construction of a congenic strain, more than 99% of its genetic background is that of the
recipient strain. 123 The possibility remains that the blood pressure effect observed in
the congenic strains could be explained by residual donor genotype rather than by the
region studied. In the original publication of the chr. 2 congenic strains, 2 different
strains were obtained from independent breeding $.WKY-D2N35/Nep and S.MNS
Adh/D2Mit5, both of which showing a significantly lower blood pressure than the DSS
rat. 229 Therefore, it is unlikely that the blood pressure lowering the congenic strains
discussed in the present work is explained by the presence of residual background since
2 independently derived congenic strain showed the same effect. Because the position
of residual background is determined by chance only, it is highly unlikely that the same
region would be obtained in 2 independent crosses.
7.8.1.2 Background of the recipient strain
The effect of the genetic background on expression of blood pressure controlling alleles
lias been well illustrated in a study of the effect of specific renin alleles on BP.23°
Cosegregation of blood pressure with the RFLP in intron 1 of the renin gene was
evaluated in different populations issued from DSS X DSR crosses where the amount of
genetic background coming from the DSR rat varied. A positive association between the
renin alleles and blood pressure was observed in the F2 (DSS X DSR) and in Fi (DSS X
DSR) X D$S cross but flot in the Fi (DSS X DSR) X DSR population. It was
concluded that the relationship of genes to blood pressure was highly dependent on the
genetic background since the Fi population backcrossed to DSR did not show the
association, thus indicating that having too much background from DSR prevented the
blood pressure effects of the renin alleles. 178 The choice of the normotensive
contrasting strain also influences the expression of the high blood pressure alleles.
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Evaluatïon of the SA gene in F2 populations showed a positive correlation with blood
pressure in the F2 (Lew X DSS) cross but flot in a F2 (WKY X DSS) cross. 178
7.9 Relevance to other rat models of hypertension
Since the different genetic models of hypertension in the rat were bred separately, we
can expect that the pathophysiology of the disease differs in each mode!. For example,
the DSS rat is derived from outbred Sprague-Dawley rats but the genetic basis of this
model depends on the alleles present in the few individuals from which the une was
established. Therefore, it is likely that the DSS model of hypertension bas retained only
a proportion of the genes involved in the genetic determination of blood pressure in
outbred stocks. Animal models of hypertension therefore present a reductionist
experimental approach. From these observations, one can wonder how can the results
obtained for the DSS rat be generalized to other rat models of hypertension?
Several groups of investigators have been interested in the mapping of the chromosome
2 QILs and some groups were using different rat models. The figure 7 compares BP
QTLs on rat chr. 2 identified by other groups of investigators to the regions presented in
this work. 231 The regions we have identified correlate with those of other studies
involving different crosses. 226,232-237 This indicates that our QTL5 are not unique to the
Dahi rats and that the potential genes responsible for the B? effect in C2QTL1, C2QTL2
and C2QTL3 are likely to be relevant to other genetic rat models of hypertension.
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Even if rat genetic models of hypertension present a simplified form of the human
essential hypertension etiology, study of the DSS pathophysiology (1.3.2.2.2) clearly
indicates that several systems are altered to contribute to the high BP phenotype.
Therefore, simultaneous studies of the several rat models may be the solution to ensure a
complete coverage of the genetic components accounting for the more heterogeneous
human essential hypertension.
7.10 Relevance human hypertension
Comparative mapping using the information available on the National Center for
Biotechnology Information (NCBI) lias aÏlowed us to determine that the chromosome 2
regions of interest in the rat are homologous to segments of chr 13, 3 and 4 in human
Within each synthenic segment, gene order is conserved between rat and human. In the
human genes present in these regions of interest, more than a thousand single nucleotide
polymorphisms (SNPs) have been inventoried in the coding and regulatory regions
(unpublished observations). These resuits indicate that the human homologues of the rat
genes in the regions of interest show inter-individual variability potentially important for
blood regulation.
7.11 Perspectives
7.11.1 Basic sciences
Identification of the genes involved in hypertension is promising from a clinical point of
view but also to gain a better understanding of the normal BP regulatory systems and of
the pathophysiology of hypertension. Using a global positional approach rather than a
candidate approach may Ïead to the discovery of new pathways involved in the control
of blood pressure. The identification of Nef] as a gene responsible for rheumatoid
arthritis also lcd to the discovery that NADPH oxidase complex was involved in the
progression of severe autoimmune diseases. 219
The current work combines positional cloning approach and global genomics approach.
The Agtr]b gene was identified on the basis of its function. C2QTL2 and C2QTL3
contain potential gene candidates whose function is known to be associated with the
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cardiovascular system. Despite the presence of candidate genes in C2QTL2 and
C2QTL3, it is flot excluded that a yet unknown gene is responsible for the blood
pressure effects. To date, C2QTL1 region doesn’t include any obvious candidate genes.
Identification of the genes at the molecular level may contribute to defining the
mechanisms and regulation of known cardiovascular pathways or to discover new
cascades and molecules.
7.11.2 Ctinical
Hypertension is a major risk factor for the onset of lethal cardiovascular diseases.
However, detection and control is achieved in only 13% of hypertensive patients. 61
Identification of genes for hypertension is necessary for the development of genetic
diagnostic tools, design of new medications and a personalized treatment based on the
genetic profile of a given patient, a field known as pharmacogenomics. Prevention and
individualized treatment may translate into a reduction in cost and optimal efficiency of
health delivery system.
In hypertension, it has been estimated that several genes are involved in the disease,
each of them contnbuting to 30- 50% of the blood pressure phenotype. 84 Given the
number of parameters regulating blood pressure, is it realistic to expect that discoveries
of the individuals genes in animal models or human hypertension will translate into
novel therapeutic approaches, pharmacogenomics and genetic diagnostic tests?
7.11.2.1 Gene therapy
Gene therapy is most of the time associated with the correction of single gene diseases.
At first sight, given the variety of pharmacological treatments available for treating
hypertension, gene therapy may not be an appealing solution. Interestingly, it was
proposed that gene therapy offers important advantages over traditional drug treatment:
1) it would diminish the side effects and 2) compliance would be achieved more easily
since the patient would be required to take a single dose lasting several months rather
than a pilI every day. As knowledge of hypertension genes progresses, more targets will
become available. 238 However, significant technical issues such as ïnflainmatory and
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immune responses, and poor efficiency of delivery of the therapeutic gene wiIl have to
be resolved before gene therapy becomes available as a treatment for hypertension. 124
7.11.2.2 Genetic diagnosis and pharmacogenomics
Knowing the genetic variations present in the population that underlie hypertension will
allow us to diagnose individuals at risk for hypertension before the onset of
cardiovascular complications. Individuals respond differently to antihypertensive
therapy suggesting the possibility of personalized treatment. 16$ The A1166C
polymorphism of AT1R receptor in humans is associated with differences in humoral
and renal hemodynamic responses to AT1R blockade with losartan. 239 This example
illustrates how the identification of a genetic variation may lead to a pharmacogenomic
strategy of treatment.
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7.12 Summary and conclusions
Since the publication of the original congenic strain in a 80 cM region of Dahi rat
chr 2229, we have used a systematic mapping strategy to provide a comprehensive
coverage and fine analysis of the BP QTL it contains. Consequently, a total of three
QTLs were discovered. C2QTL1, C2QTL2 and C2QTL3 reside in chromosome
segments of 5.7 centiMorgan (cM), 3.5 cM and 1.5 cM respectively. C2QTL1
interacted epistatically with either C2QTL2 or C2QTL3, whereas C2QTL2 and
C2QTL3 showed additive effects to each other. In addition, the current investigation
presents the first une of evidence that a QTL for aortic SMCN exists, and it acts
independently of QTLs for BP. The SMC number QTL is also located in the segment
studied in the original chr. 2 congenic strain. A candidate gene for the SMC number
QTL, the gene Agtrlb contains two non-synonymous mutations in the coding region
between DSS and MN$ rats and a reduced contractile responses to Ang II was observed
in aortas of rats harbouring the MNS allele of the gene compared with DSS rats. Further
work will be necessary to identify the genes responsible for the BP effect in C2QTL1,
C2QTL2 and C2QTL3. Identification of genes for complex diseases remains
challenging but the new genomic tools available are promising. Genes identified will
provide new insights about the BP regulatory systems and the defects leading to
hypertension. This knowledge may be useful in the development of new therapeutic
targets, genetic diagnostic tools and pharmacogenomics.
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